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Several cardiac diseases include myocardial ischaemia (acute or chronic), 
heart failure (systolic or diastolic) and left ventricular hypertrophy (either as a 
“primary” cause or developed secondary to other diseases) share the commonality 
of myocardial energetic deficiency or suboptimal myocardial metabolism. 
Therefore, approaches to modify myocardial metabolism in order to improve 
energetics present as an attractive therapeutic option. This is particularly useful 
when other options are limited: for example, lack of optimal symptom control with 
“maximal” treatment, or contraindications to other pharmacological treatment (by 
virtue of impairment of left ventricular systolic function and/or hypotension).  
The objective of this thesis is to examine the biochemical effects of various 
pharmacological agents towards modulation of myocardial metabolism, both in the 
acute (e.g. acute coronary syndrome) and chronic cardiac disease settings (e.g. 
diabetic heart). In particular, the effects of perhexiline, an interesting drug known 
to possess not only metabolic effects (by virtue of inhibiting carnitine palmitoyl 
transferase-1 [CPT-1], thereby shifting myocardial fatty acid oxidation towards 
glycolysis) but also anti-inflammatory effects, will be further explored.  
First, the pharmacokinetics and myocardial uptake profile of the individual 
perhexiline enantiomers were examined. This study showed that the myocardial 
uptake of both perhexiline enantiomers in patients were slow; and that in 
multivariate backward stepwise analysis, (-)-perhexiline was inversely correlated 
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antagonist effect of perhexiline may potentially lie predominantly within the (-)-
enantiomer.  
Additionally, other aspects of myocardial metabolism, including the nexus 
between inflammatory activation and metabolic effect, were investigated. In a 
study involving 12 patients presenting with acute coronary syndrome and 
hyperglycaemia, rapid reversal of hyperglycaemia with insulin infusion in 12 hours 
improved the anti-aggregatory effect of platelets, independent of the platelet 
content of the pro-inflammatory marker thioredoxin-interacting protein (TXNIP).  
Furthermore, this thesis also investigated the potential insulin sensitization 
effect of perhexiline in diabetic patients. This is a corollary of increased glucose 
utilization, which appears to be relevant even against the background of 
concomitant therapy with other insulin-sensitizing agents such as AMPK activators 
or ACE-inhibitors. Furthermore, platelet content of TXNIP tended to fall slightly 
(but not significantly) after perhexiline treatment, implying its lack of significant 
critical role in the improvement of both nitric oxide responsiveness and insulin 
sensitization. However, its overall contribution still cannot be completely ruled out.  
Lastly, in an in vitro experiment, the potency of inhibition of CPT-1 by both 
perhexiline enantiomers was investigated. It was found that the 50% inhibitory 
concentrations of both enantiomers were not significantly different. This provided 
evidence that the (differential) toxicity seen with the individual enantiomers (in 
previous studies) might be independent of CPT-1 inhibition. The CPT-1 inhibitory 
potency of several other cardiac drugs, including fluorinated perhexiline 
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compound, structurally similar to amiodarone) was also determined in this thesis, 
and it was shown in particular that dronedarone was a potent CPT-1 inhibitor.  
The overall thrust of this work reinforces the concept that CPT-1 inhibition is 
seen with a large number of cardiovascular drugs, and is retained by enantiomers 
and structural analogues of perhexiline. The myocardial uptake of perhexiline and 
its enantiomers indicates a relatively slow process of equilibration with its primary 
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1.1 Myocardial energetics: physiological considerations 
 
 
“…all living things must be continuously fed with energy…” 
Hans Krebs, Nobel banquet speech, Stockholm, 1953. 
 
 
The heart is a predominantly aerobic organ which relies heavily on the 
aerobic oxidation of substrates, such as glucose, fatty acids, lactate, and even 
some amino acids, to generate adenosine triphosphate (ATP), a major cellular 
source of energy. The process of substrate selection is dynamic and is dependent 
on fetal/adult status, fed/fasting cycles, normoxic/hypoxic condition, or (sudden 
increase in) myocardial workload demand. These dynamic processes are 
integrated to ensure that the myocardial contractile performance and 
housekeeping functions are maintained. Derangements in cardiac energy 
metabolism occur in many diseases, including angina, acute coronary syndrome, 
heart failure, cardiomyopathy, and aortic stenosis [1].  
The process of cardiac energy metabolism is divided largely into three 
components (see Figure 1-I). The first process constitutes of cellular uptake of 
substrate (mainly free fatty acids and glucose), and subsequent production of 
intermediary metabolites for entry into the Krebs cycle, either via glycolysis of 
carbohydrates or β-oxidation of free fatty acids [1]. The second component is the 
oxidative phosphorylation of ADP by the mitochondrial respiratory chain into ATP. 
The third component is the ATP transport and utilization by myofibrils, via the 
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energy buffer and includes the transfer by creatine kinase of a phosphate group 
from ATP to creatine to form phosphocreatine and ADP. Phosphocreatine then 
diffuses into the myofibrils, where the myofibrillar creatine kinase catalyses 
conversion of phosphocreatine back into creatine and ATP. The free creatine then 
diffuses back into the mitochondria [1]. During conditions when myocardial energy 
demand outweighs its supply, the level of phosphocreatine decreases to keep ATP 
at a constant level, but the free ADP level rises. The raised free ADP then inhibits 
the function of many cellular enzymes leading to impairment of cardiac 
contractility. Therefore even when ATP level remains unchanged, metabolic 
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Figure 1-I: Physiology of myocardial metabolism in relation to high energy 





Adapted from reference [1]. 
Abbreviations: GLUT = glucose transporter; NAD = nicotinamide adenine 
dinucleotide ; NADH = nicotinamide adenine dinucleotide  ; ANT = adenine 
nucleotide translocator ; PCr = phosphocreatine; Cr = creatine; CKmm = 
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The generation of ATP is a series of complex oxidation-reduction 
reactions occurring within the cell. Such reactions require several co-
enzymes, including nicotinamide adenine dinucleotide (NAD), nicotinamide 
adenine dinucleotide phosphate (NADP), and flavin adenine dinucleotide 
(FAD).   
Generation of ATP in the cytoplasm is minimal, contributing to <2% of 
the total ATP generated [3]. Cytoplasmic generation is predominantly from 
glycolysis, which involves ten enzyme-mediated steps to breakdown six-
carbon monosaccharides (e.g. glucose, fructose) into two molecules of 
pyruvate, two molecules of ATP, two molecules of NADH, two molecules of 




1.1.1.2.1 Citric acid cycle: Carbohydrate metabolism 
 
Upon entry into the mitochondria matrix, pyruvate is converted to 
acetyl-CoA by pyruvate dehydrogenase, before entering into the citric acid 
cycle (also known as tricarboxylic acid cycle or Krebs’ cycle). This cycle 
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generation of ATP. They include one molecule of FADH2, three molecules 
of NADH, and one molecule of guanosine triphosphate (see [5] for review).  
The subsequent metabolic pathway, oxidative phosphorylation, 
occurs exclusively within the inner mitochondrial membrane, utilizing the 
differences in product concentrations from the citric acid cycle to form ATP 
[6]. Such process involve the respiratory chain (which includes four 
complexes: complexes I-IV and a Q protein to transport H+ from the inner 
mitochondria to the intermembrane space) and ATP synthesis via ATP 
synthase [5,6].  
Glucose and lactate supply 10 to 40% of the energy requirement 
of the heart under normoxic conditions. Lactate, readily extracted from the 
blood, can be converted to pyruvate in the cytosol and further metabolized 
to acetyl-CoA for ATP generation [5,6].  
 
1.1.1.2.2 Long-chain fatty acids 
 
Fatty acids supply about 60-90% of the energy requirement for the 
heart and are oxidized in the mitochondria. Upon entry into the cytoplasm, 
either via passive diffusion or uptake by fatty acid translocase or fatty acid 
binding protein (FABP), the non-esterified fatty acids are then esterified to 
fatty acyl-CoA by fatty acyl-CoA synthase [7]. Following this, fatty acids 
with less than 12 carbons in length can cross the mitochondrial 
membranes readily. However, saturated fatty acids longer than 12 carbons 
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Carnitine palmitoyltransferase-1 (CPT-1), located at the outer 
mitochondrial membrane, is responsible for catalyzing the metabolism of 
water-soluble fatty acyl-CoA to lipid-soluble fatty acylcarnitine in the 
compartment between the inner and outer mitochondrial membranes [5,6]. 
Then this long-chain fatty acylcarnitine is transported by carnitine 
acyltranslocase across the inner mitochondrial membrane in exchange for 
free carnitine. Finally, carnitine palmitoyltransferase-2 (CPT-2) 
regenerates the long-chain fatty acyl-CoA in the mitochondrial matrix. Out 
of the three enzymes involved in the “carnitine shuttle”, CPT-1 is the rate-
limiting enzyme in controlling fatty acid uptake into the mitochondria [5,6].  
Once inside the mitochondria, fatty acid breakdown continues via 
β-oxidation, a four-step reaction with specific enzymes involved in each 
stage: acyl-CoA dehydrogenase, 2-enoyl-CoA hydratase, 3-hydroxyacyl-
CoA dehydrogenase, and 3-ketoacyl-CoA thiolase. The reactions, 
removing 2 carbons each cycle, continue until the entire fatty acid chain is 
degraded into acetyl-CoA, which then enters the citric acid cycle (see 
section above) to generate ATP [5,6].  
Very long chain fatty acids (> 22 carbons), cannot be broken down 
by the mitochondria. They are broken down by peroxisomes in the 
cytoplasm into medium or short chain fatty acids, before entering β-






Chapter 1: Introduction 
 
 
Page | 8 
 
1.1.2 Interactions between pathways (Randle Cycle): checks and balances  
 
The flux between fuel utilization by mammalian organs is governed by the 
“Randle cycle”, a biochemical process described by Philip Randle, Peter Garland, 
Nick Hales and Eric Newsholme in 1963 [8]. This process described a reciprocal 
and non-dependent metabolic relationship between glucose and fatty acids: that 
the utilization of one nutrient inhibited the uptake of another directly and without 
hormonal mediation. Such dynamic adaptation to nutrient availability applies to the 
interaction between adipose tissue and muscle tissue.  
As components of the Randle cycle, fatty acid utilization inhibits glucose 
metabolism by inhibiting several glycolytic steps, most significantly at the level of 
pyruvate dehydrogenase (PDH). Oxidation of fatty acid triggers an initial increase 
in the mitochondrial ratios of [acetyl-CoA]/[CoA] and [NADH]/[NAD+], both of 
which will inhibit the activity of PDH complex by activating PDH kinase causing 
phosphorylation. Such changes then lead to the accumulation of cytosolic citrate, 
which inhibits phosphofructokinase-1 (PFK-1), leading to an increase in glucose-6-
phosphate, which inhibits hexokinase eventually [5,6] (see Figure 1-II).  
Conversely, the rate-limiting enzyme of long-chain fatty acid oxidation, 
CPT-1, is strongly inhibited by malonyl-CoA, a key physiological regulator of fatty 
acid oxidation. An increase in malonyl-CoA suppresses fatty acid oxidation by 
inhibiting CPT-1 and the “carnitine shuttle”; and a reduction in malonyl-CoA 
increases fatty acid uptake and oxidation. Malonyl-CoA is formed from the 
carboxylation of extramitochondrial acetyl-CoA by acetyl-CoA carboxylase (ACC), 
and is degraded by malonyl-CoA dehydrogenase (MCD) [5,6]). Extramitochondrial 
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ATP-citrate lysate reaction (see Figure 1-II). The activity of ACC is under the 
regulation of AMP-activated protein kinase (AMPK), which will be discussed later 
in this chapter. Inhibition of fatty acid oxidation, for example associated with 
malonyl-CoA accumulation, is known to increase glucose and lactate uptake and 
oxidation. This is achieved by decreasing citrate levels and inhibition of PFK-1 and 
by lowering acetyl-CoA and/or NADH levels in the mitochondrial matrix, thereby 
reversing inhibition of PDH (Figure 1-II).  
The ATP yield and oxygen requirement for mitochondrial oxidative 
phosphorylation differs for the different metabolic substrates. Fatty acid oxidation 
yields more ATP, but requires more oxygen per ATP production, and do not yield 
ATP under oxygen-independent conditions. Therefore, during ischaemic 
conditions, promotion to glucose oxidation would be more "energy efficient", as the 
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Abbreviations:  GLUT = glucose transporter; HK = hexokinase; Gluc-6-P = 
glucose-6-phosphate; Fruc-6-P = fructose-6-phosphate; PFK-1 = 
phosphofructokinase-1; OMM = outer mitochondrial membrane; IMM = innter 
mitochondrial membrane; PDH = pyruvate dehydrogenase; LCFA = long chain 
fatty acid; CPT-1(/2) = carnitine palmitoyl transferase-1(/2); CAT = carnitine 
acyltranslocase; ACC = acetyl-coA carboxylase; MCD = malonyl-CoA 
decarboxylase; p-AMPK = phosphorylated AMP-activated protein kinase; ETC = 
electron transport chain; ADP = adenosine diphosphate; ATP = adenosine 
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1.1.2.1 Physiology of carnitine palmitoyl transferase-1 
 
The conceptual framework of how carnitine controls the oxidation of 
long-chain fatty acids by mammalian tissues first arose from studies in the 
1950s to 1960s [10-12]. These studies provided preliminary evidence 
showing that carnitine enables long-chain fatty acids to be esterified in the 
extramitochondrial compartment, in order to overcome the permeability 
barrier and gain access to the inner membrane (see Figure 1-III). Despite the 
elegance of this proposed mechanism, little attention was received until in 
the mid-1970s. At that stage, it was apparent that CPT-1 activity regulation 
plays a central role in cellular metabolic homeostasis. Furthermore, it was 
found that genetic defects at the level of carnitine palmitoyl transferase (CPT) 
system form the basis of serious human disease which lead to recurrent 
myoglobulinuria [13] and that CPT also plays an important role in the liver 
regulating fatty acid oxidation [14].  
During their investigations into how liver accelerates production of 
ketone bodies in ketotic conditions such as starvation or uncontrolled 
diabetes, McGarry and Foster [15] hypothesised that a metabolite from 
glucose oxidation is responsible for regulating fatty acid biosynthesis and 
degradation. After screening multiple intermediaries of the glycolytic 
pathway, the pentose phosphate pathway and the tricarboxylic acid cycle, of 
the ability of such intermediate to inhibit oxidation of oleate in rat liver 
homogenates, the authors found that malonyl-CoA (to be discussed in detail 
in Chapter 1.1.2.3) inhibited oxidation of oleate powerfully and this effect was 
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Although the authors also observed an inhibitory effect of malonyl-
CoA on fatty acid oxidation in rat heart and kidney, it was thought at that time 
that malonyl-CoA could not be present at inhibitory concentration as neither 
tissues had a cytosolic fatty acid synthesis pathway [15,16]. However, it was 
later found that non-hepatic tissues, such as heart and skeletal muscle, also 
contain acetyl-CoA carboxylase (ACC: to be discussed in more detailed later) 
which is responsible for the synthesis of malonyl-CoA from acetyl-CoA [17-
19]. This implied that the malonyl-CoA/CPT-1 pathway constituted a 
potentially important element of the fuel cross-talk in other non-hepatic 
tissues.  
 
Figure 1-III: The mitochondrial CPT system. 
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1.1.2.2 CPT-1 isoforms 
 
Considerations that skeletal muscle and hepatic CPT-1 are different 
from each other arise from the observation that the inhibitory effects of 
malonyl-CoA on rat CPT-1 varies with the tissue source [20]. Specifically, the 
IC50 of malonyl-CoA in liver was ~3 uM as compared to ~ 0.03 uM in skeletal 
muscle, and the Km values for carnitine were ~ 30 uM and 500 uM, 
respectively [20]. Additionally, it was found that when labelled with 
radioactive triglyceride-CoA [21] or etomoxir-CoA [22], there were two 
proteins with sizes of approximately 88kDa (L: liver) and 82 kDa (M: muscle) 
that migrated onto SDS/polyacrylamide gels. These two isoforms of CPT-1 
were later confirmed to exist in humans using genomic cloning methods 
[23,24]; and that both isoforms also exist in various other tissues. In 
particular, in rat heart mitochondria, CPT-1 displayed IC50 of malonyl-CoA 
and Km for carnitine to be intermediate between that of liver and skeletal 
muscle [20]. Rat heart tissue expresses M-CPT-1 predominantly, but it also 
contains sufficient L-CPT-1 to account for its overall responsiveness to 
malonyl-CoA [22,25]. Importantly, both isoforms are found in the human 
heart [26].  
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1.1.2.3 Malonyl-CoA: the endogenous inhibitor of CPT-1 
 
Malonyl-CoA is an endogenous inhibitor of mitrochondrial CPT-I, thus 
providing a potential limit to the rates of oxidation of fatty acid [27] 
irrespective of synthetic rates. It has a rapid turnover, with half-life of 
approximately 1.25 minutes [27]. Therefore, both the production and 
degradation of malonyl-CoA are important determinants of malonyl-CoA 
levels and thus of subsequent fatty acid oxidation. Consistent with this, a 
reduction in malonyl-CoA level increased the uptake and oxidation of fatty 
acids [28-30]; whereas an increase in malonyl-CoA suppressed fatty acid 
oxidation [31,32].  
Malonyl-CoA is synthesized via carboxylation of acetyl-CoA by acetyl-
CoA carboxylase (ACC) (Figure 1-IV). There are two isoforms of ACC in the 
myocardium: the α and the β-isoforms, with the latter being the predominant 
isoform in the heart [17]. It has been suggested that malonyl-CoA produced 
by the β-isoform of ACC is more involved in the regulation of fatty acid 
oxidation [31]. This role contrasts to that of the high abundance of ACC-α in 
the liver, which produces malonyl-CoA primarily for the regulation of fatty 
acid biosynthesis [33]. The activity of ACC is also postulated by 
phosphorylation or dephosphorylation of AMPK (described in Chapter 1 
section 1.2.3.1), which has a key role in the cardiac energy metabolism (see 
Figure 1-IV).  
Malonyl-CoA is degraded via decarboxylation by malonyl-CoA 
decarboxylase (MCD). Previous studies showed that inhibition of MCD led to 
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oxidation and caused a secondary increase in glucose oxidation [34,35]. This 
activity of MCD represents a potential therapeutic target. Additionally, the 
expression of MCD has also been shown to be regulated by peroxisome 
proliferator activated receptor alpha (PPARα), a transcription factor involved 
in fatty acid oxidation. Activation of PPARα increased MCD expression, 
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Malonyl-CoA is synthesized via carboxylation of acetyl-CoA by acetyl-CoA 
carboxylase (ACC), and degraded via decarboxylation by malonyl-CoA 
decarboxylase (MCD). ACC is negatively regulated via phosphorylation by AMPK. 
Increased malonyl-CoA production inhibits fatty acid oxidation. During stressful 
conditions when ATP is low (e.g. ischaemia), adenosine monophosphate (AMP) 
and AMPK kinase (AMPKK) are increased and activated, leading to a very rapid 
activation of AMPK. This then inhibits ACC, which caused a rapid fall in malonyl-
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1.1.3 ATP transport between nucleus and cytoplasm 
 
Despite a huge fluctuation in the demand for ATP, the human heart 
maintains a relatively constant cytosolic ATP concentration at 10 mM [39]. This is 
achieved by matching the rate of ATP synthesis with that of ATP utilization (by 
myosin, ion pumps, synthesis and degradation of large or small molecules). The 
reversible interconversion of creatine into phosphocreatine is controlled by 
creatine kinase (CK), a central controller of cellular energy homeostasis.   
In principle, the phosphocreatine-CK shuttle serves as an “energy shuttle”, 
providing bridges between the sites of ATP generation and ATP consumption. This 
is largely because the velocity of the CK reaction is approximately ten times faster 
than the velocity of oxidative phosphorylation (to synthesize ATP) [40]. There are 
two isoforms of CK, the dimeric cytosolic CK and the mostly octameric 
mitochondrial CK localized in cristae and intermembrane space. Both isoenzymes 
contribute to the build-up of a large intracellular pool of phosphocreatine [40]. 
Phosphocreatine serves as an energy buffer that rapidly donates its phosphorus 
group to ADP in order to maintain a relatively constant global ATP concentration.  
Creatine and phosphocreatine accumulate, in the excitable tissues via the 
Na+/Cl- transporters. The creatine transporter in the sarcolemma then moves 
creatine against a concentration gradient into the tissue [40]. Creatine is either 
extracted directly from diet or synthesized from a two-step biosynthesis pathway 
occurring in liver, kiney or pancreas, that involves arginine:glycine 
amidinotransferase and guanidineoacetate methyltransferase. Interestingly, in a 
study of the development of creatine transport in rats, both of these enzymes are 
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The other function of CK is based on its subcellular compartmentation. 
Such compartmentation of CK isoenzymes allows it to supply ATP from PCr during 
acute increase of energy demand. Such ATP synthesis not only functions to 
maintain a constant supply of ATP, but also functions to maintain a high ratio of 
ATP relative to its hydrolysis products, namely ADP and phosphate. This ratio, 
expressed as the maximal ∆G (change in Gibbs free energy) for the free energy of 
ATP hydrolysis, is the chemical driving force of all ATP-requiring reactions [40].  A 
low concentration ratio of ATP to ADP will therefore stimulate mitochondrial 
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1.1.4 Modulation of mitochondrial function and energetics 
 
1.1.4.1 Role of uncoupling proteins 
 
Uncoupling proteins (UCP) were first identified in 1976 in brown 
adipose tissue (now also found in white adipose tissue and termed UCP-1) 
[42]. They are members of the mitochondrial anion carrier family located in 
the mitochondrial inner membrane, and are thought to play a role in 
dissipitating the proton electrochemical gradient by transferring proton ions 
generated during oxidative phosphorylation back into the mitochondrial 
matrix (Figure 1-V). Uncoupling proteins all share the property of dissociating 
metabolism from high energy phosphate generation, and thus act as “energy” 
sinks (see Chapter 1.2.2).  
During oxidative phosphorylation, protons are being pumped out from 
the inner mitochondrial matrix into the intermembrane space by complexes I, 
III and IV of the electron transport chain. This establishes a proton motive 
force (∆p) across the inner membrane. The re-entry of protons into the 
mitochondrial matrix through ATP synthase (or complex V) couples the 
release of ∆p to ATP synthesis. All other forms of proton re-entry, including 
through the uncoupling proteins or adenine nucleotide translocase are 
considered to be “proton leak” [43].  
Activation of proton leak through UCP is thought to be controlled by 
reactive oxygen species (ROS) (especially superoxide and perhydroxyl 
radical HO2). There is also recent evidence that glutathionylation acts as a 
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low dose of ROS leads to deglutathionylation and proton leak; whereas 
prolonged high level of ROS deactivate UCP by reglutathionylation, 
potentially to avoid the collapse of the mitochondrial membrane potential and 
induction of cell death (see Figure 1-V B) [44].  
UCP-2 and UCP-3 are structural homologs of UCP-1. While much 
debate occurs regarding the physiological roles of the UCPs, it is known that 
UCP-1 is responsible for heat generation; while UCP-2 and UCP-3 are not 
associated with non-shivering thermogenesis. In regards to location, there is 
also some controversy of whether or not UCP-2 is expressed in heart (this 
may be species-specific), but UCP-3 is known to be expressed in the inner 
mitochondrial membrane of the heart’s skeletal muscle.  
UCP-3, in particular, is thought to protect the cells from oxidative 
stress injury. It mitigates reactive oxygen species release from the electron 
transport chain, and this may involve the glutathionylation of the protein. For 
example, in UCP-3 knock-out mice, the production of reactive oxygen 
species from harvested isolated skeletal mitochondria is significantly higher 
compared to that from wild-type animals [45]. Additionally, there is also 
evidence that UCP may participate in ischaemic preconditioning: the levels of 
UCP (both mRNA and protein expressions) are inversely correlated with 
infarct size [46]; and UCP may also limit atherosclerotic plaque formation by 
reducing the formation of reactive oxygen species [47]. 
In 2004, Murray and colleagues found a positive correlation between 
the concentration of circulating free fatty acids and the content of cardiac 
mitochondrial UCPs (UCP-2 and UCP-3) from tissue samples of patients 
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does not explain whether it is beneficial or harmful (as a maladaptive 
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Figure 1-V: Mitochondrial metabolism and the role of uncoupling proteins 
 
 
Adapted from references [49,50].  
A) Protons generated during oxidative phosphorylation and electron transport 
chain are “leaked” back into the mitochondrial matrix through uncoupling protein. 
B) Hypothetical scheme of the regulation of ROS emission as controlled by 
glutathionylation/deglutathionylation state of uncoupling proteins. (Red round dots 
represent protons). During physiological conditions (i), minimal ROS is generated. 




Chapter 1: Introduction 
 
 
Page | 23 
 
extended periods of oxidative stress lead to uncoupling protein re-
glutathionylation.  
Abbreviations:  OMM = outer mitochondrial membrane; IMM = inner mitochondrial 
membrane; I, II, III, IV, V = mitochondrial complex I-V; UCP = uncoupling proteins; 
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1.1.4.2 Mitochondrial Permeability Transition Pore and effects of 
oxidative stress with mitochondria 
 
Apart from energy production, mitochondria also participate in Ca2+ 
signaling, production of reactive oxygen species, cross-talk with other 
organelles, biogenesis, fusion or fission, and orchestration with other cell 
death modalities.  
Oxidative stress, together with calcium overload and ATP depletion, 
lead to the opening of mitochondrial permeability transition pore (mPTP), with 
high conductance channels (see Figure 1-VI). Three key proteins are 
generally accepted as the key structural components of the mPTP: the 
adenine nucleotide translocase (ANT) in the inner mitochondrial membrane, 
the mitochondrial cyclophilin D (cyclo D) in the mitochondrial matrix, and the 
voltage-gated anion channel (VDAC) in the outer mitochondrial membrane 
[51]. Other proteins, such as the peripheral benzodiazepine receptor (PBR), 
hexokinase (HK) and creatine kinase (CK), might also be associated with the 
mPTP.  
Although the physiological role of mPTP is incompletely understood, it 
is centrally involved in mitochondrial dysfunction. Under conditions such as 
increased intracellular calcium, high oxidative stress, ATP depletion, and 
mitochondrial depolarization, the complex forms an open pore, resulting in 
influx or increased permeability of solutes with molecular masses up to 1.5 
kDa. This eventually leads to mitochondrial matrix swelling, membrane 
rupture and release of pro-apoptotic or pro-inflammatory proteins such as 
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During myocardial ischaemia, the accumulation of lactic acid inducing 
an acidic environment exerts a strong inhibitory effect on mPTP opening, 
despite an accumulation of intracellular calcium and oxidative stress 
mediators. During reperfusion, the rapid washout of lactic acid, restoration of 
cellular pH in the presence of increased reactive oxygen species release and 
re-activation of ion-transporters lead to the opening of mPTP, contributing to 
ischaemia-reperfusion injury [53].  
While investigating the mechanism of nephrotoxicity caused by 
cyclosporine on mitochondria, Crompton and colleagues found that 
cyclosporine inhibited the opening of mPTP and reduced calcium efflux [54]. 
Since then, many studies used cyclosporine as an investigative tool, and 
continued to investigate the pharmacological modulation of mPTP on various 
areas. This include the reduction of ischaemic-reperfusion injury [53], 
restoration of spontaneous circulation post cardiac arrest [55,56] or reduction 
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Modified and adapted from reference [58]. The opening of the mPTP ultimately 
results in mitochondrial swelling, mitochondrial Ca2+ efflux and the release of 
apoptotic proteins, such as cytochrome c and procaspases.  
Abbreviations: ∆ψm = mitochondrial membrane potential; BAX = BCL2-associated 
X protein; ROS = reactive oxygen species; PBR = peripheral benzodiazepine 
receptor; VDAC = voltage-dependent anion channel; HK = hexokinase; ANT= 
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1.2 Disordered myocardial energetics and cardiovascular 
disease states 
 
1.2.1 Redox stress and the mitochondria 
 
Cytoplasmic generation of reactive oxygen species (ROS) reflects activity of 
NADPH oxidase, xanthine oxidase, uncoupled (endothelial) nitric oxide synthase, 
lipoxygenase and cytochrome P450 monoxygenase. However, mitochondrial 
oxidative phosphorylation accounts for substantial ROS generation [59,60]. 
Monocytes and neutrophils also use myeloperoxidases to produce ROS, which 
affect neighbouring cells upon their release. The range of ROS includes the 
hydroxyl radical (OH●), superoxide (O2-), hydrogen peroxide (H2O2), hypochlorous 
acid (HOCl-) [60]. Furthermore, ROS frequently generate reactive nitrogen species 
(RNS): nitric oxide (NO●) reacts particularly with O2- to generate peroxynitrite 
(ONOO-), which is relatively cell-permeable, and causes lipid peroxidation and 
protein modification [59].  
Under physiological conditions, ROS/RNS production is generally 
counterbalanced by clearance via the cellular antioxidant defense systems. The 
usually resultant low steady-state level of ROS/RNS serves to exert physiological 
functions, including acting as signaling molecules involving in cell growth, host 
defence, inflammation or oxygen sensing [59,61]. In particular, low levels of H2O2 
are known to activate elements of protective signaling pathways, such as 
phosphatidylinositol-3-kinase, protein kinase C, or mitogen activated protein 
kinase [59]. However, under many pathological conditions (such as aging, 
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accumulation of ROS/RNS and causes nonspecific oxidative/nitrosative damage to 
DNA, proteins, lipids or other macromolecules [59].  
There are many studies suggesting a potential association between the 
level of ROS/RNS and the integrity of mitochondrial function. Under physiological 
settings, mitochondria undergo continuous changes in morphology and size, 
including fusion and fission [62]. A healthy balance between mitochondrial fusion 
(joining ≥ 2 mitochondria to form one mitochondrion) and mitochondrial fission 
(splitting one mitochondrion into ≥ 2 mitochondria) is required to maintain overall 
cellular homeostasis [63]. Although this may be cell or tissue-dependent, several 
of the core proteins (for example, dynamin related protein-1, or Drp1) and 
participating proteins that are involved in the mitochondrial fusion/fission process 
contain redox-sensitive motifs, therefore subjecting themselves to potential post-
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1.2.2 Role of energetic “sinks” 
 
The physiological roles of the various uncoupling proteins have been 
described in Chapter 1.1.4.1: these represent significant mechanisms for control of 
high energy phosphate generation. Recently attention has been directed to the 
role of poly(ADP-ribose) polymerase (PARP).  
Peroxynitritre (generated from the reaction between nitric oxide and 
superoxide) is a key trigger for DNA single strand breakage and the subsequent 
poly(ADP-ribose) polymerase (PARP) activation. Overactivation of PARP during 
stressful condition will lead to the depletion of its substrate NAD+, slowing the rate 
of glycolysis, ATP formation and eventual cell death (see Figure 1-VII) [61].  
PARPs are predominantly nuclear enzymes that are involved in cellular 
stress responses, both as sensors of cellular damage and as participants in stress 
response. Human PARPs comprise of a family of 17 enzymes that share common 
catalytic domain, but the majority (85-90%) of these is PARP-1, and the remainder 
is predominantly PARP-2. Activated PARPs cleave NAD+ into nicotinamide and 
ADP-ribose [64]. This process depletes NAD+ to 10-20% of its normal levels within 
minutes upon DNA damage, forces the cell to synthesize NAD+ using salvage 
pathways in attempt to maintain viability. These salvage pathways, however, are 
ATP-consuming. Therefore, persistent PARP activation will ultimately result in ATP 
depletion, creating a “vicious” feedback loop that jeopardizes cell survival [64]. 
Additionally, reduced NAD+ will also impair glycolysis, where NAD+ is a major 
cofactor. This leads to reduced glycolysis-derived metabolite that feeds into the 
mitochondrial tricarboxylic acid cycle, further compromising overall cellular 
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In animal models, PARP-1-/- and PARP-2-/- animals displayed enhanced 
energy expenditure, increased hypoglycaemic response to insulin, altered 
mitochondrial mRNA expression of genes involved in respiration, uncoupling and 
fatty acid oxidation, but also protection against age- and high fat diet-induced body 
weight gain [66-68]. Perhaps more excitingly, PARP-1-/- mice were resistant to the 
development of streptozocin-induced diabetes while maintaining normal pancreatic 
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Under physiological conditions, nitric oxide activates soluble guanylate cyclase 
and produces cyclic GMP, which exerts a range of cardioprotective effects. 
However, during pathological states, over-activation of PARP leads to depletion of 
NAD+ and ATP.  
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1.2.3 Role of energy sensors  
 
1.2.3.1 AMP-activated protein kinase 
 
The adenosine 5’-monophosphate activated protein kinase (AMPK) is 
a heterodimeric complex containing catalytic α subunits and regulatory β and 
γ subunits [70]. It is activated by an increase in the AMP: ATP or ADP: ATP 
ratios, which occur during metabolically stressful conditions. Its main role, 
upon activation, is to restore metabolic homeostasis by inhibiting ATP-
consuming processes and activating alternate catabolic processes to 
generate ATP [70].  
Upstream kinases that activate AMPK include liver kinase B1 (LKB1), 
calcium/calmodulin-dependent kinase kinase β (CaMKKβ) and transforming 
growth factor-β-activated kinase 1 (Tak1). During metabolic stress, LKB1 is 
the predominant activator of AMPK [71].  
The γ subunit of AMPK contains four nucleotide-binding sites, which 
allow the competitive binding of AMP, ADP or ATP. During metabolic 
stressful conditions, the increased AMP or ADP replaces ATP and binds to 
AMPK. Such binding exchange leads to an activation of AMPK, which 
phosphorylates downstream targets and regulates a range of catabolic 








Chapter 1: Introduction 
 
 
Page | 33 
 
Figure 1-VIII Activation of AMPK and its downstream signaling. 
 
 
Adapted from reference [72].  
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One of these processes is to translocate glucose transporter-4 from 
intracellular vesicles to the plasma membrane, promoting insulin release (in 
pancreatic β-cells) and subsequent muscular glucose uptake [73,74]. In cells 
that express only glucose transporter-1 which are already expressed at the 
plasma membrane (i.e. most cells except those in muscle, liver and adipose 
tissue), activated AMPK also promotes glucose uptake to generate ATP. 
Moreover, AMPK can also promote the translocation of the fatty acid 
transporter to the plasma membrane to facilitate fatty acid uptake [74].  
Other important processes activated by AMPK include mitochondrial 
biogenesis, which generates increased capacity for the oxidative catabolism 
of both glucose and fatty acids in the longer term. AMPK directly activates 
peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α), the 
direct regulator of mitochondrial biogenesis and a co-activator that increases 
the activity of several transcription factors acting on nuclear-encoded 
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Sirtuins, a family of conserved NAD+-dependent protein deacetylase, 
play a crucial role in a variety of cellular process, including energy 
metabolism, stress response to tumorigenesis and aging [75]. As protein 
deacetylases, sirtuins have a broad range of substrates, and are able to 
shuttle form cytosol to nucleus in response to certain environmental stimuli. 
The expression of SIRT1 (one of the sirtuins) is closely controlled by a 
number of factors that alter the cellular NAD+ availability, such as a low-
energy environment (e.g. fasting and exercise) that can increase NAD+ [75]. 
It is known to control key aspects of fat and glucose metabolism by 
influencing several transcription factors involved in cardiac energy turnover, 
for example PGC-1α, a transcriptional cofactor involved in fatty acid/glucose 
metabolism and mitochondrial biogenesis [76]. Additionally, it has also been 
previously shown that the deletion or inhibition of PARP-1 elevates NAD+ 
levels and promotes the activity of SIRT-1 [67,77]. The major roles of PARP-
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Sirtuins and PARP are both competitive NAD+-consuming enzymes. One of the 
target proteins of SIRT-1 is PGC-1α, which is activated upon deacetylation 
coactivates a number of mitochondrial genes. AMPK also activates and 
phosphorylates PGC-1α. 
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1.2.4 Inflammatory activation and disordered energetics 
 
As previously stated, redox signals to and from mitochondria are central to 
a number of biological processes, including cell proliferation, differentiation, 
adaptation to hypoxia, autophagy, immune function, hormone signaling, and 
overall cell survival.   
Inflammation, occurring in the vasculature often as a response to injury, 
lipid peroxidation, and perhaps infection, has recently been found to be associated 
with a range of cardiovascular risk factors. These include diabetes, hypertension 
and hypercholesterolaemia. Chronic inflammatory activation not only is linked to 
increased potential for vulnerable "plaques", being prone to plaque rupture and 
thereby thrombosis, but also diabetes and metabolic syndrome [78].  
A recent study aimed to explore the possible association of high-sensitive 
C-reactive protein (hs-CRP) expression in otherwise healthy individuals with 
metabolic syndrome. Fourteen thousand apparently healthy women,  
approximately a quarter of whom had metabolic syndrome, were followed up for 
about an 8-year period for major cardiovascular events (myocardial infarction, 
stroke, cardiovascular death, and coronary revascularization). It was found that at 
all levels of metabolic syndrome, CRP improved risk prediction for future 
cardiovascular events [79]. Additionally, CRP also predicted the onset of type 2 
diabetes [80].  
Many inflammatory stimuli also are linked to energetic depletion. One such 
example is thioredoxin-interacting protein (TXNIP), an intracellular protein that 
exerts its biological effect partially via inhibition of the anti-oxidant thioredoxin 
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a number of clinical conditions such as diabetes mellitus and myocardial infarction. 
Many of the effects of TXNIP including Trx-independent actions [81] are initiated 
by its dissociation from intra-nuclear binding with Trx or other SH-containing 
proteins or PARP-1: these effects include migration of TXNIP to cytoplasm, 
modulating stress responses and potentially activating apoptotic pathways [82] 
(see Figure 1-X for further schematic display of increased TXNIP expression).  
TXNIP also functions as a general metabolic sensor and modulator of 
cellular energetics, a stimulus for abnormal calcification, with impact as an immune 
modulator and vascular mechanosensor (Table 1 provided an overview of major 
pathophysiological effects of TXNIP relevant to cardiovascular disease). Finally, 
TXNIP has recently been shown to be a principal activator of the nucleotide-
binding oligomerization domain-like receptors pyrin domain-containing 3 (NLRP3) 
inflammasome [83,84], which modulates innate immune function by regulating 
maturation and secretion of pro-inflammatory cytokines The pathophysiology of 
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Figure 1-X: Schematic representation of the impact of increased TXNIP 




Published in reference [81].  
Abbreviations: ASK1 = Apoptosis signaling kinase; Nrf = Nuclear receptor factor; 
TNF = Tumour necrotic factor; IL = interleukin; MAPK-JNK = mitogen activated 
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Table 1-I: Major pathophysiological effects of TXNIP relevant to 




Regulation of hypertrophy 
Activation of apoptosis/ ischaemia-reperfusion injury 
Pro-inflammatory effect in myocardium and valves 
Modulation of myocardial metabolism 
 
2. Vascular 
Suppression of angiogenesis/ interaction with VEGF 
Induction of inflammation with non-laminar flow 
?Pro-atherogenesis 
?Suppression of NO effect 
 
3. Platelet 
?Suppression of NO effect  
 
Published in reference [81].  
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1.2.5 Diabetes mellitus, heart failure and myocardial ischaemia as disorders 
of cardiac energetics 
 
Pancreatic islet β-cell dysfunction, associated with potential impairment of 
appropriate insulin secretion and signaling, has the ultimate outcome of diabetes, 
with exogenous insulin-dependence. In health, following post-prandial 
hyperglycaemia, β-cells secrete insulin [via generation of mitochondrial adenosine 
triphosphate (ATP)] for the closure of the ATP-sensitive KATP channel, leading to 
the influx of Ca2+, and the ultimate exocytosis of insulin [85]. Any form of 
dysfunctional mitochondria (for example, defective "fuel-sensing", reduction in 
mitochondrial mass, or reduction in the ability to generate ATP) contributes to 
deterioration of not only β-cell function and glucose control, but also increases the 
adverse effects of hyperglycaemia on other organs [85]. Therefore, interventions 
to improve mitochondrial energy pathways might also engender protection against 
organ failure in diabetics. Indeed, it has been shown that exercise [86] and/or 
metformin [87], which improve efficiency of ATP generation, also offer benefits of 
reduced morbidity and mortality in T2DM.  
In 1996, Nascimben et al demonstrated, in biopsies of human hearts 
obtained during surgery, that there was an approximately 30% reduction of ATP 
concentrations in patients with systolic heart failure (HF) [39]. Additionally, many 
human inborn errors of metabolic deficiencies (e.g. Leigh’s syndrome, systemic 
carnitine deficiency) often co-exist with HF. Subsequent studies also demonstrated 
that, compared to left ventricular ejection fraction and New York Heart Association 
functional class, cardiac energetic status is a better predictor of both total and 
cardiovascular mortality in patients with HF [88]. The hyperadrenergic state of HF 
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not only uncouple mitochondrial respiration, but also diminish the efficiency of 
contraction (that is, ATP generation per unit oxygen consumption) of the heart. 
Additionally, increases in free fatty acid concentrations also decrease glycolysis, 
which further diminishes efficiency (see Figure 1-XI). Overall, such a metabolic 
“vicious cycle” argues in favour of a metabolic approach to the treatment of HF. 
Intriguingly, many of these homeostatic anomalies are also present in diabetics, 
affecting the efficiency of the heart and predisposing to HF symptoms.   
 




Abbreviations: SNS = sympathetic nervous system; RAS = renin angiotensin 
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A similar “metabolic vicious cycle” has also been described in the early 
phase of acute coronary syndrome (ACS). High plasma free fatty acid levels have 
been found in patients with acute myocardial ischaemia (MI) within 30 minutes of 
the onset of chest pain. Such levels of free fatty acid could be reduced by glucose-
insulin-potassium (GIK) [89]. Additionally, in 1972, Braunwald’s group found that in 
dogs, GIK infusions commenced 30 minutes after experimental coronary occlusion 
had a protective effect against ischemia and reduced myocardial necrosis [90]. 
Several other animal studies also confirmed the presence of metabolic dysfunction 
during the early stage of MI and the benefits of metabolic manipulation by GIK in 
the reduction of oxygen wastage and the prevention of cardiac remodeling 
[35,91,92]. 
However, the translation of GIK (or components thereof affecting metabolic 
manipulation) during MI from animal to human clinical studies has been largely 
unsuccessful, with the possible exception when used chronic ischaemic LV 
dysfunction in the viable myocardium, as assessed by dobutamine 
echocardiography [93], or of the recent IMMEDIATE [94] trial. Howell et al also 
reported that perioperative GIK improved haemodynamic stability in high-risk 
patients undergoing aortic valve replacement, with an associated increase in 
AMPK phosphorylation within the myocardium [95]. It has been proposed that 
timing and metabolism have been the critical factors contributing to the results 
[96]:  much of the clinical applications of GIK reported commencement at variable 
time post onset of symptoms, by which time myocardial ischaemia could have 
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1.3 Physiological consequences of energetic impairment  
 
“The failing heart – an engine out of fuel.” 
S. Neubauer, NEJM, 2007. 
 
1.3.1 Disordered inotropic state and energetic state 
 
The physiological performance of the heart is regulated primarily by 
variations in the contractile force developed by individual myocardial fibres, based 
largely on the Frank-Starling principle. In the heart, the majority of ATP formed 
during mitochondrial oxidative phosphorylation is used for the mechanical 
contraction, while a minority is used in the maintenance of other aspects of cellular 
homeostasis, for example modifying substrates, producing glycogen, synthesizing 
lipids or proteins, and maintaining the integrity of cellular membranes [97]. Any 
mismatch or “uncoupling” between ATP demand and generation is likely to lead to 
an impairment of cardiac function. Although the mechanosensory effects occur 
within single cells, it is known that such effects can also affect neighbouring cells 
or even the entire organ’s function, perhaps via transmission to the cytoskeleton or 
an alteration in the duration of action potential. ATP is an important immediate 
energy source for the interaction between actin and myosin (thus promoting 
myocardial contraction), and is rapidly replenished by the hydrolysis of creatine 
phosphate [98].  
It has previously been shown that inborn errors of metabolism (such as 
Leigh’s syndrome, malonyl carboxylase deficiency) lead to congestive 
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of the heart (for example, during heart failure) potentially leads to dysregulation of 
substrate metabolism and an eventual “vicious cycle” of metabolic dysfunction.  
Recently, epidemiological studies showed that diabetes mellitus (a disease 
characterized by metabolic and mitochondrial dysfunction), increases the 
incidence of heart failure by 2.5-fold, independent of age or concomitant 
hypertension, obesity, dyslipidaemia or coronary heart disease [99,100]. Previous 
studies showed that diastolic dysfunction occurs in 50-75% of asymptomatic, 
normotensive diabetic patients with preserved left ventricular ejection fraction and 
no known coronary disease [101-103], when ejection fraction was used as the 
measure of cardiac function. Nowadays, detection of subclinical dysfunction is 
made available via the use of echocardiographic strain imaging or cardiac 
magnetic resonance, with reduced longitudinal contractility and impaired systolic 
circumferential strain in patients with diabetes [104,105]. Additionally, it has 
become possible to assess the impact of both diabetes and heart failure on 
myocardial energetics in vivo using phosphorus magnetic resonance spectroscopy 
(MRS). A study in apparently uncomplicated type 1 diabetes was associated with 
impaired myocardial phosphocreatine to ATP equilibrium as measured by MRS 
[106].   
 
1.3.2 Perpetuation of redox stress 
 
During the initial insult causing redox stress, physiological compensation 
occurs towards restoring homeostasis. However, such homeostatic response is 
often inadequate during pathological conditions, leading to a self-perpetuating 
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“metabolic vicious cycle” as mentioned in Chapter 1.2.5). For example, in atrial 
fibrillation (the most common form of arrhythmia) [107,108], myocardial ischaemia 
[109], and stress cardiomyopathy (or known as Takotsubo cardiomyopathy) 
[110,111], inflammatory activation persists beyond the initial insult and appears to 
contribute to the gravity of the resultant clinical syndromes. For example, in the 
case of coronary disease, a reduction in coronary perfusion leads to a deprivation 
of blood flow that first affects the subendocardium. Histological findings of fibrosis 
and vacuolization in this area together with ATP depletion provide evidence that 
such culmination of events often leads to the gradual loss of subendocardium 
[109].  
While perpetuation of redox stress may occur as a result of the loss of 
balance between compensatory and the "insulting" mechanisms, another 
possibility is a paradoxical effect of the "compensatory" hormone(s) contributing to 
this perpetuation. For example, natriuretic peptide, a "compensatory" hormone 
upregulated in the setting of heart failure, which acts by increasing intracellular 
cyclic GMP, is theoretically "protective" through smooth muscle relaxation and 
vasodilation. In 2012, Chan and colleagues [112] found that in isolated hearts, 
natriuretic peptides and other cell-permeable cyclic GMP analogues cause 
catecholamine exocytosis. Such a proadrenergic action may have counteracted 
any potential protective effect of natriuretic peptide, providing an explanation for 
not only the self-perpetuating redox stress process in heart failure but also for the 
loss of beneficial effect of natriuretic peptide analogues in the treatment of heart 
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1.4 Measurement of energetic impairment and its determinants 
 
1.4.1 Experimental  
 
Myocardial energetic status can be assessed by measuring the various 
components of energy metabolism in the heart, utilizing standard methods in 
myocardial specimens obtained by a biopsy or tissue collection from animals. 
However, due to the instability of the molecules, the measurement of ATP and 
phosphocreatine is challenging, requiring care to minimize ex vivo degradation.  
Under conditions of high energy phosphate depletion, for example 
associated with increased demand within the myocardium, repletion of ATP can 
occur approximately 100 times faster than that of phosphocreatine; hence 
phosphocreatine to ATP ratios tend to fall [1]. 
 
1.4.2 Clinical  
 
Clinically, the assessment of cardiac energy status can be performed in a 
number of ways, for example via determination of the ratio of phosphocreatine to 
ATP non-invasively utilizing cardiac phosphorus-31 magnetic resonance 
spectroscopy (31P-MRS) [1]. 31P-MRS yields peaks for phosphocreatine and the 
three phosphorus atoms of ATP, all of which are proportional to the cellular 
concentrations of these metabolites. The system also provides potential 
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The ratio of phosphocreatine to ATP has been found to correlate well with 
New York Heart Association (NYHA) functional class and indices of systolic and 
diastolic dysfunction [115]. In a study of 39 patients with dilated cardiomyopathy, 
PCr: ATP ratio was found to be a stronger predictor than functional (NYHA class) 
or clinical indices of systolic function of both total mortality and mortality rates 
attributable to cardiovascular diseases [88].  
The measurement of intracellular and compartmental ATP, especially the 
availability of ATP at the sarcoplasmic reticulum or ion channels, instead of 
average cellular level of ATP, should theoretically provide better insight into the 
energetic status. However, no currently available method is able to make such 
subcellular measurements.  
A method for the assessment of consequences of cardiac energetic status 
is to determine the cardiac mechanical efficiency:- the ratio of useful energy 
produced (or, stroke work) to oxygen consumed. This can be achieved invasively 
via coronary catheterization or non-invasively via positron emission tomography 
[116,117]. The former is considered the "gold standard": it measures cardiac work 
relative to myocardial oxygen consumption (MVO2) and correlates with high-fidelity 
catheter-derived pressure-volume loops as indices of changes in LV contractility 
and stiffness. This method is invasive, unable to assess compartmental (rather 
than global) oxygen consumption and the needs to correct for LV mass to 
calculate oxidative metabolism per gram of tissue. It is more suitable for assessing 
changes in energetic status than for single estimates per patient [116,117].  
The latter non-invasive assessment of mechanical efficiency by positron 
emission tomography is a little less straight-forward. The input energy is assessed 
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carbon-11-labelled acetate (11C-acetate) to assess oxidative phosphorylation via 
TCA cycle and (2) oxygen-15-labelled-water and oxygen-15-labelled-carbon 
monoxide produced after inhalation of oxygen-15-labelled molecular oxygen. The 
combination of all the radio-labelled products allows the quantification of 
myocardial blood flow and oxygen extraction fraction and therefore the subsequent 
measurement of MVO2. The output energy is measured as end-systolic LV 
pressured derived either by magnetic resonance imaging or echocardiography. 
Overall, this methodology is not only a semiquantitative index of oxidative 
metabolism and likely subject to observer variability, but also the correlation of the 
metabolic fate of 11C-acetate to oxidative metabolism is also highly subject to 





Chapter 1: Introduction 
 
 
Page | 51 
 
1.5 Scope of the present study 
 
The current thesis aims at exploring the mechanisms of effect and safety of 
long-term treatment with perhexiline, its enantiomers, and other aspects of 
myocardial energetic therapeutics. See Figure 1-XIII for schematic representation 
of experimental design.  
Chapter 2 discusses the current pharmacological aspects of modulating 
myocardial metabolism; including the modulation of long chain fatty acids, 
mitohondrial protective agents and the metabolic "sensors" AMPK activators. 
Other agents discussed include insulin and the impact of its signaling pathway, 
which affects not only metabolism but also cell signaling, inflammation and platelet 
aggregability. TXNIP, of which production is mainly stimulated by hyperglycaemia, 
also has adverse effects on inflammation and apoptosis and its expression is 
affected by a number of pharmacological agents used either clinically or under 
investigation. Lastly, the history of use and development of perhexiline, its 
mechanisms of actions, and the recent development are discussed.   
Chapter 3 investigates the current status of chronic use of perhexiline in 
170 patients, during the modern era of regular therapeutic drug monitoring. Apart 
from investigating the incidence of serious adverse effects in patients taking long-
term perhexiline, determinants of mortality events in this cohort of ageing 
population are also reported.  
Chapter 4 describes the modulation of pharmacokinetics and its relationship 
with effects are reported in patients treated with short-term perhexiline (for an 
average of 9 days) prior to coronary bypass surgery. During bypass, biopsies of 
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plasma and myocardial perhexiline (enantiomer) concentrations, and the 
modulation of myocardial uptake are described.   
Chapter 5 investigates the relationship between oxidative stress, insulin 
sensitization, nitric oxide signaling and therapeutic approaches to improved 
myocardial efficiency. This chapter begins with the investigation of the 
mechanism(s) of benefits associated with rapidly correct hyperglycaemia in the 
presence of acute coronary syndrome using insulin infusion, an effect potentially 
reflecting the benefit of myocardial metabolic intervention.  
In a further cohort of patients (Chapter 6), the interaction between 
perhexiline, TXNIP and insulin sensitivity is explored via an investigation of the 
potential insulin sensitizing effect of perhexiline in thirty stable diabetic patients. 
Plasma samples were collected before and after two weeks of perhexiline 
administration. Association of biochemical correlates are reported.  
Chapter 7 compares the effects of various myocardial drugs modifying 
myocardial energetics on activity of CPT-1 in myocardium, focusing on the 
enantiomers of perhexiline as well as analogues of perhexiline currently in 
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Insulin is synthesized, packaged and secreted by the pancreatic β-cells. 
The action of insulin is initiated via binding to the heterodimeric insulin receptor on 
the cell surface of target cells. Insulin receptors are composed of two α-subunits 
(insulin-binding) and two intracellular β-subunits (signal transduction domains). 
The binding of insulin to the receptor results in conformational change of the α-
subunits, which enables the subsequent binding of ATP to the intracellular β-
subunits. ATP binding leads to the phosphorylation of the receptor, which then in 
turn phosphorylates other protein substrates such as insulin-receptor substrate 1 
and 2 [118,119]. The signal is then further propagated through a network of 
phosphorylation that involves other intracellular substances.  
These signaling pathways enable insulin to act as an important regulator of 
metabolic function. Importantly, insulin-receptor activation of the mitogen-activated 
protein (MAP) kinase pathway has been implicated in the insulin’s effects on 
vasoconstriction, growth and proliferation [119].  
Insulin receptors are widely represented on the surface of cells lining the 
vascular walls. Apart from the above, the activation of insulin receptor substrate 
leads to the activation of the phosphatidylinositol 3-kinase-Akt pathway, which 
eventually activates the endothelial nitric oxide synthase [120]. Additionally, insulin 
also stimulates the production of prostaglandin PGI2 from vascular endothelium 
[121], which, together with nitric oxide produced via eNOS, plays a role in 
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than vasodilation; it also inhibits platelet aggregation, reduces vascular smooth 
muscle cell proliferation, and reduces the adhesion of inflammatory cells [120,123] 
(see Figure 2-I). 
 
 
Figure 2-I Effects of insulin: molecular mechanisms 
 
 
Adapted from reference [120].  
Abbreviations: IRS = Insulin receptor substrate; PI3K-Akt = Phophatidylinositol-3-
kinase and protein kinase B; eNOS = endothelial nitric oxide synthase; VSMC = 
vascular smooth muscle cell; MAPK = mitogen activated protein kinase; ET-1 = 
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2.1.2 AMPK activators 
 
AMPK, a "universal sensor" of energy status, plays a key role in the 
regulation of whole body metabolic homeostasis. Many classical agonists activate 
AMPK indirectly by altering the AMP/ADP:ATP balance intracellularly. Such drugs, 
for example the biguanides metformin and phenformin, act by inhibiting the 
electron transport chain complex I. Other drugs such as 5-aminoimidazole-4-
carboxamide-1-D-ribo-furanoside (AICAR) inhibit adenosine deaminase causing 
an increase in ATP and adenosine concentrations.  
Metformin, as a classical AMPK activator, is one of the most widely 
prescribed anti-diabetic agents, which reduces cardiovascular mortality in type 2 
diabetic patients [87] . It has been in clinical use for more than 50 years and is 
weight-neutral (hence beneficial in obese diabetic patients) [124]. Metformin has 
been shown to reduce cardiovascular mortality when compared to non-intensive 
treatment [87] and  more recently, to induce a potential reduction in cancer 
incidence in most [125-127], but not all [128] studies. Apart from its effect on the 
reduction of gluconeogenesis [129], metformin also inhibits mitochondrial complex 
1 [130], and has been shown to reduce reactive oxygen species [131] and 
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2.1.3 TXNIP: Impact on energetics and modulation of expression  
 
Thioredoxin interacting protein (TXNIP), also known as vitamin D-
upregulated protein, may be regarded partially as a component of the thioredoxin 
system, which also consists of thioredoxin (Trx), nicotinamide adenine dinucleotide 
phosphate (NADPH) and thioredoxin reductase (Trx). TXNIP inhibits Trx, and this 
effect has been demonstrated in diabetes and cardiovascular diseases. However,  
TXNIP effects are also partially Trx-independent, and these include direct 
activation and inhibition of glucose uptake.  
The potential involvement of TXNIP in cardiovascular or non-cardiovascular 
pathological processes is central to its extensive physiological significance. In 
particular, TXNIP activates inflammation (by antagonizing the antioxidant 
transcription factor nuclear factor erythroid factor-2 related factor 2 [133], produces 
superoxide [134], and activates the NLRP3 inflammasome to produce interleukin-
1β  [135])  and activates apoptotic signaling pathways [136]. In addition, TXNIP 
also interferes with nitric oxide signaling [137,138], potentially via augmentation of 
superoxide production. Such effects are potentially critical to survival rates of both 
β-cell and cardiomyocytes.    
In 2002, TXNIP was discovered to be the most upregulated gene in 
response to elevation of tissue glucose concentrations in human islet 
oligonucleotide gene expression microarray study [139]. This suggested that 
TXNIP is potentially implicated in the pathogenesis of diabetes. TXNIP-related 
activation of inflammasome has been shown to induce inflammation and 
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in the pathogenesis of diabetic cardiomyopathy [83,141], and shown to mediate 
renal fibrosis [142].  
TXNIP is known to reside mainly in the nucleus. In 2010, Saxena and 
colleagues found that TXNIP “shuttles” from nucleus to mitochondria under 
oxidative stress [143]. It was found that such “shuttling” allowed TXNIP to bind to 
and oxidize Trx2, therefore allowing ASK1 phosphorylation/activation, leading to 
induction of mitochondrial apoptosis with release of cytochrome c and caspase-3 
cleavage [143]. In another study of TXNIP knock-out mice, TXNIP deletion led to 
decreased mitochondrial function and morphological changes [144]. In particular, 
mitochondrial ATP synthesis was decreased by TXNIP deletion, along with a 
reduction in cellular ATP content and an increase in lactate formation [144]. 
Recently, a targeted metabolomics study utilizing TXNIP knock-out mice found 
that TXNIP deficiency is associated with a reduction in enzymes not only required 
for the catabolism of substrates (amino acids, ketones, and lactate), but also those 
required for β-oxidation and the tricarboxylic acid cycle [145]. Therefore the 
available data suggest that TXNIP mobilization may act as an energetic "switch", 
increasing ATP generation.  
The dissociation of TXNIP from its binding protein leads to its accelerated 
clearance. Therefore, a fundamental mechanism for the rapid clearance of TXNIP 
involves the ubiquitination-proteasomal pathway. [146] It has been demonstrated 
that insulin accelerates this process in some tissues [146,147]. Four hours of 
insulin treatment was associated with reduction in TXNIP mRNA expression, and 
was dependent on intact insulin receptor signaling rather than simply a reduction 
in circulating glucose levels. This was supported by the observation that insulin 
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AMPK activation has been shown to accelerate degradation of TXNIP in 
some key experiments. It has been shown that AMPK regulates the 
responsiveness of the carbohydrate-response element binding protein on TXNIP 
promoter gene [148]. Glucose “starvation” in Hep G2 cells resulted in the AMPK-
activation-dependent phosphorylation of TXNIP [149] (a process mimicking the 
pharmacological activation of AMPK). Such a process results in increased 
degradation of TXNIP, resulting in prolonged increases of glucose utilization. 
Other insulin secretogogues like glucagon-like peptide 1 (GLP-1) agonists 
also accelerate TXNIP degradation via similar ubiquination/proteasomal pathway. 
Exenatide, a GLP-1 agonist, reduced levels of pancreatic TXNIP expression in 
vitro, and was found to be associated with an increase in cAMP signaling, 
involving not only protein kinase A but also exchange protein activated by cAMP 
(Epac) singaling [150,151]. 
There is also substantial evidence that the angiotensin converting enzyme 
inhibitor ramipril reduces tissue content of TXNIP. First, in a vitamin D-treated 
rabbit model, aortic valve expression of TXNIP was shown to be increased; 
conversely, ramipril reduced TXNIP content and retarded valvular fibrosis [152]. A 
subsequent human study also showed that two weeks of ramipril treatment in high 
risk acute coronary syndrome patients reduced platelet TXNIP levels, and that this 
effect was associated with improved platelet responsiveness to nitric oxide [138].   
The L-type calcium channel antagonists, verapamil and diltiazem, also 
suppress TXNIP expression. In cultured cardiomyocytes, Chen et al showed that 
verapamil and diltiazem reduced TXNIP transcription and protein expression [153]. 
Futhermore, three weeks of verapamil treatment in streptozocin-treated animals 




Chapter 2: Pharmacological approaches to improve energetics 
 
 
Page | 61 
 
Perhexiline was also recently found to reduce TXNIP expression in non-
diabetic patients awaiting coronary artery bypass surgery [155]. The 
pathophysiological consequences of this change have not been explored to date.  
Figure 2-II provides an overview of the potential site of pharmacological 
modulation of TXNIP expression, including some experimental agents currently 
under investigation.  
Although hyperglycaemia is associated with incremental oxidative stress 
and impaired nitric oxide signaling, as well as poor outcomes in patients with 
concomitant cardiovascular disease, it remains uncertain whether suppression of 
TXNIP plays a major role in the restoration of cardiovascular homeostasis on 
reversal of hyperglycaemia. Additionally, it remains a theoretical [156-158] and 
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Figure 2-II Activation/ inactivation pathways of TXNIP: Potential sites for 
therapeutic manipulations 
 
Published in reference [81]. Blue box or dash line arrows indicate inhibitory effects; 
pink box or solid line arrows indicate stimulatory effects.  
Abbreviations: NO = nitric oxide; Nrf2 = nuclear receptor factor erythroid 2-related 
factor 2; O2- = superoxide; CCBs = calcium channel blockers, ACE-i = angiotensin 
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2.2 Mitochondrial protective agents  
 
Given that mitochondria plays a significant role in the development of a 
number of myocardial and metabolic diseases, this organelle has become a 
potential site of therapeutic target.  
Initial experiments concerned compounds named Szeto-Schiller (SS) 
peptides that selectively target the mitochondrial electron transport chain. These 
were discovered while scientists were working on a synthetic opioid peptide with 
high affinity and selectivity for the µ–opioid receptor [162,163]. The index 
compound in this group, despite a molecular weight of 640 and being highly polar, 
was readily taken up by a variety of cells without involvement of transporters or 
receptors. It was later found out that this compound was selectively partitioned to 
the inner mitochondrial membrane (thus colocalizing with the electron transport 
chain) with minimal concentrations in the matrix. A number of peptide analogues 
were later designed (named SS-31 and SS-20), with negligible affinity for the 
opioid receptors [163], thus presumptive selectivity for mitochondrial metabolic 
effects. 
The selective binding of SS-31 and SS-20 to cardiolipin has been found to 
account for their relative concentration on the inner mitochondrial membrane. 
Cardiolipin, a dimeric phospholipid with small acidic head group and four acyl 
chains, decreases water permeability of the lipid membrane and decreases the 
energy required to create folds or cristae in the inner mitochondrial membrane 
[164]. It is important for cristae formation, and cardiolipin deficiency, such as 
occurrs in Barth syndrome, leads to loss of cristae and mitochondrial failure [163]. 
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associated with reduced efficiency of electron transport, inhibition of oxidative 
phosphorylation and increased leakage of reactive oxygen species [165,166]. This 
attenuation also plays a role in a number of pathological conditions, such as 
ischaemia-reperfusion injury, heart failure [164], diabetes [167], and cancer 
cachexia [168].  
SS-31, also known as Bendavia or MTP-131, has now entered into clinical 
trial development for a variety of complex diseases. First, the administration of 
Bendavia in a number of animal models of ishcaemia-reperfusion injury led to 
reduced infarct size and reduced cellular levels of reactive oxygen species 
[169,170]. In a canine model of heart failure induced by repeated intracoronary 
embolizations, daily administration of Bendavia for three months was associated 
with contractile improvement (left ventricular ejection fraction, cardiac output, 
stroke volume, and contractility index) without affecting vasomotor tones, and 
improvement in mitochondrial potential and increased ATP synthesis [171-173].  
A subsequent randomized, double blinded, placebo-controlled trial 
(EMBRACE STEMI) for patients with first-time anterior STEMI undergoing primary 
percutaneous coronary intervention has been recently completed (NCT01572909) 
[174]. Patients were randomized to receive MTP-131 at 0.05mg/kg/hour or 
placebo as an intravenous infusion. The primary endpoint of the study was infarct 
size, as measured by both creatine kinase release and cardiac magnetic 
resonance imaging with gadolinium enhancement [174]. Data from the phase 2a of 
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2.3 Agents modulating long-chain fatty acid uptake or utilization  
 
Perhexiline (to be discussed in detail in Chapter 2.4) is (inter alia) an 
inhibitor of the rate-limiting enzyme of fatty acid oxidation, carnitine palmitoyl 
transferase (CPT)-1, and to a lesser extent CPT-2 [176].  
Etomoxir is another inhibitor of CPT-1 [177], which was initially developed 
as a potential insulin sensitizer. It was shown to improve left ventricular ejection 
fraction and exercise haemodynamics in patients with chronic heart failure [178]. 
In a model of transverse aortic constriction, etomoxir also limited the extent of 
resultant left ventricular hypertrophy, an effect of potential interest in the context of 
the current use of perhexiline in hypertrophic cardiomyopathy [179]. However, 
there was also substantial toxicity. In some models of heart failure, etomoxir 
increased left ventricular wall thickness, although it is unclear whether this 
represented hypertrophy, oedema or infiltration [180-184].  
Oxfenicine, another irreversible CPT-1 inhibitor, also retards the 
development of heart failure in a canine rapid pacing model [185]. However, when 
given in higher doses for prolonged periods of time, it also caused what was 
labeled as “hypertrophy” of the heart, but actually represented cardiac 
phospholipidosis [186].  
Trimetazidine inhibits the intramitochondrial enzyme long-chain 3 ketoacyl 
CoA thiolase, causing a reduction in fatty acid oxidation and increasing glucose 
oxidation [34]. Thus it can be termed a partial fatty acid oxidation inhibitor, but it 
also is a weak CPT-1 inhibitor [187]. It improved cardiac energetic status (as 
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fluorodeoxyglucose positron emission tomography [189]) in patients with non-
ischaemic systolic dysfunction [188,189] and was shown to be effective as an add-
on therapy to heart failure management [190]. This was also confirmed in a recent 
meta-analysis of randomized controlled trials (with a total of 326 patients) showing 
that trimetazidine as an add-on therapy reduced all-cause mortality and increased 
event-free survival time in patients with systolic heart failure [191]. Interestingly, 
little effect on cardiac fatty acid uptake was observed, despite a significant 
reduction in fatty acid utilization from intracellular stores [189]. Additionally, in the 
trial comparing trimetazidine with placebo as an “add-on” therapy for heart failure, 
there was an increase in the intraventricular septal thickness in patients taking 
trimetazidine after approximately 6 months of therapy (from 8.5 ± 2.0 to 10 ± 1.4 in 
the trimetazidine group versus 8.4 ± 1.1 to 8.4 ± 0.5 in the placebo group; 
p<0.002) [189]. This process has not yet been evaluated fully, but resembles the 
effects of oxfenicine.  
Given such similar findings (albeit in animal studies) involving etomoxir and 
oxfenicine, this was an unexpected, and potentially undesirable consequence of 
heart failure treatment even though it is uncertain whether this represents 
phospholipidosis. Currently, the use of trimetazidine is diminishing, largely due to 
associated reports of Parkinsonism syndrome [192-194].  
Ranolazine is an effective prophylactic antianginal. It is also a partial 
inhibitor of fatty acid β-oxidation [195]. However, this may not be its principal 
mechanism of action under therapeutic conditions. Recently, ranolazine has also 
been shown to be an inhibitor of the late inward sodium channel, reducing 
intracellular calcium (via the sodium calcium exchange channel), and reducing the 
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effects have been demonstrated [197], no clinical studies to date have evaluated 
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Around 1960, Richardson-Merrell Pharmaceuticals (Cincinnatti, USA) 
attempted to develop novel vasodilator anti-anginal agents. Hexadiline and 
prenylamine, both structurally similar to perhexiline, were developed prior to the 
development of perhexiline (see Figure 2-III for structures). Hexadiline has never 
been used clinically:- its role is limited to serving as an internal standard to the 
chromatography assay of perhexiline [198] or other laboratory purposes. 
Prenylamine, on the other hand, was used once as an anti-anginal [199]. 
However, it was pro-arrhythmic [200,201] and as such, its indication for angina 
treatment diminished over time after being replaced by other safer agents. Its use 
has recently been resurrected as a potential local anaesthetic. It was 
demonstrated that prenylamine is metabolized to amphetamine in vivo [202].   
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Perhexiline was first marketed in France in the 1970s as a prophylactic 
antianginal. It was an extremely effective antianginal given as monotherapy, 
typically in doses of 200 to 400mg per day [203,204]. However, in the late 1970s, 
several reports of hepatotoxicity and peripheral neurotoxicity appeared: these 
were poorly understood at that time, but led to the gradual withdrawal of the drug 
worldwide in the 1980s, except in Australia and New Zealand.  
Through continual research to better understanding of the cellular 
mechanisms of the drug and careful plasma drug concentration monitoring, the 
drug now is regarded as potentially conferring great benefits to patients with 
refractory angina. Perhexiline has been re-registered in several European 
countries, due to favorable clinical trials (to be discussed later), and has also very 
recently approved by the Food and Drug Administration (United States of America) 
for development in the treatment of non-obstructive hypertrophic cardiomyopathy 
(NCT02431221).  
 
2.4.2 Mechanistic insights 
 
In 1980, Vaughan Williams [205] first proposed that perhexiline's 
mechanisms of action might be based upon changes in myocardial metabolism, 
but did not identify the specific changes involved. Jeffrey et al [206] also provided 
evidence that perhexiline might increase efficiency of myocardial oxygen 
utilisation, consistent with the presence of such an effect. However, only in 1996 
after perhexiline had been utilized clinically as an anti-anginal for over 20 years, 
was it found that it was a potent inhibitor of the carnitine "shuttle", which transports 
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[176]. Inhibition of the enzymes CPT-1, and to a lesser extent, CPT-2 [187] would 
result in secondary activation of glucose utilization via increased activity of the 
pyruvate dehydrogenase complex, a process which is a component of the so-
called "Randle cycle". This metabolic shift results in increased glucose utilization, 
and ATP production per unit of oxygen consumption. 
In 2005, Unger and colleagues found that in isolated non-ischaemic working 
rat hearts, pretreatment with perhexiline increased cardiac efficiency by about 
30%. However, this effect was independent of palmitate oxidation [207]. This was 
the first evidence to suggest that perhexiline may exert effects beyond CPT-1 
inhibition, and it is quite possible that these contribute to both its therapeutic 
efficacy and potential toxicity. 
Indeed, it was subsequently found that perhexiline inhibited the 
preassembled neutrophil NADPH oxidase [208]. This effect seems to occur 
selectively: being present in the membranes of pig valve interstitial cells, human 
umbilical vein endothelial cells and cardiac fibroblasts, but not in the rat aorta. 
Such an effect in neutrophils and/or platelet may also contribute to effect of 
potentiation of platelet responsiveness to nitric oxide by perhexiline utilizing whole 
blood aggregometry [209]. Liberts et al (2007) [210] documented that perhexiline 
potentiated the effects of infused glyceryl trinitrate in suppressing neutrophil 
superoxide release without accentuating the vasomotor effects of the nitrates.  
Although known to cause phospholipidosis (to be explored further in 
Chapter 2.4.4: Early and late toxicity), the effect of perhexiline on lipid metabolism 
has never been investigated fully. In a recent study, perhexiline was found to 
activate Kruppel-like factor 14 (KLF14) and increase high density lipoprotein 
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of perhexiline retarded the progression of atherosclerosis development [211]. 
Although it is not known if perhexiline, when administered in therapeutic 
concentrations, has any effect on the metabolism of HDL-C, this study provides a 
potential for the development of newer therapeutic agents in this area. It should 
also be noted that previous genome-wide association studies found genetic 
variance of KLF14 associated with HDL-C [212,213]; and epidemiological studies 
and experimental observations revealed decreased levels of HDL-C and 
apolipoprotein A-I (ApoA-I) to be independent predictors of coronary heart disease 
[214-217].  
Perhexiline was once thought to be a potential antiarrhythmic and a 
significant L-type calcium antagonist [218,219]. The former mode of action was 
later disputed as perhexiline’s main action, as it was found that perhexiline 
administration did not markedly affect QT interval, QRS duration, PR interval, 
intra-atrial conduction time, atrioventricular nodal conduction time, and His-
Purkinje conduction velocity significantly [219]. Indeed it has been shown that 
perhexiline has some inhibitory effects in vitro on a number of potassium channels 
in myocardium [220], a finding which may account for the single report in the 
literature of perhexiline-induced torsades de pointes [221]. On the other hand, 
perhexiline was shown to be a calcium channel antagonist in early studies 
[222,223], as it was found to reduce heart rate significantly, though at doses at 
least ten times higher than established calcium channel antagonists [222]. In 1985, 
Barry and colleagues compared the 50% inhibitory concentrations (IC50) of several 
calcium channel antagonists on spontaneous contractile amplitude in chick 
embryo ventricular cells (which are L-channel-dependent), and found that 
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for diltiazem and verapamil were 13.5 and 10.0 x 10-8 M respectively, compared 
with 83 x 10-8 M for perhexiline [224]. Clinical evidence of the minimal potency of 
perhexiline in the treatment of Prinzmetal angina [225] attests to the concept that 
its calcium antagonist effects in vascular smooth muscle are minimal.  
Some recent studies have suggested additional mechanisms of action of 
perhexiline. First, in a desperate attempt to search for potential treatments of 
otherwise untreatable fibrodysplasia ossificans progressiva (FOP), a rare 
autosomal dominant disorder caused by gain-of function mutation in ACVR1 bone 
morphogenic protein type II receptor and characterized by progressive heterotopic 
ossification, Yamamoto and colleagues [226] screened 1040 FDA-approved drugs 
that suppress Id1, a transcriptional factor upregulated by the mutant receptor. 
They found that perhexiline (together with another similar hexadiline derivative 
fendiline) suppressed the Id1 promoter in a dose-dependent manner. Furthermore, 
perhexiline treatment also downregulated the phosphorylation of Smad1/5/8, 
driven by bone morphogenetic protein-2. Animal experiments showed promising 
results, that perhexiline treatment reduced the volume of heterotopic ossification 
by approximately 40% compared to controls. However, a subsequent open-
labelled clinical trial in five patients failed to show prevention of heterotopic 
ossifications in FOP patients [227].  
In another study searching for chemical modulators of autophagy, Balgi and 
colleagues used an automated cell based assay and screened > 3500 chemicals 
[228]. They found that perhexiline, together with amiodarone, niclosamide and 
rottlerin, were capable of increasing autophagosome content. Further assays 
showed that they inhibit signaling to mammalian target of rapamycin complex 1 
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compensates for the lack of extracellular nutrients by engulfing cytoplasmic 
components and also potentially increases efficiency of metabolism of residual 
mitochondria. Therefore, an increase in autophagy might contribute to the effects 
of perhexiline in increasing efficiency of myocardial metabolism. Although the 
therapeutic application is unclear, such results should facilitate the preclinical and 
clinical testing of autophagy induction.     
In a similar bulk-screening process, it was found that perhexiline possesses 
some unique anti-cancer properties. It was found to internalize and degrade 
human epidermal growth factor receptor HER3, which is implicated in promoting 
the aggressiveness and metastatic potential of breast cancer [229]. A subsequent 
in vivo study showed that perhexiline inhibited breast cancer proliferation and 
tumour growth [229]. Another study found that perhexiline antagonized Hairy and 
Enhancer of Split 1 (HES1), a critical mediator required for tumour cell survival in 
T-cell acute lymphoblastic leukaemia, both in vivo and in vitro [230]. 
 
2.4.3 Spectrum of clinical efficacy: cardiac therapeutics 
 
As originally marketed, perhexiline is useful for the prophylactic treatment of 
chronic exertional angina. It was highly effective, not only as an adjunct therapy 
but also as monotherapy, resulting in improved exercise tolerance and reduced 
consumption of glyceryl trinitrate [204,231]. With careful plasma drug 
concentration monitoring, Horowitz et al first demonstrated improved angina 
symptoms while avoiding significant adverse effects [232]. Cole et al further 
consolidated the effectiveness of therapeutic drug monitoring of perhexiline, 
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coronary revascularization, perhexiline treatment (subject to therapeutic drug 
monitoring) effectively improved angina symptoms [233]. Similarly, in an open-
labelled study, perhexiline was also reported to be associated with symptom 
improvement in patients with severe aortic stenosis unsuitable for valve 
replacement surgery [234]. A critical feature of these reports was the safety of 
perhexiline in the presence of systolic left ventricular dysfunction, in contrast to 
other calcium antagonists. 
Perhexiline has more recently been investigated clinically both in the 
treatment of heart failure [235] and symptomatic non-obstructive hypertrophic 
cardiomyopathy [179]. For example, 56 chronic heart failure patients (with or 
without underlying myocardial ischaemia) with left ventricular ejection fraction of 
<40% (NYHA class II or III) on optimal drug therapy were randomly assigned to 
perhexiline or placebo. After 8 weeks of treatment, patients on perhexiline 
demonstrated significant improvement in oxygen consumption during peak 
exertion (peak VO2), quality of life, and left ventricular ejection fraction [235]. When 
46 symptomatic patients with non-obstructive hypertrophic cardiomyopathy were 
randomized to perhexiline or placebo for duration of 3 to 6 months, patients on 
perhexiline demonstrated improved myocardial ratios of phosphocreatine to ATP, 
left ventricular diastolic function, quality of life, and peak VO2 [179].  
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2.4.4 Early and late toxicity 
 
Early trials of perhexiline reported occasional nausea, epigastric pain and 
dizziness in patients at the beginning of therapy. In 1996, Stewart et al 
hypothesized that the emergence of nausea/dizziness was related to elevated 
plasma perhexiline concentrations [236]. It was found that such symptoms 
occurring during the first three days, following commencement of therapy was 
indeed strongly correlated with “toxic” plasma perhexiline concentrations. This 
suggested that in such patients, the development of nausea and/or dizziness is 
strongly predictive of accumulation of perhexiline beyond the therapeutic range of 
the drug (to be discussed further in the next section).  
Consistent with the previously described effects of other CPT-1 inhibitors 
[237,238], there are also occasional reports of hypoglycaemia in diabetic patients 
associated with initiation of perhexiline treatment [239-242]; this change may be 
sufficient to require reduction in dosage of other hypoglycaemic agents.  
Limited previous studies in patients with stable angina also indicated that 
utilization of a loading dose of 400mg per day of perhexiline maleate for three days 
is generally associated with therapeutic perhexiline concentrations within two to 
three days [232,236]. With such a loading regimen, 10 to 28% of patients 
experienced transient dizziness and/or nausea. Nevertheless, the lack of an 
intravenous preparation prompted the investigators to also evaluate a more 
aggressive loading regimen of perhexiline: - 800mg on the first day followed by 
therapeutic drug monitoring and 200mg daily on the next day in ten consecutive 
patients who were prescribed perhexiline, in order to attain therapeutic 
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of reported adverse effects (apart from nausea and vomiting) in the study, such a 
rapid loading regimen has since been adopted widely [243], especially for high risk 
patients (see Table 2-I for general guidance on commencement of therapy and 
subsequent dose adjustment).    
Reports of hepatic injury associated with chronic perhexiline began to 
emerge in the 1970s, after the drug was widely used for the prevention of angina 
pectoris [244-248]. In severe cases, cirrhosis and death have been reported [248]; 
while histological findings showed enlarged lysosomes containing myeloid figures, 
and phospholipidosis consistent with that seen with alcoholic liver disease [248].  
Similarly, reports of peripheral neuropathy associated with long term 
treatment also have been reported [249-253]. An in vivo study found that four 
weeks of perhexiline treatment induced heavy lipid deposition in the neurons of the 
dorsal root and sympathetic ganglia in the rats. Furthermore, there was also a 
significant reduction in neuronal motor latency; and these effects were correlated 
with increased plasma and tissue concentrations of the drug [254]. When 
discovered early and treatment withdrawn, most of the adverse effects were 
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Table 2-I: General algorithm for commencement of perhexiline therapy and 
interpretation of results. 
 
Day Dosage Additional note 
1 600-800mg stat Measure plasma perhexiline and OH-
perhexiline concentrations 12-24 
hours post loading dose 
2 onwards 200mg daily (or adjust 
as follows) 
Continue on 200mg daily until results 
of day 1 returns.  
 
Interpretation of result post loading of perhexiline:  
 
If [OH-perhexiline] = 0 mg/L or undetectable (indicating poor metabolizer),  
then hold dose for one week and change immediately to 100mg WEEKLY.  
Repeat TDM after 4-6 weeks.  
 
If [OH-perhexiline] is detectable but  
(1) [Perhexiline] > 0.6mg/L or if patient develops nausea or vomiting, then hold 
dose for about 5-7 days and repeat TDM.  
(2) [Perhexiline] falls between 0.15 – 0.60 mg/L, then continue on 200mg daily. 
Repeat TDM in about 5-7 days.  
(3) [Perhexiline] falls between 0.10 – 0.15 mg/L, then increase dose to 250mg 
daily. Repeat TDM in about 5-7 days.  
(4) [Perhexiline] < 0.10 mg/L, then increase dose to 400mg daily. Repeat TDM 
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Recommended New Daily Dosage 
< 0.15 Double daily dose 
0.15 to 0.59  No change 
0.6 to 0.89 Reduce by 25% 
0.9 to 1.19 Halve daily dose 
> 1.2 Cease for 1 week, then reduce daily dose to 
25% of previous dose 
 
OH-perhexiline/perhexiline ratio: indicates metabolising ability. 
 
 Ratio of <0.3: indicates poor metaboliser status.  Poor metabolisers will 
have a very low metabolite level (or no metabolite) and generally require 
doses of 50-100mg per week. 
 Ratio of 0.3 to < 2.5:  may indicate intermediate/saturated metabolism or 
inhibition of CYP2D6 by concurrent drugs. When increasing dose use very 
small (50mg) increments. These patients may require daily doses of 
<200mg. 
 Ratio >2.5 to 20:  indicates normal/ extensive metabolizer. 
Normal (intermediate) metabolisers generally require a dose of 100-200mg 
daily. 
 Ratio of >20:  may indicate ultra-rapid metaboliser.  
These patients may require a dose of >400mg daily. 
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2.4.5 Pharmacokinetics, pharmacogenetics and clinical utility of therapeutic 
drug monitoring 
 
2.4.5.1 From pharmacokinetics to therapeutic drug monitoring of 
perhexiline 
 
The (almost) global withdrawal of perhexiline from the market during 
the mid and late 1980s was not due to its lack of efficacy for the treatment of 
refractory angina pectoris. As mentioned in the previous sections, perhexiline 
was found to be very effective. Instead, it was the toxicities of perhexiline, 
which were poorly understood at that time, that led to its gradual withdrawal. 
Several observations during the late 1970s and early 1980s paved the way to 
better understanding the role of pharmacokinetics, pharmacogenetics and 
the metabolism of perhexiline play in its toxicities.  
First, it was observed by Singlas et al [256] that plasma 
concentrations of perhexiline were elevated in patients with long-term 
therapy and experienced hepatotoxicity and neurotoxicity, when compared to 
unaffected individuals. They reported that the mean ratio of plasma 
concentrations of the parent drug to those of its major metabolite, 
monohydroxy-perhexiline, was up to nine times higher in the patients who 
experienced neuropathy than the unaffected patients [256], suggesting at 
that time that the accumulation of perhexiline was likely causative of its 
toxicities, and raising the possibility that accumulation reflected saturability of 
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Perhexiline is a lipophilic drug, well absorbed from the gastrointestinal 
tract. Its elimination is dependent on its metabolic oxidation to the more polar 
monohydroxylated and dihydroxylated metabolites which are cleared renally 
[257]. There is a large interindividual variation in the apparent plasma half-life 
of perhexiline [258]. It was suggested that perhexiline-induced neuropathy 
was secondary to some latent inborn metabolic disorder which increased 
individual’s susceptibility [259].  
In 1982, Shah et al [260] suggested genetic mutation in the 
metabolism of debrisoquine and perhexiline as a basis of impaired 
metabolism and potential toxicity. Twenty patients who had developed 
perhexiline-induced neuropathy had significantly lower oxidation of the 
antihypertensive drug debrisoquine than fourteen who did not. Eight hour 
urinary samples were collected after a single oral dose of 10mg 
debrisoquine, and the urinary ratio of unchanged debrisoquine over 4-
hydroxy-debrisoquine (metabolite) was determined. The patients who had 
neuropathy had a median ratio of 14.4, compared to 0.65 in unaffected 
patients, suggesting an impairment of metabolic oxidation of both 
debrisoquine and perhexiline in affected patients. Furthermore, such 
impaired metabolism was independent of the patients’ hepatic function, 
concurrent drug therapy, and tobacco or alcohol consumption [260]. Hence it 
was suggested that perhaps monitoring the phenotype of drug oxidation may 
provide a better prediction of potential risk of long-term toxicity in  patients 
treated with perhexiline. Monitoring of levels might also facilitate appropriate 
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Parallel with these findings, Horowitz et al [261] demonstrated that the 
metabolism of perhexiline in unselected patients with angina was nonlinear. 
This implied that the risk of disproportionate increase in plasma 
concentrations with small increase in daily drug dosage. Subsequently, it was 
observed that by adjusting steady-state doses of perhexiline to achieve 
plasma concentrations between 0.15 mg/L to 0.6 mg/L, long-term toxicity of 
perhexiline can be avoided [232]. This therapeutic range was later employed 
in a double-blinded placebo-controlled crossover trial of 3-month perhexiline 
in patients who already on maximal conventional antianginal therapy. During 
this trial, more than 60% of patients on perhexiline had significant 
symptomatic improvement (compared to none in the placebo group), without 
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2.4.5.2 Pharmacogenetics and clinical practice in relation to the 
administration of perhexiline 
 
Having recognized the dependence of perhexiline (and debrisoquine) 
metabolism on the capacity of the individual to oxidatively metabolize the 
drug concerned in the liver, the mechanisms underlying such polymorphic 
variation was left to be recognized. During that time, it was known that the 
metabolic pathways of debrisoquine were also important for clearing many 
other drugs. Phenotypically, extensive metabolizers may excrete 10-200 
times more of the urinary metabolite of debrisoquine than poor metabolizers 
[262-264]. Family studies also showed that the poor metabolizer phenotype 
behaved as an autosomal recessive trait with an incidence between 5% to 
10% in the Caucasian population of Europe and North America [262-264]. In 
1988, a study by Gonzalez et al [265] cloned and sequenced the human 
P450db1 complementary DNA, the molecular basis of this inherited trait. It 
was found that three variant messenger RNAs are products of mutant genes 
producing incorrectly spliced db1 pre-mRNA, providing a molecular basis for 
such defective gene. This member of the P450 family was later called 
CYP2D6, which is now known to affect the metabolism of more than 30 
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Table 2-II Currently used drugs affected by CYP 2D6.  
 











Substrates of CYP2D6 
 
Amitriptyline, aripiprazole, atomoxetine 
Bortezomib 
Carvedilol, chlorpromazine, cinacalcet, clozapine, codeine 
Dapoxetine, darifenacin, dextromethorphan, donepezil, duloxetine 







Olanzapine, ondansetron, oxycodone 
Paroxetine, perhexiline, propranolol 
Risperidone 
Tamoxifen, tolterodine, tramadol 
Venlafaxine, vortioxetine 
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Confirming the central role of CYP2D6 in the hydroxylative 
metabolism of perhexiline has a number of implications. First, to genotype 
patients who are likely to be on long-term treatment to identify at-risk patients 
and individualize therapy would seem ideal. However the benefit of such 
process might be outweighed by the potential for more than one metabolic 
pathway involved, need for prospective testing, lack of correlation between 
pharmacology and genetic testing (for example, via drug-drug interactions), 
and an unnecessarily high cost associated with genetic testing [267]. 
Therefore, in the case of perhexiline, phenotypic expression of perhexiline 
metabolism was usually derived, using the ratio of plasma cis-OH-
perhexiline/perhexiline concentrations. In 70 patients who had attained 
steady-state plasma perhexiline concentrations, it was found that the 
clearance of plasma perhexiline was correlated not only with steady-state 
daily dose but also with the ratio of metabolite/parent drug [255]. This 
phenotypic metabolizer ratio of metabolite/parent drug concentration ratio 
provided a guide to individualize therapy and drug dosage determination at 
steady-state. CYP2D6 “poor metabolizers” were identified as those with a 
concentration ratio of cis-OH-perhexiline to perhexiline of ≤ 0.3; ultra-rapid 
metabolizers were defined as those with a ratio of > 20; and those with a 
metabolizer ratio in between were identified as intermediate to extensive 
metabolizers [255]. 
Such metabolizer ratio status was later evaluated in prospective 
studies. Patients with one functional allele of CYP2D6 had significantly 
higher plasma perhexiline concentration and lower metabolic ratio compared 
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for the metabolism of perhexiline [268,269]. Furthermore, such a relationship 
between genotype and metabolic ratio of perhexiline was established in 
patients who had a standard loading dose regimen consisting of 200mg of 
perhexiline maleate twice daily for three days [269]. This suggested that 
assessing the relative CYP2D6 metabolic capacity using concentration ratio 
of cis-OH-perhexiline and perhexiline during the early phase of therapy is 
useful for dosage individualization and determining potential long-term 
maintenance dosage regimens.  
Today, CYP2D6 is one of the best characterized polymorphic CYP 
enzymes, with more than 75 allelic variants identified [270], resulting in a 
spectrum embracing increase, reduction, or complete loss of enzyme activity. 
Phenotypically, this variable activity corresponds to classification as either 
poor, intermediate, extensive and ultrarapid metabolizers. In general, the 
prevalence of "ultra-rapid metabolizers" among the Ethiopians is probably 
highest at about 29% [271]. On the other hand, the prevalence of "poor 
metabolizer" in the Caucasian population ranges from 7 to 10%, the 
Hispanics and the African-Americans only about 2-6%, and among East 
Asians are less than 2% affected [270]. The issue of regional heterogeneity 
of CYP2D6 status among Asians remains incompletely evaluated [272].  
While accounting for only 2-5% of all hepatic CYP enzymes, CYP2D6 
is known to affect the metabolism of approximately 25% of all clinically used 
pharmaceutical agents [270]. The investigation of CYP2D6-related 
metabolism of drugs had originally proven to be difficult in animals. It was not 
known until later that the expression of the CYP2D6 enzymes, like in 
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affecting the kinetics of drugs depending on the species or strain of animals 
used in the experiments [273]. In general, female Dark Agouti rats serve as 
phenotype of "poor metabolizer" [274], and male Sprague Dawley or Wistar 
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2.4.5.3 Impact of drug-drug interactions 
 
In general, any drugs with pharmacokinetics that are affected by 
CYP2D6 have the potential to affect the kinetics of perhexiline. Reported 
cases have involved antifungals like terbinafine [275] and selective serotonin 
reuptake inhibitors like paroxetine and fluoxetine [276]. However, given the 
availability of therapeutic plasma drug monitoring, it is likely that the adverse 
effects arising from such predictable drug-drug interactions may be 
minimized via increased frequency of plasma drug concentration monitoring. 
There is also theoretical scope for drug interactions based on 
overlapping biological effects. First, given that perhexiline is a known inhibitor 
of CPT-1, it could be speculated that concurrent treatment with another CPT-
1 inhibitor may increase potential neuro- or hepatotoxicity. Additionally, 
excessive inhibition of fatty acid metabolism without adequate compensation 
of increased glucose oxidation could also be potentially detrimental to 
myocardial energetics. In a retrospective case series of twenty six patients 
on concomitant treatment with amiodarone (another CPT-1 inhibitor [176]), of 
whom twenty were on long-term treatment, none of the patients had either 
medication ceased due to adverse effects. Additionally, onset of 
hypoglycaemia (acute adverse effect) was also rare (occurring only in five of 
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2.4.5.4 Impact of disease-drug interactions  
 
After the hepatic hydroxylation of perhexiline into mono- or 
dihydroxylated metabolites, the (predominantly) inert metabolites are 
cleared renally. To date, there is no evidence that these metabolites cause 
any clinically significant effect. However, despite a lack of supporting 
evidence to suggest that renal failure affects the safe use of perhexiline, 
the product information still cites renal dysfunction as a contraindication. In 
a retrospective study involving two hundred patients on steady-state long 
term perhexiline, it was found that a positive correlation was observed 
between creatinine clearance and maintenance dose on a univariate 
comparison. However, on a multivariate analysis, this relationship was 
insignificant as weight and renal function were interdependent. Although 
statistical association may not suggest causation, and a role for renal 
dysfunction cannot be completely excluded, the prediction of maintenance 
dose does not require adjustment for renal function per se [277].  
In the same study, it is also found that impaired left ventricular 
systolic function does not influence the maintenance dose of perhexiline 
required, suggesting that despite perhexiline's narrow therapeutic index 
and potential toxicity, dosage adjustment is not required in patients with 
systolic dysfunction. Additionally, the study also found a decrease in the 
maintenance dose with age, but an inverse relationship with weight. Such 
a finding may reflect the influence of age-related muscle wasting on the 
volume of distribution or changes in first-pass metabolism and 
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2.4.6 Enantiomer-specific actions 
 
Many drugs are marketed as a racemic mixture of two enantiomers. Given 
that most drugs often exert their effects on proteins, which are three-dimensional 
in nature; it is no surprising that pharmacokinetic and pharmacodynamics 
differences often exist between the enantiomers. Pharmacokinetic processes may 
be enantioselective at the level of absorption, distribution, metabolism and 
excretion. Genetic considerations and patient factors such as age, concomitant 
drugs or disease state can also play a role in determining the relative 
concentration of enantiomers of a racemic drug. Perhexiline is clinically 
administered as a 50:50 racemic mixture of (+) and (-)-enantiomers. Some 
previous studies have suggested that these enantiomers may exert different 
effects.  
This was first investigated by Gould et al in 1986 [278]. In this study eight 
healthy volunteers were given 300mg of individual enantiomers and racemate 
perhexiline. Blood samples were collected every two hours and urine samples 
were also collected for measurement of perhexiline metabolites. The study 
showed that there were higher plasma and urine cis-hydroxyperhexiline 
concentrations for those who were administered (-)-perhexiline than its antipode. 
However, none of the volunteers were phenotyped or genotyped with respect to 
their CYP2D6 metaboliser status and hence the potential contribution of metabolic 
heterogeneity to the results was uncertain. 
Recent (unpublished) work in our laboratory suggested that while the 
different enantiomers exerted similar effects on superoxide production from 
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in neutrophils when stimulated with N-formylmethionyl-leucyl-phenylalanine (fMLP) 
or phorbol 12-myristate 13-acetate (PMA)], in the Dark Agouti rats which were 
treated with individual enantiomers, the enantiomers induced differing histological 
changes in hepatocytes. In the rats that were treated with (+)-perhexiline, histology 
showed increased fatty deposits throughout hepatocytes, suggesting that (+)-
perhexiline is potentially associated with inhibition of fatty acid utilization. In 
addition, von Frey filament testing (study of neuronal function) and electron 
microscopy studies on the dorsal root ganglion of the treated animals suggested 
that (+)-perhexiline is associated with impaired neuronal function and neuropathy. 
These hepatic and neuronal effects of (+)-perhexiline are similar to the toxicity 
profile of chronic perhexiline clinically, and potentially resulted from extensive 
CPT-1 inhibition resulting in reduction of fatty acid oxidation (one of the hypothesis 
to be explored in this thesis: see Chapter 7).  
On the other hand, the rats that received (-)-perhexiline seemed to display 
different metabolic effects. Both histological and biochemical results indicated that 
there was a significant higher glycogen content and lack of lipid droplets in the 
hepatic tissue of rats that were treated with (-)-perhexiline, suggesting that a 
potential independent effect of (-)-perhexiline in association with increased 
carbohydrate utilization. This indicated that metabolic pathways other than that of 
CPT-1 inhibition might be involved with the administration than perhexiline. In 
addition, in a rat model of myocardial necrosis induced by isoprenaline injection, 
the extent of cellular necrosis (as measured by an elevation of troponin levels) was 
greater in the group that was previously treated with (-)-perhexiline. This disparity 
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enantiomers and in their potential clinical effects. However, these results should 
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2.5 Unanswered questions regarding perhexiline 
 
“New tricks for an old drug.” 
M Frenneaux, 2002. 
 
2.5.1 Is perhexiline safe when used long-term in the modern era of 
therapeutic drug monitoring?  
 
The currently used therapeutic range for perhexiline concentrations in 
plasma has been utilized in short term trials, ranging from three to twelve months 
[97,233,235]. As demonstrated in previous sections, significant adverse effects are 
rarely reported when therapeutic monitoring of perhexiline is in place. However, 
given the increasing recognition that heart failure and many other myocardial 
disease states (including hypertrophic cardiomyopathy) share a common 
association with myocardial energetic impairment, the spectrum of clinical 
indications for perhexiline long-term therapy will potentially increase and therefore 
an understanding of its long-term safety is warranted. When used in the long-term, 
it is also recommended that plasma level monitoring is required every three 
months. However, in the modern era of regular therapeutic monitoring of 
perhexiline, it is unknown whether such precautions achieve their safety 
objectives.  
 
2.5.2 Modulation of kinetics  
 
Although the utility of therapeutic drug monitoring is predicated on the idea 
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it represents target tissue for efficacy or toxicity), such a hypothesis has rarely 
been tested in the case of cardioactive drugs in humans, including perhexiline. 
Additionally, the uptake of this drug into the myocardium, have not previously been 
reported, due to the inherent difficulty in obtaining human myocardial tissue 
samples. On the other hand, animal studies have provided adequate information 
on the principles modulating myocardial drug uptake, which is not affected by 
plasma drug concentration but by heart rate and the relative octanol: water 
partition coefficients [279]. Additionally, active transport mechanisms may also 
further modulate the uptake kinetics and therefore, in theory, the ratio of plasma to 
myocardial drug concentrations may vary between individuals. This area of 
interaction is potentially further complicated by the concept that fibrotic infiltration 
of myocardium might affect the uptake of perhexiline into this ultimate "central" 
compartment.  
 
2.5.3 The pleiotropic effects of perhexiline 
 
2.5.3.1 Energetics-based effects (other than CPT-1)  
 
Previous chapter (Chapter 1.5.1.3) discussed the effects of perhexiline on 
the expression of TXNIP, an inflammatory modulator highly expressed in diabetics. 
It was found that TXNIP expression in human myocardium was lower in 
perhexiline-treated patients than in those receiving placebo [280]. The relevance 
of this to the clinical utility of perhexiline is unknown. First, it is unclear if the 
occasional hypoglycaemic events observed with commencement of perhexiline in 
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glycolysis or improved insulin sensitivity. It is possible that suppression of TXNIP 
secretion contributes to the favourable impact of perhexiline on energetics; with 
TXNIP changes being driven by activation of AMPK. Potential comparison of 
perhexiline effects in mice with intact versus knockout [144] TXNIP expression 
might delineate the potential role of TXNIP in mediating perhexiline effects.    
 
2.5.3.2 Non-energetics based effects  
 
Perhexiline is known to exert anti-inflammatory effects [187,209,281], 
essentially involving NOX-2 production by leukocytes. While these are 
desirable in cardiovascular disease, it is again unknown if these biochemical 
effects contribute to the clinical benefits of perhexiline. The recently 
described effect of perhexiline to potentially increase HDL is surprising [211] 
and may serve as basis for future therapeutic development. Finally, within 
the last 2 years, a number of preclinical studies have suggested that 
perhexiline may represent an adjunctive treatment for various neoplasms: 
again it is not yet clear whether such anti-neoplastic effects are entirely CPT-
1 dependent [229,282-285].  
 
2.5.4 Enantiomer-specific actions of perhexiline: unanswered questions 
 
Previous research within the Clinical Pharmacology Deparment, the Queen 
Elizabeth Hospital showed that long-term administration of individual perhexiline 
enantiomers resulted in differential neuropathic and hepatotoxic effects in Dark 
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major pharmacological actions. If one of the enantiomers possess favourable-
effect-versus-side-effect profile, this may lead to further pharmaceutical 
development. The ongoing search of the other non-energetic based effects of the 
enantiomers (as described above about perhexiline) is warranted.  
Parallel to this is the development of "new" perhexiline analogues by 
chemists at the Kosterlitz Institute, Aberdeen, United Kingdom. These analogues 
would ideally mitigate the necessity a derivative's being a substrate of CYP2D6 
(and thence its susceptibility to human genetic variance and necessity for clinical 
therapeutic drug monitoring). Their mechanism(s) of actions, and therefore clinical 
utility, warrant further investigation but shed light on the potential future role of 
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Chapter 3: An audit of current outcomes in 
patients treated chronically with perhexiline 
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Perhexiline, originally utilized as a first-line prophylactic anti-anginal agent, 
is now regarded primarily as a treatment for otherwise refractory myocardial 
ischaemia. Recent studies have also demonstrated its short-term utility in heart 
failure, hypertrophic cardiomyopathy and inoperable aortic stenosis. Its benefits on 
myocardial energetics state are potentially counter-balanced by risk of 
hepatotoxicity and peripheral neuropathy during long-term treatment if drug 
accumulation occurs. Since perhexiline exhibits complex pharmacokinetics with 
wide inter-individual variabiltiy, its long-term use requires regular plasma level 
monitoring. In the current study, the risk of neuro- and hepato-toxicity during long-
term perhexiline therapy in relation to the intensity of therapeutic drug monitoring 
was investigated. Furthermore, determinants of mortality during perhexiline 




In 170 patients treated with perhexiline for a median of 50 months (IQR: 31 
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Rationale for treatment with perhexiline included myocardial ischaemia (in 
88%), and severe systolic heart failure in 38%. Plasma concentrations were within 
the therapeutic range of 150-600ng/ml on 65% of assay occasions and toxic levels 
accounted for 8.8% of estimates. No patient developed hepatotoxicity attributable 
to perhexiline while three developed peripheral neuropathy possibly induced by 
treatment. Actuarial 5-year survival rate was 83% overall, and 76.3% in patients 




This first audit of a large population treated long-term perhexiline 
demonstrates that:- 
(1) therapeutic drug monitoring effectively limits occurrence of toxic drug 
levels and virtually eliminates long-term hepato/neurotoxicity. 
(2) mortality rates during long-term therapy, notably for patients with 
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Perhexiline maleate (discussed in detail in Chapter 2) was used originally 
as a first-line, prophylactic anti-anginal agent, both as monotherapy and later as 
add-on therapy. Despite its efficacy, reports of development of long-term adverse 
effects (hepatitis and/or peripheral neuropathy) and increased availability of other 
anti-anginals led to its gradual decline in usage in the 1980s.  However, later 
recognition of the mechanism of perhexiline toxicity and its prevention via 
therapeutic drug monitoring had kept the agent in clinical usage, usually as a last-
line therapy. Subsequent studies had also provided evidence that it might improve 
symptomatic status in patients with aortic stenosis [234], systolic heart failure 
(ischaemic or otherwise) [235] and hypertrophic cardiomyopathy [179].  
In the current analysis, the long-term safety of perhexiline in a cohort of 
Australian patients treated, in the main, for otherwise refractory ischaemia and/or 
heart failure were evaluated. It was sought to determine:- 
1. The incidence and determinants of serious long-term perhexiline 
toxicity (that is, hepatotoxicity and/or peripheral neuropathy).  
2. Mortality rates during perhexiline therapy for the entire patient cohort 
and for those with concomitant systolic heart failure.  
3. The relationships between long-term outcomes and  
(a) achievement of therapeutic drug concentrations 
(b) frequency of monitoring of steady-state perhexiline 
levels, given that 3-monthly determination of levels is 
currently recommended [266].  
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The results provide incremental evidence of the safety of perhexiline in 
long-term treatment. Furthermore, the survival data raise the possibility that this 
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3.3.1  Patient selection 
 
Patients were evaluated on the basis of at least 12 months of perhexiline 
therapy for a currently recommended indication with associated records of follow-
up including cardiac clinic review.  
The only criteria for non-prescription of perhexiline in this cohort were: - 
(1) Severe chronic hepatocellular disease 
(2) Previous severe adverse reaction to perhexiline 
(3) Anticipated inability to comply with monitoring requirements 
Diabetes mellitus (with or without associated peripheral neuropathy), 
concomitant renal insufficiency, and treatment with potentially interacting drugs 
(such as amiodarone [240], selective serotonin reuptake inhibitors [276] or 
antifungal terbinafine [275]) were not contraindications to perhexiline therapy at 
entry.   
 
3.3.2 Therapeutic drug monitoring 
 
Determinations of plasma perhexiline concentrations (and those of its major 
mono-hydroxylated metabolite) were performed via high-performance liquid 
chromatography as previously described [261]. Ideally, monitoring was repeated 
frequently until levels were stable within the previously described therapeutic 
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range and then repeated 3-monthly [266]. However, this was a suggested rather 
than strictly enforced frequency of monitoring. Actual frequency of monitoring was 





Hepatotoxicity, whether likely due to perhexiline or otherwise, was defined 
on the basis of at least 3-fold elevation of liver function tests beyond the upper limit 
of the testing laboratory. Peripheral neuropathy, whether predominantly sensory, 
motor or autonomic, was diagnosed only in the presence of objective clinical 
abnormalities. In all cases, appearance of such anomalies was correlated with 
simultaneous plasma perhexiline concentrations.  
Data regarding mortality rates were retrieved from the Registry of Births, 
Deaths and Marriages of South Australia and presumptive causes of death 
recorded. Variables selected for multivariate backward logistic regression analyses 
to identify independent predictors of mortality were age, gender, duration of 
perhexiline therapy, history of coronary artery disease, presence of aortic stenosis, 
heart failure, diabetes mellitus, proportion of drug assays within therapeutic range, 
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All data for normally distributed parameters are described as mean ± SEM; 
for skewed data medians and interquartile ranges are given. 
Survival rates (overall and for patients who had concomitant heart failure) 
were quantitated by Kaplan-Meier analysis, and correlates of survival rate were 
evaluated by multiple logistic backward regression analysis. All analyses were 
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Table 3-I summarizes the clinical demographics of the 170 patients in this 
study cohort. In general, patients were elderly. Known coronary disease and 
therefore potential myocardial ischaemia was present in 88% of cases while 
37.6% had symptomatic heart failure. Furthermore, aortic stenosis represented an 
occasional component of the indication for perhexiline therapy (12.9%).  
Figure 3-I summarizes metaboliser phenotype. The majority of the patients 
were intermediate to extensive metabolisers (see Figure 3-I for criteria [255]) and 
received daily doses of perhexiline maleate between 125 mg and 200 mg; 1.8% 
were poor metabolisers who received 50 to 100 mg weekly; and 4.12 % were 
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Table 3-I: Baseline characteristics of the 170 patients in this study cohort. 
 
Male (%) 58 
Age (years) 74 (65 – 81)* 
Duration of treatment (months) 50 (31 – 94)* 
Cardiovascular History 
Coronary artery disease (%) 88.2 
Previous myocardial infarction (%) 58.8 
Previous coronary artery bypass (%) 37.6 
Previous percutaneous coronary intervention (%) 33.5 
Aortic stenosis (%) 12.9 
Systolic heart failure (%) 37.6 
Atrial fibrillation (%) 17.1 
Non-cardiac disease 
Diabetes mellitus (%) 37.1 
┼ Known peripheral neuropathy (pre perhexiline) (%) 7.1 
∆ Known hepatic disease (pre perhexiline) (%) 1.2 
Significant alcohol intake (%) 2.4 
 
* median (interquartile range) 
∆ mild abnormalities of liver function tests at entry 
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Metabolizer status was defined by the ratio of plasma concentrations of cis-
hydroxyperhexiline to perhexiline at steady-state. Poor metabolizer was defined by 
a ratio of ≤ 0.3; intermediate metabolizer was defined by a ratio of 0.3 to 2.5; 
extensive metabolizer was defined by a ratio of 2.5 to 20; and ultra-rapid 
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Over the period of follow-up, as shown in Table 3-II, 65% of drug 
concentrations measured were within the therapeutic range of 150 to 600 ng/L 
[232], the majority of other levels were subtherapeutic (26.2%) rather than 
potentially toxic (8.8%). The overall frequency of monitoring appeared suboptimal: 
only 32% of patients had at least 3-monthly drug monitoring, as currently 
recommended by the Australian guidelines [266]. 
 
Table 3-II: The distribution of concentrations with respect to therapeutic 
range of 150-600 ng/ml and the frequency of monitoring during study period. 
  
Quality of monitoring 
Proportion of concentration within therapeutic range (%) 65 
Proportion of concentrations above therapeutic range (%) 8.8 
Proportion of concentrations below therapeutic range (%) 26.2 
Frequency of monitoring over total study period  
At least three monthly (%) 32 
Three to six monthly (%) 48 
Less than six monthly (%) 20 
 
 
Elevation of hepatic enzyme levels beyond population norms, usually 
transient, occurred in 51 cases. Of these, potential causes included 21 cases of 
gastrointestinal disease (cholecystitis, pancreatitis and gallstones), 2 of known 
hepatitis B or C, and 2 of metastatic hepatic infiltration. There were also 8 cases of 
ischaemic hepatitis associated with acute heart failure. Two of the cases appeared 
to be related to other drugs such as HMG-CoA inhibitors (statins). In 12 cases of 
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hepatitis, although of uncertain cause, could not be attributed to perhexiline as the 
elevation of plasma concentrations of hepatic enzyme was transient and resolved 
despite continuation of therapy.  Overall, none of the cases of abnormal hepatic 
function appeared likely to be related to perhexiline therapy. In particular, in no 
case was there "classical" perhexiline hepatotoxicity: that is simultaneous 
elevation of perhexiline levels and development of abnormal liver function 
[231,232,287].  
There were also a total of four new cases of presumptive peripheral 
neuropathy in the course of the study, although in one case objective signs were 
never elicited. In the three other suspected cases, perhexiline could not be 
excluded as a potential cause of peripheral neuropathy. One of these three 
patients was a diabetic. In the two non-diabetic patients with define peripheral 
neuropathy suspected to be perhexiline-induced, one had known peripheral 
vascular disease. Once again, none of these cases were associated with supra-
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As regards to mortality, actuarial survival of the entire cohort and that of 
patients with concomitant systolic heart failure is shown in Figure 3-II. Five and 
ten-year survival rates were 83% and 72.6% % respectively for the entire cohort, 
and 76.3% and 63.4% for patients with heart failure. On multivariate analyses 
(Table 3-IV), deaths on perhexiline tended to occur significantly more commonly 
during initial years of therapy (p=0.021), and there were trends towards increased 
mortality with advanced age (p=0.064) and for patients with associated coronary 
artery disease (p=0.068).  
 
Figure 3-II: Kaplain-Meier curves over the first ten years of therapy for all 
patients (n=170), and for those who had concomitant systolic heart failure 
(n=82). 
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Table 3-IV: Multivariate (backward stepwise multiple logistic regression 
analysis) correlates of mortality in the current study cohort (n=170).  
 
Parameter β-coefficient p-value 
Age 0.026 0.064 
Duration of perhexiline 
treatment 
-1.447 0.021 
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The current data represent the most extensive documentation of long-term 
safety of perhexiline in the modern era of routine therapeutic drug monitoring. 
Initial experience with perhexiline, confined to its role as a prophylactic anti-anginal 
agent, suggested remarkable clinical efficacy, but the serious long-term 
complications of hepatitis and peripheral neuropathy were documented in as many 
as 40% of cases [204]. In the current series, presumptive long-term toxicity (limited 
to three cases of peripheral neuropathy) occurred with an incidence of only 
approximately one case per 236 patient-years’ utilization.  
The basis for this vastly improved safety profile was superficially routine 
monitoring of plasma perhexiline concentrations. There is ample evidence that 
most cases of previously reported long-term toxicity occur with prolonged (>3 
months) elevation of plasma perhexiline concentrations, beyond 600 ng/L 
[231,232]. The strategy of maintaining levels below that point has been successful 
in limiting toxicity, although this has been tested previously mainly in short-term 
exposure [179,235]. Plasma level monitoring at frequencies of at least 3 monthly 
has been recommended, and the lower limit of the therapeutic range has been set, 
largely on an arbitrary basis at 150 ng/L [232].  
The current data confirm the considerable inter-individual variability in 
perhexiline pharmacokinetics. As expected, daily dosage to achieve therapeutic 
levels ranged widely (from less than 100mg per week to 400mg per day). Fewer 
patients than expected were poor metabolizers of the drug. Furthermore, very few 
monitored levels (approximately 8.8% of total readings, occurring in 57% of 
patients) were above the therapeutic range, and levels of more than twice the 
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therapeutic range were virtually never seen. Hence the avoidance of toxicity was 
less than surprising.  
However, this occurred despite apparently suboptimal frequency of 
monitoring in two thirds of cases. In some cases, the associated plasma 
perhexiline levels were below the therapeutic range (i.e. <150 ng/L). The issue of 
extent of therapeutic effect associated with such low levels should therefore be 
evaluated in placebo-controlled studies.  
The other important change, which has occurred in the general utilization of 
perhexiline in the last 20 years, has been the transition from use only as a 
prophylactic anti-anginal agent to that of a second-line treatment for systolic heart 
failure [235,288], particularly in patients with contra-indications to use of other 
agents. A substantial minority of the current patient series had heart failure, often 
with associated renal insufficiency. The 5-year survival rate of the entire cohort 
was 83%, while in the presence of heart failure that fell slightly. While these data 
are not placebo-controlled, the very extensive survival of a group of elderly 
individuals with serious and multiple morbidities seems remarkable, as other heart 
failure studies (without perhexiline) demonstrated a lower 5-year survival rate at 
26-55% [289]. On multivariate analyses, ischaemic heart disease, rather than 
heart failure, tended to predict increased death rates: these results are 
superficially surprising.  
Furthermore, it is even possible that perhexiline may improve outcomes in 
patients with myocardial ischaemia secondary to coronary atherosclerosis: a 
recent study in mice demonstrated that perhexiline functions as an activator of 
Kruppel-like factor 14, thus elevating concentrations of Apo-A [211]. Therefore, 
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perhexiline might exert additional anti-atherogenic effects with consequent 
cardioprotection.  
The study has several limitations. In the three cases of hepato- and neuro-
toxicity of uncertain cause: perhexiline was potentially, but not definitely, 
implicated. Indeed, none of these cases had associated “toxic” drug levels. 
Secondly, measurement of hepatic and neurological functions may have only 
occurred in patients with clinical symptoms, which may itself present as a source 
of bias for the study. Thirdly, although most patients would have had moderate to 
severe impairment of exercise capacity at entry, this was not recorded in all cases, 
hence the omission. Lastly, given the current study is not placebo-controlled, the 
therapeutic and mortality efficacy of perhexiline cannot adequately be determined.  
However, the current data demonstrate considerable safety, and provide 
preliminary evidence that therapy with perhexiline should be considered as an 
appropriate option for difficult cases of myocardial ischaemia and/or heart failure. 
Future prospective randomized controlled placebo trials evaluating the mortality 
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This chapter forms the basis of publication in Therapeutic Drug Monitoring 
2015 (see Appendix). Helen Phuong, Bo Y Choi and Betty Raman had provided 
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Perhexiline is a prophylactic anti-ischaemic agent with weak L-type calcium 
antagonist effects which has been increasingly utilized in the management of 
refractory angina. The metabolic clearance of perhexiline is modulated by 
CYP2D6 metaboliser status and stereoselectivity. The current study sought to 
determine (1) whether the acute accumulation of perhexiline in the human 
myocardium is stereoselective, and (2) to investigate the relationship between 
duration of short-term therapy and the potential stereoselective effects of 
perhexiline within myocardium.  
 
4.1.2 Method  
 
Patients (n=129) from the active arm of a randomised controlled trial of 
preoperative perhexiline in cardiac surgery, were treated with oral perhexiline for a 
median of 9 days. Correlates of atrial and ventricular concentrations of 
enantiomers were sought via univariate followed by multivariate analyses.  
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Myocardial uptake of both (+) and (-)-perhexiline was greater in ventricles than 
atria, and there was more rapid clearance of (-) than (+)-perhexiline. The main 
determinants of atrial uptake of both (+) and (-)-perhexiline were the plasma 
concentrations [(+)-perhexiline: β=-0.256, p=0.015; (-)-perhexiline: β=-0.347, 
p=0.001] and patients' age [(+)-perhexiline: β=0.3, p=0.004; (-)-perhexiline: 
β=0.288, p=0.005]. Atrial uptake of (+)-enantiomer also varied directly with 
duration of therapy (r=0.29, p=0.004), while atrial uptake of (-)-perhexiline varied 
inversely with simultaneous heart rate (r=-0.22, p=0.03).   
 
4.1.4 Conclusion  
 
(1) Uptake of both perhexiline enantiomers into human atrium is greater with 
advanced age, and displays evidence of both saturability and minor 
stereoselectivity.  
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4.2 Introduction  
 
Perhexiline is a metabolic modulating agent that was first introduced into 
clinical practice as a prophylactic anti-anginal drug in the 1970s. It exerts multiple 
effects which increase efficiency of myocardial metabolism: amongst these it is 
known to inhibit mitochondrial carnitine palmitoyl transferase-1 [176], potentially 
resulting in a shift from fatty acid to glucose utilisation with more adenosine 
triphosphate production per unit oxygen consumption.  
Despite the considerable clinical efficacy of perhexiline in prophylaxis of 
exertional angina [203,204], its use declined because of the substantial risk of 
hepato- and neuro-toxicity during chronic therapy [290-292]. However, it emerged 
that this toxicity reflected drug accumulation in plasma [256] which in turn resulted 
from inter-individual variability in CYP2D6-mediated metabolism [293,294]. With 
widespread availability of therapeutic drug monitoring [232,233] and greater 
understanding of its potential widespread utility for disorders of cardiac energetics 
[2], the clinical use of perhexiline is now increasing.  
A number of studies have specifically evaluated short-term utility of 
perhexiline in the management of potential cardiac crises, such as the 
management of high risk patients with unstable ischaemia and for cardioprotection 
during coronary revascularisation [210,236,243]. The recently reported CASPER 
trial evaluated its use as an adjunct to myocardial protection in patients 
undergoing coronary artery surgery but found no clear-cut beneficial effect of 
prophylactic perhexiline therapy [295]. During this trial, atrial and ventricular 
myocardial biopsies were taken at the time of surgery. We have previously 
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reported on analyses of these samples to evaluate the relationship between 
plasma and myocardial drug concentrations [296]. The objective of the current 
analysis stems from our recent observation that the effects of racemic perhexiline 
may result from unequal steady-state concentrations of its two enantiomers [269]. 
In human liver microsomes, the intrinsic clearance of (-)-perhexiline is 
greater than that of the (+)-enantiomer [297], which explains the greater clearance 
rate of (-)-perhexiline at steady state in patients receiving racemic perhexiline 
[278]. Interestingly, it appears from studies in a rat model, that the safety of the 
two enantiomers may vary, with greater hepatotoxicity associated with the (+)-
enantiomer [286].  
Therefore, the CASPER data was re-evaluated in order to determine: 
(1) Whether atrial and ventricular myocardial accumulation of perhexiline 
during short-term treatment are stereoselective, and whether this reflects 
similar trends in plasma enantiomer concentrations. 
(2) The relationship between duration of (short-term) perhexiline therapy 
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Data were mainly derived from patients in the active treatment arm of the 
CASPER (Coronary Artery Surgery with PERhexiline therapy) trial 
(NCT00845364). In brief, this was a double-blind, randomized, placebo-controlled 
clinical trial evaluating whether preoperative oral perhexiline to improve myocardial 
protection in patients undergoing cardiac surgery. Non-diabetic patients, who were 
not taking CYP2D6 inhibitors, undergoing first time coronary artery bypass graft 
surgery, were randomized to either perhexiline maleate or placebo for at least five 
days prior to surgery. All patients received the following medication regimen: 
200mg twice daily for three days then 100mg twice daily until the morning of the 
surgery [295].  
Following induction of anaesthesia but prior to commencing surgery, the 
haemodynamic status of each patient, including heart rate, arterial pressures and 
cardiac index were determined. Plasma collected at this time point was centrifuged 
and stored at -80°C; this has previously been used to phenotype patients for 
CYP2D6 metaboliser status [295] according to the plasma concentration ratios of 
perhexiline monohydroxylated metabolite to parent drug [255]. During preparation 
for cardiopulmonary bypass but prior to aortic cross-clamping, right atrial and left 
ventricular myocardial biopsies were obtained, as previously described [295]. 
These biopsies were initially snap-frozen in liquid nitrogen and stored at -80°C, 
then later digested in 0.15 M of phosphate buffer solution (pH 6.0) using a 
homogenizer and tissue grinder to form a suspension (approximately 100mg 
tissue in 5ml buffer). Plasma and myocardial perhexiline enantiomer 
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concentrations were determined utilizing a modification of a previously described 
HPLC assay [298]. Thresholds for detection of myocardial (+) and (-) perhexiline 
were 0.01mg/L.  
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4.4 Analysis of results 
 
4.4.1 Determination of relative uptake of enantiomers 
 
Concentrations of each enantiomer in atrial and ventricular myocardium 
were correlated with plasma enantiomer concentrations to derive tissue to plasma 
concentration ratios. 
Potential stereo-selectivity of uptake was evaluated via determination of:  
I. Differential (+) to (-)-enantiomer ratio in myocardium versus plasma 
(in order to determine whether uptake, rather than clearance, might engender 
stereoselective myocardial effects). 
II. Percentage of (+)-enantiomer concentrations in plasma and 
myocardium, in relation to time (in order to determine the net effects of 
stereoselective kinetics on the myocardial uptake of the drug).  
 
4.4.2 Identification of determinants or correlates of myocardial (+) and (-)-
perhexiline uptake 
 
Univariate followed by multivariate analyses were utilized for assessment of 
the atrial uptake of enantiomers. Parameters evaluated were plasma 
concentration, metaboliser status, age, weight, duration of therapy, heart rate, 
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creatinine clearance, and cardiac index. Multivariate backward stepwise analyses 
were performed using statistical software SPSS (version 20, Chicago).  
I. Data from poor metabolisers (n=7) were excluded from analysis 
(unless specified otherwise) because of potential for differential clearance 
mechanisms and non-attainment of near steady-state kinetics. 
II. Data are expressed throughout as mean ± SD for normally 
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4.5.1 Patient demographics: metaboliser status and absence of dose titration 
 
129 patients from the active arm of CASPER trial were included and their 
clinical characteristics are summarised in Table 4-I. While patients had well-
preserved renal function, their pre-treatment cardiac function is not known, with 
formal estimation of cardiac indices and heart rates performed following the 
induction of anaesthesia for surgery; these data therefore reflect the potential 
interaction of perhexiline and pre-treatment status. However, the generally low 
cardiac indices in these patients imply some degree of systolic left ventricular 
dysfunction at least at the time of measurement. The median plasma 
concentrations of perhexiline at the time of blood sampling were 0.27mg/L (IQR: 
0.13 - 0.47), with approximately one third of patients having subtherapeutic levels 
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Table 4-I: Clinical characteristics of all patients (n=129). 
Parameters  
Age (years) a 66 (58-73) a 
Weight (kg) 83 ± 14 
Creatinine clearance (ml/min) a 70 (60 - 85) a 
Baseline cardiac index 2.04 (1.78 - 2.34) a 
Heart rate (beats per minute) ┼ 59 ± 10 
Duration of therapy (days)a  9 (6 - 12) a 
 
a. Expressed as median (interquartile range) 
┼ Measured immediately prior to coronary surgery, that is, on treatment.  
 
Figure 4-I examines the relationship between plasma cis-OH-perhexiline/ 
perhexiline ratio (used to categorise metaboliser status) and plasma perhexiline 
concentration at the time of surgery. It is apparent that there was substantial 
variability in racemic perhexiline concentrations, such that therapeutic 
concentrations were not generally attained in rapid metabolisers. There were a 
total of 7 poor metabolisers, all of whom attained therapeutic or potentially toxic 
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Figure 4-I: The relationship between rate of perhexiline's metabolism and 
plasma perhexiline enantiomer concentrations at the time of surgery. 




























P la s m a  (+ ) -p e rh e x ilin e
P la s m a  ( - ) -p e rh e x ilin e
r= -0 .9 1 ; p < 0 .0 0 1
r= -0 .9 1 ; p < 0 .0 0 1
 
Perhexiline’s metabolism is expressed as cis-OH-perhexiline to perhexiline ratio. 
Data to the left of the dashed line (ratio <0.3) correspond to "poor metaboliser" 
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4.5.2 Myocardial concentrations of enantiomers 
 
The relationships between plasma and atrial or ventricular concentrations of 
(+) and (-)-perhexiline are depicted in Figures 4-II A and B respectively. There 
were strong linear correlations for both enantiomers, with slightly greater 
concentrations of both enantiomers in ventricle than atrium (p<0.001 for both, 
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Figure 4-II: Correlations between plasma and myocardial concentrations for 
(A) (+)-perhexiline, and (B) (-)-perhexiline. 
 
A. (+)-Perhexiline 





































A tria l (+ )-p e rh e x ilin e
V e n tric le  (+ )-p e rh e x ilin e
r =  0 .9 1 ; p <  0 .0 0 0 1









































A tria l (-)-p e rh e x ilin e
V e n tricu la r (-)-p e rh e x ilin e
r =  0 .9 2 ; p  <  0 .0 0 0 1
r =  0 .8 1 ; p  <  0 .0 0 0 1
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The impact of metaboliser status on these plasma: myocardial 
concentration relationships is summarised in Table 4-II. In summary, plasma 
concentrations of (+)-perhexiline tended to be greater than those of (-)-perhexiline 
for both plasma and myocardium, irrespective of metaboliser status.  
 
Table 4-II: Perhexiline enantiomer concentrations in plasma, atrium and 













(+) (-) (+) (-) (+) (-) 
Poor 
metabolizer 



































































Metabolizer status was defined by the ratio of plasma concentrations of cis-
hydroxyperhexiline to perhexiline as previously stated [255].  
* p<0.05 vs antipode (Wilcoxon); ∆ p<0.005 vs atrial:plasma ratio  
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It was next sought to determine whether stereoselective clearance of 
perhexiline and/or of its uptake into myocardium might vary with duration of 
therapy. The proportion of (+)-perhexiline in plasma did not vary significantly with 
duration of therapy (Figure 4-III A), while that in atria increased significantly 
(p=0.004) with time (Figure 4-III B). Thus the ratio of (+)-perhexiline in the atrium 
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Figure 4-III: Variations in the percentage of (+)-perhexiline in (A) plasma, and 
(B) atrium relative to duration of therapy. 
A.  
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Concentrations of both (+)- and (-)-perhexiline into the ventricle increased 
significantly with time (p=0.005 and 0.004 respectively, Figure 4-IV), with no 
significant difference between the enantiomers.  
 
Figure 4-IV: Impact of duration of treatment on concentrations of perhexiline 
enantiomers in ventricular myocardium. 
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4.5.3 Multivariate correlates of uptake of enantiomer 
 
Table 4-III summarizes atrial: plasma concentration ratios, with all patients 
(excluding poor metabolisers) evaluated. Plasma perhexiline concentration was a 
strong negative correlate and age was a positive correlate of this ratio for both 
enantiomers.  
 
Table 4-III: Correlates of the atrial: plasma ratio (net uptake) of each 
enantiomer on multivariate analyses. 
 






Plasma (+)-perhexiline concentration -0.256 0.015 
Duration of therapy 0.228 0.025 




Plasma (-)-perhexiline concentration -0.347 0.001 
Age 0.288 0.005 
On-treatment heart rate -0.240 0.015 
 
Poor metabolisers were excluded. 
 
 
Uptake of (-)-perhexiline also varied inversely with simultaneous heart rate. 
Similar trends were also apparent with univariate correlations (Figure 4-V).  
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Figure 4-V: Univariate comparisons (Spearman's correlation) between (A) 


































(+ )-A tr ia l: P la s m a  P e rh e x ilin e
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r =  0 .2 0 ; p  =  0 .0 5 3
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(+ )-A tr ia l: P la s m a  P e rh e x ilin e
(-)-A tr ia l: P la s m a  P e rh e x ilin e
r =  -0 .0 1 ; p  =  0 .3 7
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The current analyses complement previously published evaluation of the 
uptake of racemic perhexiline into the human myocardium [296]. It is apparent 
from the current studies that the perhexiline dosing regimen utilized, with 
inadequate time available for adjustment of dosage on the basis of metaboliser 
status, led to wide variability in plasma and myocardial drug concentrations, but 
nonetheless, allowed exploration of determinants of myocardial uptake of 
perhexiline enantiomers.  
The main findings of the current analysis are that: 
1. The main determinant of concentrations of both (+)- and (-)-
perhexiline into atrial and ventricular myocardium is plasma concentration of that 
enantiomer.  
2. Just as plasma (+)-enantiomer concentration exceeds that of (-)-
enantiomer, similar trends are present in myocardium, especially atrial muscle.  
3. Myocardial uptake of each enantiomer also depends on plasma drug 
concentrations and patients' age, where a strong inverse relationship is present.  
4. Atrial uptake of (+)-perhexiline varies positively with duration of 
therapy.  
5. Atrial uptake of (-)-perhexiline varies inversely with simultaneous 
heart rate.  
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These findings carry a number of important implications regarding the 
myocardial handling and effects of perhexiline enantiomers.  
The higher concentrations of (+)- than (-)-enantiomer in plasma are 
consistent with more rapid clearance of the latter. These data are consistent with 
previous publications regarding stereoselective clearance of perhexiline [278,297]. 
On the other hand, myocardial concentration ratios of the enantiomers generally 
parallel those in plasma, suggesting absence of major stereoselectivity in 
myocardial uptake. The exception to this is the small but statistically significant 
increase in the proportion of (+)-enantiomer in the atrial myocardium with time 
(Figure 4-V A). These data suggest that myocardial uptake and efflux of (-)-
perhexiline may be slightly more rapid than that of the (+)-enantiomer. 
The relatively prolonged time required to reach steady-state perhexiline 
concentrations in the ventricular myocardium may reflect greater distribution into 
mitochondria [299], known to represent a site of intracellular drug accumulation for 
perhexiline in hepatocytes [300].  
As regards the interactions between advanced age and cardiac uptake of 
the enantiomers, the current data suggest that uptake of both perhexiline 
enantiomers is greater in older patients, perhaps related to decreased skeletal 
muscle mass. Indeed we have previously also shown that steady-state dosage 
requirements for perhexiline tend to fall with age [277], and in the current study 
plasma perhexiline concentrations increased with patient age (r=0.24, p=0.029). 
Together, these data suggest that elderly individuals may benefit from perhexiline 
therapy despite apparently borderline subtherapeutic plasma drug levels.  
 
 
Chapter 4: Perioperative Perhexiline: Pharmacokinetics versus Effect Considerations 
 
Page | 139 
 
Finally, atrial uptake of (-)-perhexiline varied inversely with concurrent heart 
rate. Perhexiline is a weak L-type calcium antagonist [224,301], although its 
effects on the myocardium have undergone only limited study. The IC50 for 
inhibition of calcium fluxes in chick embryo ventricular myocardium by racemic 
perhexiline was 8.3 x 10-7 M [224]. In the current study, atrial concentrations of (-)-
perhexiline approximated to these values. It is therefore possible that the calcium 
antagonist effect of racemic perhexiline is mediated primarily by the (-)-
enantiomer.  
The current study has several limitations. Most importantly, correlation with 
cardiac effects of perhexiline is limited by the absence of true pre-treatment data. 
Second, myocardial drug content after a median of 9 days of therapy reflects both 
uptake into and efflux from the myocardium, and there is no way to determine the 
precise component of each, given that steady state has not been reached. Finally, 
the full implications of the widely variable plasma perhexiline concentrations on 
variability in drug uptake cannot be fully understood without a strategy of multiple 
drug dosing per patient.  
The current results also need to be related to the clinical context. Recently 
the effects of acute loading of perhexiline in patients with severe ischaemia are 
reported [236,243]. The current data are consistent with the idea that there may be 
early onset of cardioprotective effects, especially in the elderly, at a time when 
plasma drug concentrations are notionally subtherapeutic. Furthermore, the data 
regarding heart rate correlations should stimulate evaluation of whether the 
calcium antagonist effects of perhexiline can be dissociated from its “metabolic” 
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4.7 Where do we stand regarding the uptake of perhexiline 
overall?  
 
Generally, it was shown that, in non-poor metabolizers, steady state 
concentrations of perhexiline were not reached within the ventricles after a week of 
treatment, even though this has been reached within the atrium [72,296]. 
Additionally, while the plasma concentrations of perhexiline were well correlated 
with its myocardial concentrations, the concentrations of perhexiline were almost 
twice as high in the ventricles than in the atrium. This raised the possibility of not 
only potential compartmental accumulation of perhexiline, but also possible 
differential uptake or clearance of perhexiline in the myocardium. Local factors 
such as heart rate may also have played a role in the slow uptake of perhexiline, 
especially the (-)-enantiomer [72]. Additionally, patient’s age also correlated with 
increased myocardial uptake of perhexiline, which may be a reflection of 
decreased skeletal muscle mass; suggesting that older patients may benefit from 
subtherapeutic levels or the lower threshold of the plasma therapeutic range of 
perhexiline [72,296].  
Although it has been appreciated for many years that myocardial drug 
concentrations may not be readily predictable on the basis of plasma drug 
concentrations and methodology for assessment of effects has remained limited, 
the current studies suggested that assessment of the effect of such metabolic 
agent may be more difficult than expected. It was possible that without adequate 
myocardial accumulation of perhexiline in ischaemic patients (plus a lack of 
adequate dose individualization), cardioprotective effects of perhexiline have failed 
to be demonstrated in a recent trial [295].  
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5.1 Benefits of restoring insulin signaling in acute coronary 
syndrome 
 
It is known that patients with diabetes mellitus are at increased risk for the 
occurrence of acute coronary syndromes [302], heart failure [303] and atrial 
fibrillation [304]. However, the contribution of acute elevation of blood glucose 
level to the overall cardiovascular risk is incompletely understood. For example, 
while it is known that acute elevation of blood glucose level increases oxidative 
stress [305], the impact of such oxidative stress on the physiology of vasculature, 
myocardium and platelets is unknown. 
The potential role of impaired NO signaling in the setting of hyperglycaemia 
and acute coronary syndromes (ACS) was investigated in this chapter: it was 
shown reduced platelet responsiveness to the anti-aggregatory effects of NO is 
negatively correlated to admission blood glucose levels (BGL) during ACS [306]. 
In the study, rapid correction of BGL by intravenous insulin therapy not only rapidly 
improved platelet responsiveness to NO, resulting in a potential reduction in 
thrombogenecity, but this was also associated with a reduction of plasma 
superoxide content and plasma ADMA levels. Given that aggressive correction of 
hyperglycaemia with intravenous insulin improves NO response, we hypothesised 
that this effect was also associated with a reduction in TXNIP expression by vurtue 
of the reciprocal relationship between TXNIP expression and platelet responses to 
NO at steady-state [138]. In addition, we also sought to assess changes in other 
markers which are associated with NO signaling, namely plasma ADMA levels, 
superoxide content, endothelial progenitor cells' function and thrombospondin-1.  
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5.2 Background of current study 
 
Hyperglycaemia during acute coronary syndromes is associated with 
substantial mortality [307,308]. Theoretically, this might reflect a number of 
processes including impaired glycolysis, increased fatty acid levels, increased 
cytokine activation, platelet hyperaggregability, and impaired microcirculatory 
function [309].  
Hyperglycaemia is also accompanied by rapid up-regulation of thioredoxin-
interacting protein (TXNIP). TXNIP is a physiological inhibitor of thioredoxin (Trx), 
and suppression of Trx by TXNIP has been demonstrated in diabetes and many 
cardiovascular diseases (see Chong et al [81] for review). TXNIP also exerts Trx-
independent effects, which include direct activation of inflammation and inhibition 
of glucose uptake [82]. The production of TXNIP is stimulated by increased 
glucose levels, hypoxia, and several inflammatory activators (e.g. increased shear 
stress, transforming growth factor β-1 and interleukin 1-β [81]). Insulin therapy 
may reduce TXNIP levels in tissues both via reduced synthesis and increased 
clearance [146], although each of these effects may be organ-specific. For 
example, in human skeletal muscle and adipocytes in cell culture, it was also 
demonstrated that four-hour treatment with insulin significantly reduced mRNA 
expression of TXNIP [147].  Furthermore, insulin accelerates degradation of 
TXNIP via activation of the ubiquitin-proteasome pathway in some, but not all, 
tissues [146]. 
Hyperglycaemia is also linked to reduced availability of nitric oxide (NO), 
perhaps by virtue of increased scavenging by superoxide (O2-) or by increased 
generation of the endogenous NO synthase inhibitor, asymmetric dimethylarginine 
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(ADMA).  There is increasing evidence that suppression of NO generation may be 
in part TXNIP-mediated and indeed that TXNIP may function as a physiological 
antagonist to NO signaling, both in animals [137,150,310] and in humans [138]. 
For example, in aging normal subjects, platelet TXNIP content varies inversely 
with platelet NO responsiveness, with a highly significant negative correlation 
between these two parameters.[138]  
The potential role of impaired NO signaling in the setting of hyperglycemia 
and acute coronary syndrome (ACS) has previously been investigated, showing 
that reduced platelet responsiveness to NO varies inversely to admission blood 
glucose levels (BGL) [306].  The precise mechanism(s) by which correction of 
hyperglycaemia normalises NO signaling remain uncertain. In the initial 
investigation, it was demonstrated that baseline blood O2- content varied inversely 
with NO responsiveness, and rapid reversal of hyperglycaemia reduced O2- 
content and potentiated platelet NO responsiveness [306]:- this would suggest 
diminished NO "scavenging" [123]. In this regard, the potential role of 
thrombospondin-1 (TSP-1), a matrix glycoprotein derived from platelet α-granules 
[311], was not initially evaluated. However, TSP-1 has recently emerged as a 
potent inhibitor of the NO-soluble guanylate cyclase (sGC) signaling cascade 
[311]. 
Furthermore, formation of NO, rather than just integrity of its signaling, may 
also be important. Correction of hyperglycaemia was associated with significant 
fall in plasma ADMA concentrations [306], which have been shown to correlate 
with improved NO generation and with improved function of endothelial progenitor 
cells (EPCs), and thus vascular stabilization [312] (see Figure 5-I for schematic 
view). So far, this has not been explored in the context of ACS or hyperglycaemia.  
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Endothelial progenitor cells are increasingly recognised as important 
biomarkers of vascular function, particularly during the process of "vascular 
repair". Originating from bone marrow, EPCs have proliferative capacity [313]. Not 
only do they repair ongoing vascular damage, promote vascular growth, but they 
also improve endothelialization [313,314]. Additionally, NO and eNOS also play a 
role in EPC-mediated angiogenesis [315]. Thus changes in EPC function may 
potentiate vascular damage associated with hyperglycaemia. 
Given that aggressive correction of hyperglycaemia with intravenous insulin 
infusion improves platelet NO responsiveness [306], it was hypothesised that this 
effect is associated with a reduction in platelet TXNIP content. In addition, the 
changes in other biomarkers associated with NO signaling, including TSP-1 
concentrations, ADMA concentrations, O2- content, and EPCs' function were also 
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Interacting mechanisms impeding nitric oxide generation / signaling and those 
inducing nitrosative stress are indicated. The generation of nitric oxide from L-
arginine is controlled by the nitric oxide synthase (NOS), of which is inhibited by 
asymmetric dimethylarginine (ADMA). Upon release, nitric oxide exerts its effects 
[which includes improvement of the function of endothelial progenitor cells (EPC)], 
via soluble guanylate cyclase (sGC) - cyclic GMP (cGMP) pathway. Although the 
protein affected is unclear, this pathway was previously shown to be inhibited by 
thrombospondin-1 (TSP-1) [311]. It is also known that the pro-inflammatory protein 
thioredoxin interacting protein (TXNIP) inhibits the effect of nitric oxide [138]. 
During acute hyperglycaemia, the superoxide generated scavenges nitric oxide 
and contributes to "nitric oxide resistance" [306], by virtue of increased 
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inflammatory and apoptotic responses. Therefore, restoration of insulin signaling 
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5.3.1 Patients and study protocol 
 
This study was approved by the Ethics of Human Research Committee of 
the Queen Elizabeth Hospital (protocol number: 2010163). Informed consent was 
obtained prior to study entry in all cases. Patients presenting with ACS (angina 
pectoris or non-Q-wave myocardial infarction) excluding S-T elevation infarction 
and an admission BGL > 11.1 mmol/L to correspond to the entry criteria for the 
DIGAMI trial [307] were recruited.  
Criteria for exclusion were:  
1) Concurrent treatment with ADP-receptor blockers (e.g. clopidogrel), 
glycoprotein IIb/IIIa inhibitors or perhexiline, which is known to potentiate NO 
response and lowers BGL [209];  
2) moderate to severe renal insufficiency (serum creatinine > 0.3 mmol/L).  
After baseline investigations, all of the identified patients were subjected to 
intravenous Actrapid® insulin infusion according to the DIGAMI protocol [307], with 
the aim of restoring normoglycaemia within 12 hours. Peripheral venous blood 
samples were collected prior to and 13 ± 0.8 (SEM) hours after the 
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5.3.2 Investigations performed were as follows: 
 
(1) Platelet responsiveness to NO 
This was determined as previously described [316]. Briefly, 10ml of blood 
was collected in tubes containing acid citrate anticoagulant. Platelet aggregation 
was studied in dual-chamber impedance aggregometer (Model 560, Chrono-Log, 
Havertown, Pennsylvania, USA). Aggregation was induced by 2.5 μmol/L of ADP. 
The NO donor sodium nitroprusside (SNP, 10 μmol/L) was used to quantitate 
platelet responsivess to NO, with results expressed as percentage inhibition of 
ADP-induced aggregation.  
 
(2) Total ROS content in whole blood and isolated neutrophils 
a. Blood sampling and preparation of neutrophils 
Blood samples were drawn by venesection from an antecubital vein. Blood 
was collected into heparinized vacutainer tubes for whole blood total ROS 
assessment, or into 24 mmol/L EDTA tube for neutrophil preparation. 
For neutrophil preparation, blood samples were centrifuged at 150 g for 10 
minutes, and plasma was replaced by an equal volume of Hanks’ balanced salt 
solution (HBSS) pH 7.4. Neutrophils were isolated using a Ficoll-Hypaque gradient 
as previously described [209]. The viability of neutrophils was shown to be over 
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b. Electron Paramagnetic Resonance Spectroscopy measurement of 
Reactive Oxygen Species  
Whole blood:   
Quantitation of total ROS in whole blood was performed utilizing electron 
paramagnetic resonance (EPR) spectroscopy, as previously described [317]. All 
samples were prepared for EPR using the spin probe CM-H (1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl pyrrolidine, 400µmol/L) in Krebs-HEPES 
buffer (pH 7.35) in the presence of 25µmol/L deferoxamine and 5µmol/L 
diethyldithiocarbamate, and placed in 50μL glass capillaries (NOXYGEN, Elzach, 
Germany). Reaction of ROS with CM-H generates a stable nitroxide radical, the 
formation of which was measured by monitoring the amplitude of the low-field 
component of the EPR spectrum as previously described [318], and calculated 
from the accumulation of nitroxide, obtained from a calibration curve for intensity of 
the EPR signal of 3-carboxyproxyl. EPR spectra were recorded using an e-scan M 
EPR spectrometer (Bruker, Rheinstetten, Germany) and super-high Q microwave 
cavity with the following settings: field sweep, 10 G; microwave frequency, 9.75 
GHz; microwave power, 19 mW; modulation amplitude, 2 G; conversion time, 
10.24 ms; time constant, 40.96 ms; receiver gain, 3.2 x 102. Data were expressed 
as µM/mL/min of nitroxide accumulation. 
 
Isolated neutrophils: 
For O2- determination by EPR, neutrophils were stimulated with phorbol 12-
myristate 13-acetate (PMA) (100nmol/L, for 20min) at room temperature, and then 
samples were scanned immediately after supplementation of the spin probe CM-H 
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(200μmol/L). EPR settings were identical to those utilized for whole blood ROS 
determination. All EPR experiments were performed in triplicates.  
 
(3) Platelet TXNIP content 
TXNIP content within platelets was analysed by immunohistochemistry 
[138]. Briefly, peripheral blood collected in EDTA-containing tubes were used to 
prepare platelet rich plasma, which was then smeared onto a microscope slide 
and stored at -80°C until further analysis. On the day of analysis, defrosted slides 
were washed with phosphate buffered saline and incubated with 5% goat serum 
for an hour, then with 2% of anti-rabbit VDUP (Invitrogen Corporation, CA, USA) in 
1% of bovine-serum albumin for overnight. On the next day, after the slides were 
washed, they were incubated with 2% of phycoerythrin (PE)-labelled CD41 
antibody (Becton, Dickinson and Company, NJ, USA) as platelet marker, and 1% 
of secondary fluorescein isothiocyanate (FITC)-labelled anti-rabbit antibody 
(Becton, Dickinson and Company, NJ, USA). The slides were then studied using 
inverted fluorescence microscope (Carl Zeiss Microscopy, Oberkochen, 
Germany). Analyses were performed using image analysis software (AxioVision 
40 verion 4.8.2, Carl Zeiss Microscopy, Oberkochen, Germany), and an average 
value was obtained per slide.  
 
(4) Plasma ADMA concentration 
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Plasma ADMA concentrations were determined utilizing derivatization with 
AccQ-Flor to generate stable fluorescent derivatives followed by high performance 
liquid chromatography [319].  
 
(5) Plasma TSP-1 
Plasma TSP-1 concentrations were determined by ELISA according to 
manufacturer's instructions (R&D Systems, MN, USA).  
 
(6) Endothelial Progenitor Cell count 
10mls of blood were collected into an EDTA tube, and then transferred into 
a 50ml tube where 10ml of phosphate buffered saline (PBS) was added and 
underlaid with 15mls of Lymphoprep® or Ficoll-Hypaque® (Axis-Shield, Oslo, 
Norway). The sample was then centrifuged at 550 g for 30 minutes. After 
centrifugation, the "buffy" coat containing mononuclear cells was collected using a 
pipette (see Figure 5-II).  
Circulating endothelial progenitor cells (EPC) were quantified using flow 
cytometric analysis (FACScan, BD Bioscience, NJ, USA) of cells positive for both 
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Figure 5-II: Schematic representation of the various phases of blood 




(7) Endothelial Progenitor Cell function: formation of early colony-
forming units 
EPC were cultured using the method of Shintani et al [314]. Briefly, 
mononuclear cells were isolated using a Ficoll-Hypaque® gradient density 
centrifugation similar to how mononuclear cells are collected in (6). After collection 
of mononulear cells, the cell suspension was cultured in fibronectin coated 6-well 
plates in medium supplemented with 20% foetal bovine serum and 
penicillin/streptomycin (Gibco®). Following 48 hours of incubation, any detached 
cells were washed away with PBS and the remaining attached cells were left to 
incubate in complete medium for 7 days to obtain early EPC. Culture medium was 
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5.3.3 Statistical analyses 
 
Effects, analysed before and after insulin infusion, were compared utilizing 
Student’s paired t-test or paired Wilcoxon test for non-Gaussian data (GraphPad 
Prism 6®). The limit of statistical significance was set at p<0.05. Data were 
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Table 5-I summarizes the clinical demographics of the twelve patients in 
this study. The mean age of these patients was 66 ± 3 years. Apart from the index 
elevation of blood glucose levels, the glycosylated haemoglobin concentrations 
suggested longstanding poor diabetic control. Only 6 of the 12 patients had 
elevation of troponin-T concentrations beyond the normal range, and none of the 
patients had peak creatine kinase > 1000U/L, consistent with minimal levels of 
myocardial necrosis.  
 
 
Table 5-I: Clinical characteristics of the twelve patients 
Age (years) 66 ± 3.2 
Men/ women (%) 58/ 42 
HbA1c (%) 9.8 ± 0.5 
Baseline BGL (mmol/L) 16..6 ± 1.6 
Peak troponin-T (ng/L)  38 (29-285) 
Peak creatine kinase (U/L) 108 (91-438) 
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After insulin infusion, the blood glucose level fell by 7.9 ± 1.4 mmol/L (p < 
0.01; 95% confidence interval: -10.9, -4.8; Figure 5-III A) over 13 ± 0.8 hours of the 
study.  This was associated with a marked improvement in platelet responsiveness 
to the anti-aggregatory effect of sodium nitroprusside (Figure 5-III B). This was 
independent of the pro-aggregatory effect of ADP, which did not change 
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Figure 5-III: Effects of insulin infusion on (A) (Mean) blood glucose level 
(BGL) (B) Platelet responsiveness to NO, measured via inhibition of ADP-
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Mean data are shown.  
 
 
Correction of hyperglycaemia was associated with a significant reduction in 
whole blood ROS (Figure 5-IV A) but no significant change in PMA-stimulated O2- 
release in isolated neutrophil (1.47 x 106 vs 1.31 x106; p=ns). 
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Figure 5-IV: Effects of insulin infusion on (A) whole blood ROS, and (B) 
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As regards potential modulators of changes in NO signaling and ROS 
production, plasma ADMA concentrations (Figure 5-V A) tended to fall (p=0.12; 
mean change -0.04 μmol/L; 95% CI-0.10, 0.01). Neither change in platelet TXNIP 
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content (mean change -18 AU; 95% CI -63, +27) or plasma TSP-1 concentration 
(mean change -246 μmol/L; 95% CI -715, +223) reached statistical significance. 
 
Figure 5-V: Effect of insulin on (A) asymmetric dimethylarginine (ADMA), and 
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While numbers of EPCs did not change significantly (p=ns; mean change -
9.90; 95% CI -52, 33), there was a substantial and significant increase in CFU 
count (Figure 5-VI).  
 
Figure 5-VI: Effects of insulin infusion on (A) endothelial progenitor cell 
(EPC) function [colony-forming unit (CFU) counts at 7 days]. Examples of 
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The current study aimed to delineate the mechanism(s) underlying the 
restoration of tissue NO responsiveness associated with correction of 
hyperglycaemia in ACS patients. It was hypothesised that the previously observed 
reciprocal relationship between glucose control and platelet NO signaling [138] is 
primarily due to a change in platelet TXNIP content, and such improvement in NO 
effectiveness would also lead to improved EPC functionality. Whilst it was 
confirmed that correction of hyperglycaemia is associated with markedly 
augmented platelet NO signaling and a reduction of ROS content, there was not 
any statistically significant reduction of TXNIP content in platelets. Additionally, it 
was considered that a reduction in plasma TSP-1 concentration might occur, thus 
sensitizing sGC to NO [311]: again, this was not observed in practice. EPC 
function (as measured by CFU formation) was increased significantly after 
correction of hyperglycaemia, consistent with increased NO effect [315], despite 
the fact that ADMA concentrations did not decrease significantly.   
Previous studies suggest that insulin exerts its effects via (i) activation of 
the phosphatidylinositol-3-kinase-AKT-eNOS signaling pathway [321] and (ii) 
suppression of both interleukins 6 and 8 and C-reactive protein [322]. It has also 
been shown that while glucose upregulates TXNIP expression [139], insulin 
suppresses TXNIP synthesis at the transcriptional level [146]. However, the 
mechanisms underlying TXNIP suppression vary between tissues and include 
both reduced synthesis and increased clearance by the ubiquitin-proteasome 
pathway [146]. In the current study, platelet TXNIP content did not fall significantly. 
One possible explanation for this lack of change (and the associated loss of 
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previously described nexus between platelet NO signaling and TXNIP content) is 
potential slow turnover of TXNIP in platelets, perhaps related to the absence of a 
nuclear-bound pool of TXNIP, which seems to play a pivotal role in rapid changes 
in TXNIP signaling in nucleated cells [143,323]. The implication, however, is that 
the suppression of ROS generation and associated sensitization of NO signaling is 
largely or entirely TXNIP-independent.  
While the primary hypothesis in the current study related to the potential 
role of insulin-induced reversal of hyperglycaemia in suppressing TXNIP 
expression, a number of other potential biochemical modulators of NO signaling 
were also evaluated serially. Both TSP-1 and ADMA concentrations tended to fall, 
but this change did not reach statistical significance (see Figure 5-V). In a previous 
larger study [306], ADMA concentrations fell to a similar extent following 12 hours 
of insulin therapy, but the change was statistically significant. It is likely that this 
change reflects the impact of diminishing redox stress on metabolic clearance of 
ADMA [324]. However, as ADMA may contribute to O2- generation via NOS 
"uncoupling" [325,326], the diminution of ADMA effect may have supported the 
restoration of NO responsiveness. As regards TSP-1, there was an approximately 
60% fall in concentrations over the study period, but this did not reach significance 
largely due to extreme variability of baseline concentrations. TSP-1 is released 
into plasma via platelet degranulation: the baseline variability suggests 
considerable platelet activation in the presence of hyperglycaemia, in accordance 
with previous data [327]. If indeed a decrease in TSP-1 plasma concentration 
occurs with insulin therapy, this might contribute to increase NO effect, largely via 
improved functionality of sGC [311].  
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While TXNIP suppression may not be the major mechanism for acute 
sensitization of platelets to NO with correction of hyperglycaemia, there are other 
potentially important contributing pathways. Apart from the issue of NOS 
"uncoupling", increased O2- production in hyperglycaemic diabetics might reflect 
activation of a number of redox pathways. For example, in vascular smooth 
muscle of hyperglycaemic rats, insulin limited O2- production not only by NOS, but 
also by NAD(P)H oxidase and xanthine oxidase [328]. Indeed the specific 
contribution of TXNIP to the overall increases in O2- production during 
hyperglycaemia has not been formally evaluated in any tissue to date. However, it 
certainly seems likely that the kinetics of TXNIP responses to variable tissue 
glucose and insulin levels may be far slower in platelets than in nucleated cells.  
Correction of hyperglycaemia during ACS is an important aspect of 
management and impaired platelet NO signaling may predispose to increased 
acute thrombogenesis [329]. Additionally, platelet hyporesponsiveness to NO is an 
independent predictor of all-cause mortality and cardiovascular readmissions in 
high risk ACS patients [330]. Furthermore, improved NO signaling could potentially 
be a mediator of the improvement in EPC functionality currently observed and 
perhaps also of angiogenesis [313,331]. Importantly, these mechanistic 
considerations would apply only to regimens involving actual reversal of 
hyperglycaemia in ACS patients, and thus exclude the glucose-insulin-potassium 
regimen employed in the recently reported CREATE-ECLA trial [332]. 
The results of the current study do not totally exclude involvement of 
changes in TXNIP and TSP-1 effect in modulating NO re-sensitization: they merely 
exclude substantial roles by virtue of the 95% confidence limits on the 
experimental data. It remains possible that diminution in TXNIP effect actually 
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occurred via either a (small) fall in overall platelet content or by changes in 
intracellular TXNIP distribution [143,333]. As regards uncertainty as to whether 
TSP-1 was suppressed, apart from the issue of Type II error, it is possible that 
TSP-1 concentrations within platelets may have changed in a relevant manner, as 
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5.6 Clinical Perspectives 
 
Rapid correction of severe hyperglycaemia with insulin infusion has been 
shown to improve clinical outcomes in acute coronary syndrome but the 
mechanisms underlying this benefit remain unclear. The current investigation 
confirms that in such patients, treatment of hyperglycaemia reverses impairment of 
platelet nitric oxide signaling, and demonstrates improvement of endothelial 
progenitor cell function, without significant reduction in platelet thioredoxin-
interacting protein content. These data emphasize the benefit of urgent reversal of 
hyperglycaemia in all patients with acute myocardial ischaemia.  
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6.1 Efficacy of perhexiline in restoring insulin signaling  
 
6.1.1 Diabetes mellitus: a "precursor" of cardiovascular disease 
 
Although great progress has been made in recent years regarding the 
management of both type 2 diabetes mellitus (DM) and cardiovascular disease, in 
many patients the eventual outcomes are poor. DM is a chronic disease with 
potentially serious complications, estimated to affect over 2.5 million Australians 
within 20 years [335]. With the increasing age and longevity of the general 
population, DM not only increasingly imposes a substantial impact on the 
healthcare economy, but it is also an independent risk factor for acute coronary 
disease and cardiomyopathy [335], with  a concomitant two to four fold increase in 
risks of developing cardiovascular disease [336,337]. Modifications of traditional 
risk factors in patients with diabetes and insulin resistance have been effective, but 
these patients still have an increased morbidity and mortality compared to the non-
diabetics.  On the other hand, in the western world, heart failure (HF) often coexist 
with DM, and remains the most common cause of hospitalization [338]. Refractory 
symptoms, contraindications to surgery, and/or intolerability to the currently 
available pharmacological agents lead to many “sad survivors”.  
Epidemiological study showed that DM increases the risk of HF by 2.5-fold, 
even when adjusted for coronary artery disease and other comorbidities [99,100]. 
On the other hand, HF presents earlier in the diabetic than non-diabetic patients 
[99]. Therefore, it is likely that left ventricular (LV) dysfunction seen in diabetic 
patients is a reflection of both increased coronary disease (secondary to 
atherosclerosis), as well as a specific "diabetic cardiomyopathy" (DCM) [339].  
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In the absence of ischaemia or other concurrent cardiovascular disease, 
diastolic abnormalities are an early functional defect in the diabetic heart, with 
prevalence rates range from 15-75% in the asymptomatic normotensive patients 
[339,340]. There is often mild systolic dysfunction, often depending on the severity 
or duration of disease. However, despite the absence of systolic dysfunction and 
the lack of known coronary disease or ECG detectable ischaemic changes, 
patients with diabetes have a lower myocardial PCr to ATP ratio than the matched 
healthy controls, suggesting that patients with diabetes are “cardiac energy-
deficient” [341]. Furthermore, as previously described in Chapter 5, diabetes, 
especially with concomitant hyperglycaemia, represents the basis for 
mitochondrial dysfunction and consequent energetic impairment. Therefore, 
restoring systemic metabolic homeostasis may present a potential 
pharmacological alternative to prevent the progression of heart disease in patients 
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6.1.2 Complications of long-term diabetes: mechanisms of toxicity 
 
Glucose is the driving force of macro- and microvascular complications of 
diabetes. However, the actions of glucose alone may be inadequate to account for 
all the excess atherosclerosis and vascular disease observed in diabetics. It has 
been found that, in diabetic patients there is an increase in plasma free fatty acid 
concentrations leading to an increased in fatty acid uptake and oxidation [342]. Not 
only is this process pro-inflammatory [342], it would lead to reduced utilization of 
glucose as a source of energy during ischaemia and stress, and as suggested 
previously, would potentially increase the vulnerability of diabetic heart under 
anoxic conditions.  
Additionally, upregulation of TXNIP during hyperglycaemia (as discussed in 
Chapters 1.2.4 and 2.1.3) is not only pro-inflammatory, pro-aggregatory but also 
pro-apoptotic; thus representing a potential therapeutic target. 
In 2000, Nishikawa et al characterised four major signaling pathways 
activated by hyperglycaemia in endothelial cells: activation of the protein kinase C 
pathway via diacylglycerol, increased hexosamine pathway flux, increased 
advanced glycation end product, and increased polyol pathway flux [343] (see 
Figure 6-I). All these four pathways lead to an integrated eventual increased 
production of reactive oxygen species by the mitochondrial electron transport 
chain. Recently, Du et al showed that the downstream target of such oxidant 
stress is PARP (see Chapter 1.2.2 for discussion of effects): its activation leads to 
ribosylation and inactivation of glyceryaldehyde-3-phosphate dehydrogenase 
(GAPDH). Inhibition of GAPDH leads to increased intermediaries, which will 
eventually lead to increased mitochondrial oxidative stress [344].  
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During hyperglycaemia, excess glucose flux leads to excessive generation of 
superoxide by mitochondria when fluxed through the electron transport chain. This  
leads to the eventual DNA strand breakage and activation of PARP. Activated 
PARP inhibits GAPDH, which will then shunt glucose oxidation into the polyol 
pathway and lead to the activation of protein kinase C or advanced glycation end 
product. 
Abbreviations: GLUT = glucose transporter; DAG = diacylglycerol; PKC = protein 
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Parallel to this, there is also recent evidence that chronic supplementation 
with the antioxidant coenzyme Q10, commenced in the presence of 
hyperglycaemia (in both type 1 and type 2 diabetic mice models), induced 
attenuation of cardiac complications [345,346]. Such benefits include reduction in 
cardiomyocyte hypertrophy, fibrosis and apoptosis (all by approximately 50%), as 
well as reduced production of superoxide and expression of NADPH oxidase (a 
major cellular source of superoxide). Furthermore, it has also been shown that 
targeting ROS in vivo prevents diabetes-induced suppression of LV SERCA2a 
(sarco(endo)plasmic reticulum Ca2+-ATPase) [345], a key mechanism of diabetes-
induced LV dysfunction. Therefore, targeting elevated ROS in the diabetic 
myocardium represents an attractive therapeutic target for the prevention and/or 





Chapter 6: Perhexiline in insulin sensitization 
 
Page | 173 
 
6.1.3 Therapeutic manipulation of insulin sensitivity: current perspectives 
 
While it is known that insulin therapy augments glucose oxidation, it has 
been shown that such effect (especially during high oxidative stress, e.g. 
myocardial ischaemia) is also accompanied with increased platelet nitric oxide 
responsiveness [306]  (a prognostic marker in acute coronary syndrome [330]), 
reduced celullar oxidative stress, and possibly improved survival and long-term 
prognosis [307,347]. 
Analogously with their mechanism(s) of actions and clinical utility in the 
treatment of diabetes, it is of no surprise that a number of oral hypoglycaemic 
agents have been shown to prevent type 2 diabetes in high risk individuals. First, 
in the United State's Diabetes Prevention Program (n=3234), metformin 850mg 
twice daily reduced incidence of type 2 diabetes by approximately 30% (as 
compared to placebo) in a group of overweight patients over 3 years [348]. In the 
STOP-NIDDM trial (Study to Prevent Non-Insulin Dependent Diabetes), treatment 
with acarbose resulted in reduced rates of abnormal oral glucose tolerance test 
(relative risk reduction of approximately 30%) after two years of treatment [349]. 
Rosiglitazone, an agonist of the peroxisome proliferator activated receptor-
gamma, has also been shown to reduce incidence of type 2 diabetes and increase 
the likelihood of regression to normoglycaemia in adults with impaired glucose 
tolerance [350]. Interestingly, orlistat, an anti-obesity drug, also reduced incidence 
of diabetes by approximately 37% (compared to placebo) after a median of four 
year follow up [351].  
Importantly, angiotensin converting enzyme inhibitor (ACE-i) or angiotensin 
II receptor blocker (ARB), two classes of drugs that are commonly used in patients 
 
 
Chapter 6: Perhexiline in insulin sensitization 
 
Page | 174 
 
with cardiovascular disease, have also been shown to improve insulin sensitivity. 
A recent meta-analysis showed that in patients without diabetes, both types of 
agents improved insulin sensitivity, with ACE-i being more effective than ARB in 
ameliorating insulin resistance in hypertensive patients without diabetes [352].  
Epidemiological evidence that ACE-i or ARB limited development of 
diabetes is ample, though conflicting. The Captopril Prevention Project (CAPPP) 
showing that patients treated with captopril had 14% lower rates of newly 
diagnosed type 2 diabetes compared to controls [353]. This result was then 
confirmed in the Heart Outcomes Prevention Evaluation (HOPE) trial which 
showed that during the 4 to 5 year period of the trial, only 3.6% of those treated 
with ramipril developed diabetes as compared to 5.4% of those in the placebo 
group [354]. A similar trend was also observed in the Losartan Intervention For 
Endpoint reduction in hypertension study (LIFE), where there was a 25% reduction 
in the development of type 2 diabetes in patients randomised to losartan therapy 
[355]. However, a recent prospective trial investigating the effect of ramipril in pre-
diabetic patients showed that ramipril did not reduce the incidence of diabetes 
after a median follow up of 3 years [356]; nor did it improve β-cell functions, as 
measured by insulinogenic index and proinsulin concentrations [357]. 
The mechanism(s) of improvement of insulin sensitivity by ACE-i or ARB 
are not completely understood but several have been postulated. First, it has long 
been postulated that mitochondrial dysfunction and subsequent oxidative stress is 
a common ground for insulin resistance, diabetes and cardiovascular disease 
[358].  By virtue of reducing cellular oxidative activity, several agents, including 
calcium channel antagonist and statins may potentially improve insulin sensitivity 
(see Figure 6-II).   
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It should also be recognised that angiotensin II reduced the activation of 
insulin signaling [359,360]. Thus ACE-i or ARB therapy potentially may prevent 
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Modified from reference [358]. 
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6.1.4 Insulin sensitization by perhexiline: current relevance  
 
Perhexiline was previously reported to cause hypoglycaemia [239,242], 
particularly when utilized in conjunction with diabetic treatment regimens. The 
literature in this regard consists largely of case reports, many dating back to the 
period of initial clinical experience with perhexiline [242]. There is little information 
concerning the effects of perhexiline in patients receiving ACE-inhibitors or ARB; 
both of which insulin sensitizers. This is potentially important because recent 
clinical studies have provided a strong basis for the routine use of ACE inhibitors 
in particularly in diabetics at risk of myocardial ischaemia [354].  
There are several reasons that perhexiline may improve insulin sensitivity. 
First, it inhibits CPT-1 [176] and promote glucose uptake. In addition to that, in the 
myocardium of non-diabetic patients, perhexiline has also been shown to increase 
activation of AMPK [280], a pharmacological action shared by metformin. 
Additionaly, perhexiline reduces oxidative stress, via inhibition of NAD(P)H 
oxidase [208]; and as suggested previously (Chapter 1.2.4), reduction in oxidative 
stress activity could potentially lead to improved insulin sensitivity.  
TXNIP was shown in a recent microarray study to be the most upregulated 
gene in diabetic patients [139]; and is implicated in the complications of diabetes. 
Calcium channel antagonists reduced the expression of TXNIP in the heart and 
pancreas [154], and therefore potentially could be utilized as "first-line" agents to 
prevent diabetes-induced heart disease (assumimg a primary role for TXNIP). 
Perhexiline, either by other mechanism(s) or by its action as a  weak calcium 
channel antagonist [224], has also been shown to reduce the expression of TXNIP 
in non-diabetic patients [280].  
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Perhexiline, being a potent prophylactic anti-anginal and anti-failure agent, 
is increasingly utilized in wide range of cardiovascular disease states. Devoid of 
direct haemodynamic effects (and in particular negative inotropy), perhexiline 
presents itself as being more advantageous than other cardiovascular agents 
currently available in this regard, especially when used in elderly patients. Should 
it be proven to also improve insulin sensitivity, it is likely to be preferred in patients 
with diabetes and cardiovascular disease.  
A further dimension of interest in this regard is added by the increasing 
need to treat patients with concomitant diabetes, renal insufficiency and refractory 
cardiovascular disease. For example, in recently reported large series of patients 
with advanced heart failure, type 2 diabetes is present in approximately 20 % of 
the population studies [361,362], while approximately 16 to 40 % have moderate 
to severe renal insufficiency [363,364].  
The implications of such renal insufficiency are considerable: there is an 
incremental risk of precipitating bradyarrhythmis through hyperkalaemia if 
aldosterone antagonist are used, and the safety of ACE-inhibitors is not clear-cut. 
On the other hand, perhexiline can be used safely in such patients [277] and is 
therefore increasingly prescribed in diabetics with renal insufficiency.  
We now report an investigation to determine both the extent and 
mechanism(s) of putative insulin sensitization in a population of diabetic patients 
treated with perhexiline.   
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6.2 Objectives of current study 
 
This study tests the hypothesis that perhexiline is an insulin sensitizing 
agent in a cohort of individuals receiving prior pharmacotherapy for insulin 
resistance. 
Specifically, we sought to examine the putative insulin-sensitizing effect of 
perhexiline in the circumstance of extensive pre-treatment with ACE-inhibitor or 
angiotensin receptor blockers and/or metformin. 
Furthermore, we wished to determine whether the utilization of perhexiline 
in this cohort was:- 
(1) associated with NO sensitization (as in patients wiht unstable angina) 
(2) associated with suppression of platelet TXNIP expression, given that: 
 (i) ACE inhibitors and metformin suppress TXNIP 
 (ii) TXNIP suppression represents a possible mechanisms for NO  
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The trial was approved by The Queen Elizabeth Hospital/ Lyell McEwin 
Hospital human ethics committee (HREC/13/TQEHLMH/220) and registered in the 
Australian New Zealand Clinical Trials Registry (ACTRN12615000497505).  
Patients were recruited from the outpatient clinic of Cardiology Department, 
The Queen Elizabeth Hospital. Criteria for inclusion were: 
1. Known coronary artery disease, heart failure or symptomatic aortic 
stenosis 
2. Diagnosed with diabetes mellitus or pre-diabetes  
Exclusion criteria include: 
1. <18 years old 
2. Pregnancy, or women of childbearing age who are not using 
effective contraception 
3. Concurent treatment with any P2Y12 antagonist or perhexiline 
The regimen for initiation of perhexiline maleate was 600mg as loading 
dose on day 1, then 100mg bd from day 2 onwards or dose adjusted according to 
plasma concentration. Fasting blood sample were taken before and 2 weeks after 
perhexiline treatment (for following analyses); additional plasma samples were 
also taken on day 2 and day 14 for determination of plasma perhexiline 




Chapter 6: Perhexiline in insulin sensitization 
 
Page | 181 
 
1. Fasting glucose and insulin concentrations 
2. Platelet response to anti-aggregatory effect of NO donor sodium 
nitroprusside 
3. Platelet content of TXNIP 
4. Plasma thrombospondin-1 
5. Asymmetric dimethylarginine 
6. Myeloperoxidase, determined by enzyme-linked immunosorbent 
assay (ELISA; Mercodia, Sweden)  
7. Hepatic function tests  
Patients were divided into two groups, depending on their prior treatment 
with an ACE-inhibitor or angiotensin receptor blocker. Power calculation for patient 
sample was based on previous result within the group [138] using platelet 
expression of TXNIP as primary endpoint. In the previous study, it was shown that 
compared to control, treatment with ramipril for two weeks reduced platelet TXNIP 
expression from 286 ± 95 (SD) down to 172 ± 76. Therefore, in order to detect 
30% change with ACE-inhibitor treated patients, n=18 will provide ~80% of power 
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Thirty patients were recruited and completed 2 weeks of perhexiline 
therapy. Dosage of perhexiline was adjusted based on plasma drug level to 
achieve therapeutic concentration of 0.15-0.6 mg/L. Baseline characteristics were 
described in Table 6-I. In general, these are well-controlled type 2 diabetics; 
majority were already on ACE-inibitors or ARB. Most of the patients were on ≥ 1 
hypoglycaemic agent.  
None of the subjects experienced significant adverse effects, including 
symptomatic hypoglycaemia after perhexiline treatment.  
Of the 30 patients, 83% had been formally diagnosed with type 2 diabetes. 
All were receiving some form of insulin-sensitizing therapy, and 27% were 
receiving both metformin and an ACE-innibitor or angiotensin receptor blocker. 
Given that the primary indication for perhexiline treatment was angina 
pectoris in 70% of patients, it is not surprising that 17% were receiving calcium 
antagonists (notably verapamil or diltiazem in all cases).  
Extent of diabetic control was variable among these patients but none had 
required admission for management of hyperglycaemmia within the preceding 







Chapter 6: Perhexiline in insulin sensitization 
 
Page | 183 
 




Age (years: mean ± SD) 69 ± 11  
Female (%) 37 
HbA1c (%) 7.4 ± 1.5 
Principal indication for perhexiline therapy  
Refractory angina (%) 70 
Systolic heart failure (%) 23 
Symptomatic aortic stenosis (%) 20 
Concurrent Pharmacotherapy  
ACE-inhibitors/ ARB (%) 73 
Metformin (%) 37 
Insulin (%)  23 
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Figure 6-III: Effect of perhexiline on (A) fasting blood glucose level and (B) 




Perhexiline concentrations were within therapeutic range (0.30 ± 0.04 mg/L) 
after 2 weeks of perhexiline therapy. 4 of the patients were poor metabolisers of 
perhexiline; hence requiring weekly dosing of perhexiline only. As shown in Figure 
6-III, fasting blood glucose level did not change significantly after perhexiline 
therapy; from 6.8 (95%CI: 5.7, 8.6) to 7.0 mmol/L (95% CI: 6.0, 8.7). Plasma 
insulin level increased marginally but significantly from 18.5 (95% CI: 11.8, 25.3) to 
19.0 mU/L (95% CI: 11.8, 37.3; p<0.05).  
Insulin sensitivity increased marginally: when measured by HOMA-IR 
(Figure 6-IV A) this increase was statistically significant (median 4.5 to 6.2; 
p<0.05); while when measured by QUICKI there was a fall in overall score from 
0.158 to 0.156 (p=0.07), consistent with a minimal degree of insulin sensitization 
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Figure 6-IV: Effects of two weeks of perhexiline on insulin sensitivity, as 




Perhexiline treatment was associated with a substantial improvement in 
platelet responsiveness to the anti-aggregatory effect of the NO donor sodium 
nitroprusside (5 μM), from 16.7 ± 16.0 to 27.3 ± 19.8 % (p<0.01; see Figure 6-V). 
There was no significant change in platelet content of TXNIP [127.6 (95% CI: 91.1, 
154.4) vs 113.9 AU (95% CI: 86.3, 154.4); p=0.36], plasma ADMA concentrations 
(0.69 ± 0.09 vs 0.68 ± 0.09 μM; p=0.48), plasma thrombospondin-1 concentrations 
[94.64 (95% CI: 47.45, 133.0) vs 138.7 μM (95% CI: 43.69, 198.3); p=0.09], and 
plasma MPO concentrations [69.16 (95% CI: 46.35, 93.27) vs 61.47 (95% CI: 
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Figure 6-V: Effects of perhexiline on (A) platelet responsiveness to sodium 
nitroprusside; (B) platelet content of TXNIP; (C) NOS inhibitor, ADMA; (D) 
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6.5 Discussion  
 
The objectives of this study related to the emerging clinical roles of 
perhexiline in conditions such as severe angina pectoris and congestive heart 
failure. During the development of perhexiline, the management of patients with 
concomitant diabetes was different from that which applies today, with a central 
role for sulphonylurea derivatives in the majority of aptients who were not well-
controlled with diet, or who did not require insulin therapy. Furthermore, ACE-
inhibitors were not routinely used in type 2 diabetics for cardiovascular protection 
as they are today following the results of the HOPE [354] and EUROPA [365] 
studies. 
Thus we have arrived at a modern setting where diabetic patients with 
myocardial ischaemia or heart failure are very likely to be receiving, inter alia, 
metformin, an inhibitor of AMPK which appears to be cardioprotective [87] and 
ACE inhibitors. Both of these (group of) drugs are not only insulin-sensitizing, but 
also have been shown to inhibit TXNIP expression, perhaps via the insulin 
sensitization [138,148]. 
Perhexiline has many actions, but perhaps the best established is CPT-1 
(and CPT-2) inhibition [176]. The class of CPT-inhibitors is well known to act as 
insulin sensitizers: indeed one of this group, etomoxir, was originally evaluated for 
efficacy in the treatment of type 2 diabetes [366,367]. Hence it is not surprising 
that perhexiline has been reported both to lower blood sugar level as a “routine” 
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The question, which was addressed in the current study, was whether this 
effect would persist in the context of “modern” treatment of diabetes, with 
concomitant use in many cases of metformin and ACE-inhibitors. Indeed, in the 
group studied, 37% of patients were treated with metformin, and 73% with ACE-
inhibitors or angiotensin receptor blockers. 
Furtermore, we were interested, not only whether perhexiline might be an 
insulin-sensitizer in this setting, but whether the “accessory” 
 actions of the drug might be relevant in this therapeutic context. As regards these 
“secondary” effects, we tested for some, but not all. Specifically:-  
(1) TXNIP suppression has been observed in human myocardium with 
perhexiline [280], but only reported thus far in the non-diabetics. This 
could theoretically be less prominent in an environment including 
metformin, ACE-inhibitors, and insulin, all of which themselves 
suppress TXNIP [81]. 
(2) Potentiation of platelet NO signaling has consistently been reported 
with perhexiline [209]. The mechanism of the effect is uncertain, but 
could be: 
(a) TXNIP suppression 
(b) Decreased NOX expression 
(c) Decreased thrombospondin-1 expression, given the NO-
suppressing effects of thrombospondin-1 [311]. 
Additionally, there is preliminary evidence that perhexiline may increase 
activation of AMP kinase [280], but this was not tested in the current experiments. 
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The results of the secondary objectives of the study therefore can be 
summarized as follows:- While perhexiline is a marginal insulin sensitizer in the 
context of normal diabetic therapy, it retains a clear-cut NO-potentiating effect, and 
the mechanism of which is uncertain. 
This should be clarified on the basis that the study was of only 30 patients, 
so that small changes might have been subject to Type 2 error. Nevertheless, as 
regards the other “accessory” actions of perhexiline:- 
(1) TXNIP content tended to decrease (mean fall 6%; 95% CI -36, +27%). 
Thus a major degree of TXNIP suppression can be excluded, but 
involvement of TXNIP in insulin sensitization cannot.  
(2) NOX expression was not measured, but given the role of NOX in 
generation of reactive oxygen species [369], this remains a possible 
contributor to the observed effects. A follow-up study should evaluate 
changes in NOX expression in both platelets and leukocytes in this 
population.  
(3) Thrombospondin-1 levels in plasma tended to rise, rather than fall. Thus 
it seems most unlikely that the NO-suppressing effects of 
thrombospondin-1 [311] are relevant in this context.  
Overall, the study augments evidence for the safety of perhexiline in 
diabetics. There should be less concern about severe hypoglycaemia, and 
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7.1 Improving on perhexiline: a therapeutic holy grail?  
 
Manipulation of myocardial metabolism has proven not only to improve 
cardiac efficiency but also to exert cardioprotective effects. Currently, there are 
very few cardiovascular pharmacological agents on the market that are known to 
be "metabolic". Amongst these are perhexiline, trimetazidine, etomoxir, oxfenicine 
(all with variable adverse effects) and to a lesser extent, amiodarone and 
potentially ranolazine. Therefore investigation of other agents with increased 
therapeutic efficiency and reduced adverse effects is desired.  
First, previous pharmacokinetics and toxicology studies from our laboratory 
suggested that the enantiomers of perhexiline are different: not only that the 
pharmacokinetic profile of the enantiomers was significantly different 
[297,370,371], but the toxicology profile, especially that of (-)-perhexiline [286], 
suggested that it could potentially be utilised with less risk of known long-term 
adverse effects of racemic perhexiline. Rats that were treated with (-)-perhexiline 
displayed significantly lesser accumulation of hepatic lipid droplets and 
neurovascular toxicity [286]. Such observations prompted further investigation of 
the pharmacology profile of these agents.  
Parallel to the development of perhexiline enantiomers, biochemists from 
Kosterlitz Institute, University of Aberdeen are also investigating new forms of 
perhexiline. Analogues were designed to modify the structures of perhexiline with 
two principal objectives: (1) to reduce importance of metabolism by CYP2D6 and 
(2) to facilitate metabolism by other less variable, more rapid, pathways.  
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Thus it was hoped that an analogue with more convenient and predictable 
pharmacokinetic profile could be developed. However, the chemical structures of 
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7.1.1 CPT- inhibition by anti-arrhythmic agents: dronedarone and 
amiodarone 
 
7.1.1.1 Amiodarone: effect beyond anti-arrhythmia 
 
Amiodarone is known to be an antiarrhythmic agent that inhibits the 
sodium channel, β-adrenoceptors, L-type calcium channels and prolongs 
action potential duration via potassium channel blockade [372-374]. 
Interestingly, it was originally introduced as an anti-anginal agent. However, 
like perhexiline, amiodarone per se did not exert significant haemodynamic 
effects [375], although some may result from its dissolution in polysorbate 80 
[376,377]).  
In 1996, Kennedy et al hypothesized that like perhexiline, amiodarone 
was a CPT-1 inhibitor [176]. Indeed, it was found that amiodarone is a weak 
CPT-1 inhibitor. The IC50 for cardiac CPT-1 by amiodarone was 
approximately 200 µM, as compared to approximately 70 µM by perhexiline. 
Therefore, amiodarone was less potent (on a molar basis) than perhexiline in 
potentially decreasing fatty acid metabolism in favour of carbohydrate 
metabolism and thereby increasing cardiac efficiency.  
The finding that amiodarone inhibited CPT-1 had a number of 
implications: 
(1) It provided an explanation for the occasional development of 
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(2) It provided additional evidence for the known anti-anginal effects of 
the drug. 
(3) It provided a possible basis for the beneficial effects of amiodarone 
in systolic heart failure in the GESICA trial [386]. 
(4) It raised the issue of potential risk of incremental toxicity if 
amiodarone and perhexiline are co-administered. However, an audit 
of a small number of such patients suggested that risk is slight 
[240].  
Finally, these findings were potentially of significance beyond 
amiodarone, given that other benzofuran derivatives are being developed for 
potential clinical use [387]. One such agent is dronedarone.  
 
 
7.1.1.2 Dronedarone and amiodarone:  similarities and differences 
 
Dronedarone was developed by modifying the structure of 
amiodarone, removing iodine but retaining the benzofuran component, in an 
effort to reduce toxicity and improve pharmacokinetic profile. Indeed, iodine-
related thyroid toxicity do not occur with dronedarone [388]. In the first 
placebo-controlled, double-blinded, parallel arm clinical trial of dronedarone 
to assess the efficacy in preventing cardiovascular hospitalization or all-
cause mortality in patients with atrial fibrillation (the ATHENA trial [389]), 
dronedarone was shown to reduce the agglomerate end-point of 
hospitalization from cardiovascular events and death from cardiac 
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arrhythmia. After ATHENA, many drug regulatory authorities around the 
world approved its usage and it rapidly became part of the algorithm of 
treatment guidelines for the management of atrial fibrillation. However, the 
subsequent PALLAS trial showed (strikingly and confusingly) an increased 
incidence of heart failure with dronedarone therapy in patients with sustained 
atrial fibrillation [390]. Indeed, two other randomized studies suggested that 
there might be substantial problems with dronedarone: in the ANDROMEDA 
study [391], it was shown that dronedarone increased mortality rates in 
patients with severe systolic left ventricular dysfunction, while in the 
DIONYSOS study [392], it emerged that dronedarone was less effective than 
amiodarone in preventing AF recurrence. Such conflicting results have 
sparked various speculations around its relative efficacy versus toxicity 
profile. Additionally, a few cases of dronedarone hepatotoxicity have been 
reported [393,394]. Indeed thus far, dronedarone has not been released in 
Australia, largely because of concerns regarding its toxicity.  
The latter finding bags the question of the precise mechanism(s) of 
effect of dronedarone: it has been labelled a “multi-channel blocker”, but the 
issue of concern here was whether it retained the CPT-1 inhibition effect 
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7.2 Purpose of the study  
 
This study represented a component of the therapeutic screening process 
for: (a) enantiomers of perhexiline, (b) newly synthesized perhexiline analogues, 
and (c) dronedarone.  
The major issues to be investigated were the potency of these various 
therapeutic candidate drugs as inhibitors of cardiac and hepatic CPT-1, the main 
known mechanism of benefit and toxicity of perhexiline respectively. Although 
clinical use of perhexiline is associated with low incidence of adverse events in the 
context of regular therapeutic drug monitoring (Chapter 3), its clinical usage is 
partially hindered by the need of plasma concentration monitoring, accurate 
interpretation of results and variable dosage adjustment. It is expected that the 
newer agents (enantiomers of perhexiline or the newly synthesized analogues) 
would eliminate the need of drug monitoring and the use of a more straightforward 
dosing regimen will promote its clinical use. In the context of dronedarone, on the 
other hand, investigation of CPT-1 activity could potentially provide mechanism of 
benefit and toxicity associated with the drug, and serve as a basis for future drug 
development.  
As regards to the four newly synthesized analogues, which are fluorinated 
derivatives of perhexiline, the primary objective of it was to derive a compound 
with similar efficacy with that of racemic-perhexiline, in terms of CPT-1 inhibition, 
but more predictable metabolism. However, given that the intellectual properties of 
these compounds reside within collaborators at the University of Aberdeen (UK), 
their structural analogues are not revealed in the context of this thesis, and are 
therefore only abbreviated as FPER1, FPER2, FPER3 and FPER4.  
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Studies were performed in healthy rat tissues under normoxic conditions. 
The CPT-1 activity developed by Kennedy et al [176] (which originally adopted 
from McGarry et al [16]) was employed with modifications. Essentially, enzymatic 
activity was measured by the formation of palmitoyl-carnitine from palmitoyl-CoA 
and l-carnitine (to be discussed further in this Chapter).   
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7.3 Methods   
 
7.3.1 Animals utilized, reagents and materials 
 
Male Sprague-Dawley rats aged 6 – 8 weeks old were used. Ethics 
approval was obtained from both the University of Adelaide (M-2012-039) and SA 
Pathology (12/12).  
All reagents and materials were purchased from Sigma-Aldrich®. The only 
exceptions were D3-palmitoyl carnitine (Cambridge Isotope Laboratories®), 
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7.3.2 Sample preparation procedure: Tissue preparation and enzymatic 
assay 
 
In studies examining the IC50 for CPT-1 inhibition of investigational drugs, 
rats of 6-8 weeks were euthanised under inhaled isoflurane 2 to 3%. Once 
removed, hearts and livers were placed in ice-cold isolation buffer (pH 7.4) 
consisting of 10 mM Tris-HCl, 250 mmol/L sucrose and 1 mmol/L EDTA 
immediately 1:5 (w/v). The tissues were homogenised using a Polytron PT-3000 
(Kinematica®), with great care taken to avoid overheating by using half-maximal 
speed for three to five bursts of three seconds, separated by thirty seconds. Then 
supernatant was obtained by centrifuging the solution for ten minutes at 600 g and 
4°C. In some experiments the supernatant (homogenate) was used as such; with 
protein concentration of 2 mg/ml was used in enzyme reaction assay. In some 
other experiments where mitochondria were needed, further centrifugation at 7000 
g and 4°C for ten minutes was performed. The pellet was then resuspended to the 
original volume with isolation buffer and re-centrifuged at 7000 g for ten minutes at 
4°C. The subsequent pellet was then resuspended. Following protein estimation, a 
solution with protein concentration of 1 mg/ml was used in enzyme reaction assay.  
The incubate consisted of 400 μl of incubation buffer (pH 7.4), which 
contained 6.25 μmol Tris-HCl, 72 μmol KCl, 2.85 μmol of reduced glutathione, 
1.45 μmol of KCN, 1 μmol of MgCl2, 5 μL of ethanol, and 2.7 mg of bovine serum 
albumin without free fatty acid. 50 μl of homogenates containing CPT-1 (2 mg/ml 
of protein concentrations if whole tissue homogenate were used; or 1 mg/ml of 
protein if mitochondria was to be isolated) were added per assay to the incubate in 
a shaking water bath at 37°C for 5 minutes. Pilot experiments were conducted with 
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perhexiline to replicate the method of Kennedy et al [176], with 5 μl of the inhibitor 
(final concentration of 100 μM) with 15 minutes of pre-incubation would employed. 
The enzymatic reaction was commenced by adding 50 μL substrate mix, 
consisting of 100 μmol/L palmitoyl-CoA and 400 μmol/L of [3H]-l-carnitine 
(prepared in milliQ water). After 1.5 minutes, the reaction was terminated by 
adding 50 μL of concentrated HCl. Samples were then diluted with 1.45 mL of 
distilled water, and the product palmitoyl-[3H]-carnitine was extracted with 1 mL of 
n-butanol and measured by scintillation counting (Wallac Trilux 1450 Microbeta® 
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7.3.3 Preparation of investigational drugs 
 
7.3.3.1 Perhexiline and perhexiline enantiomers 
 
Racemic perhexiline maleate (obtained from Sigma®) was dissolved in 
sodium hydroxide solution. It was then extracted with ether, washed with 
water and dried with magnesium sulphate, to obtain pure racemic 
perhexiline. Pure (+) and (-)-perhexiline maleate were available in the Clinical 
Pharmacology department and had been prepared according to the method 
of Davies et al (2006)  [298].  
(+), (-) or racemic-perhexiline (dissolved in ethanol) at concentrations 
of 10, 20, 50, 80, 100, 150, and 200 µM were used. Fifteen minutes pre-
incubation of investigation drug  with the incubate buffer at 37 °C shaking 
water bath was employed [176]. Malonyl-CoA (1 µM) was used as a positive 
control to confirm enzyme inhibition. Hepatic tissue without the addition of 
any drug (vehicle only) was used as a measure of 100% CPT-1 activity; and 
hepatic tissue without the addition of enzymatic substrate (i.e. palmitoyl-CoA 
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7.3.3.2 Fluorinated perhexiline analogues 
 
Known weights of the four analogues (FPER1, FPER2, FPER3, 
FPER4) were received from Kosterlitz Institute, University of Aberdeen, UK. 
Except for FPER2, all other analogues were dissolved in ethanol.  
FPER1 appeared as visible powder, and a 10mM stock solution was 
prepared. FPER3 appeared as brown stain on bottle with no visible powder, 
and hence 500 μl of ethanol was added into the bottle and a stock solution of 
70.4 mM was prepared. No visible powder appeared with FPER4, and hence 
50 μl of ethanol was added into the bottle to make a stock concentration of 
74.9 mM.  
FPER2 was originally dissolved in 600 μl ethanol (to make a 
concentration of 46.7 mM). However the powder did not dissolve even after 
extensive vortexing. After consultation with Dr Iain Greig (Kosterlitz Institute, 
Aberdeen), the solution was left to dry under room temperature and 
dissolved later in 600 μl of DMSO.   
Racemic perhexiline (final concentration of 100 μM) was used as 
comparator. Similar to the previous experiments, malonyl-CoA 1μM was 
used as a positive control to confirm enzyme inhibition; hepatic tissue 
homogenate with vehicle only was used as a measure of 100% CPT-1 
activity, and hepatic tissue homogenate without substrate mixture was used 
as negative control.  
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For an experiment involving tissue homogenate (n=1) involving 
FPER1, FPER3 and FPER4, concentrations used were 10 μM and 100 μM 
only.  
For experiments involving isolated mitochondria (n=2) involving 
FPER1, FPER2 and FPER3, concentrations used were as followed: 
FPER1: 10, 50, 100, 150 and 200 μM. 
FPER2: 10, 50, 100, 150 and 200 μM.  
FPER3: 10, 50, 100, 150 and 200 μM.  
 
7.3.3.3 Amiodarone and dronedarone 
 
Dronedarone was introduced to homogenates at concentrations 5, 10, 
50, 100 and 500 µM was compared to that of amiodarone at concentrations 
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7.3.4 Data analysis 
 
Concentration-response curves for each inhibitor were expressed 
constructed by plotting the log of inhibitor concentration versus the 
percentage inhibition of palmitoyl carnitine formation. The IC50 for inhibition of 
palmitoyl carnitine formation was determined by fitting the data to a sigmoidal 
concentration response curve, using GraphPad Prism 6®, with the following 
equation: 
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7.4.1 Assay validation  
 
For pilot studies, cardiac or hepatic tissues scavenged from adult rats 
utilized in other studies (euthanized under carbon dioxide) were sourced to confirm 
the validity of the assay, adapted from Kennedy et al [176]. After several failed 
experiments (to be explained later), it was thought that potential "ischaemic" time 
of tissues might be likely to be too long for animals euthanised under such 
method, which could potentially jeopardise the retention of enzymatic activity. 
Therefore, subsequent studies used only tissues scavenged from other studies 
whereby rats were euthanised under anaesthesia. 
 
7.4.1.1 Difficulties with extraction process  
  
In view of the principle for pathology board-certified laboratory 
equipment (non-radioactive) that equipment is not to be shared with 
radioactive work, an extraction process using rotational-vacuum-concentrator 
(Christ RVC 2-33 CDplus®) (which usually provides fast extraction and drying 
process) was deemed to be unsuitable and other methods had to be 
explored. First, allowing samples to be air-dried under a fume hood in a 
radioactive room had proven to be way too time-consuming, needing several 
days to extract the final product. Then, drying under nitrogen gas under fume 
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hood in the radioactive room was trialled and adopted, with extraction time 
shown to be around 1 hour.  
 
7.4.1.2 Difficulties with scintillation counts 
 
Initial experiments (n=3) were performed without the addition of any 
potential CPT-1 inhibitor. A typical experiment would have the following 
substrate sets of positive and negative controls:  
(1) [3H]-l-carnitine and palmitoyl-CoA: this interaction would yield 
palmitoyl-[3H]-carnitine;  
(2) [3H]-l-carnitine without palmitoyl-CoA (replaced by equal volume of 
distilled water): after extraction, the water-soluble [3H]-l-carnitine would 
expectedly be extracted and hence no or little radioactivity in the end-product 
would be expected; and  
(3) palmitoyl-CoA without [3H]-l-carnitine (replaced by equal volume of 
distilled water): the end product was expected to be similar to (2).  
The yields, however, showed that there was still substantial 
radioactivity detected with (2) (see Table 7-I for example). This suggested 
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Table 7-I: Scintillation counts (arbitrary units) providing evidence of poor 
sensitivity and contamination with unreacted l-carnitine. 
   
 1 2 3 








A 102 60 34 
B 82 57 32 
 
Example of experiment. Rows A and B were duplicates of each other. Column 2 
should (theoretically) have similar low levels of radioactivity as column 3, if 
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Table 7-II illustrates scintillation counts referable to incubations of 
tissue extract with labelled carnitine and unlabelled palmitoyl-CoA for periods 
of 5 to 30 minutes. Product of the reaction being measured was theoretically 
all labelled palmitoyl carnitine. The deficiency of the methodology from 
column 5 (scintillation counts is apparent without addition of palmitoyl-CoA): 
these should in theory be identical to counts for column 6 (water only).  
The retention of radioactive signal from any source other than 
palmitoyl carnitine implies potential inaccuracy of the assay. Here for 
example, rates of apparent formation of palmitoyl carnitine appear non-linear. 
Hence this assay was regarded as unsatisfactory, and a detection method 
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Table 7-II: Scintillation counts with variable protein concentration and 
incubation times.  
  1 2 3 4 5 6 
  Incubation time   
 Protein 
concentration 
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7.4.1.3 Chromatographic conditions 
 
The HPLC system consisted of an Agilent 1100 series® (Agilent 
Technologies, CA) pump, degasser, injector, and column oven; and an API3200 
tandem mass spectrometer® (AB SCIEX Pty Ltd, MA). The assay was based on 
the method of Liu et al (2008) [395]. A C18 column (SunFireTM C18 3.5 μM; 2.1 x 
50 mm column) and two mobile phase were adopted. Mobile phase A was water: 
2mM ammonium acetate: formic acid at 100:154mg/L:0.1; mobile phase B was 
methanol: 2mM ammonium acetate: formic acid at 100:154mg/L:0.1. An injection 
volume of 20 μl was used. The final optimised conditions of both palmitoyl-
carnitine and stable isotope d3-palmitoyl carnitine were as shown in Table 7-III.  
The total duration of the acquisition was 4.902 minutes with equilibration 
time set at 1 minute. During acquisition, only column effluent from 2.5 to 4.5 
minutes was delivered to mass spectrometry. Eflluents before 2.5 minutes and 
after 4.5 minutes were delivered to waste. Binary flow mode was utilized at 0.4 ml 
per minute. From the start of acquisition up to 1 minute, the concentration of 
mobile phase B was set at 20%; with gradual increase to 95% during 1 to 2 
minutes and maintained at 95% afterwards. Oven temperature was set at 50 ºC 
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Table 7-III: Mass-spectrometry conditions for the detection of palmitoyl-
carnitine and its deuderated isotope. 
 
 Palmitoyl-carnitine D3-palmitoyl carnitine 
Q1 (Da) 402.4 405.601 
Q3 (Da) 85 85.201 
Time (milliseconds) 460 300 
Declustering potential (V) 45 34 
Entrance potential (V) 10 5 
Collision exit potential (V) 40 15 
Collision energy (V) 60 50 
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7.4.1.4 Investigation of the solubility of palmitoyl-carnitine 
 
Information from the supplier (Sigma-Aldrich®) indicated that palmitoyl-
carnitine is soluble in water with heat or with sonication. Additionally, preliminary 
work suggested that its solubility in different solvents needed to be properly 
assessed. Therefore, a low and a high concentration (0.5 or 5 μM) of palmitoyl-
carnitine were dissolved in different commonly used solvents on ice: acetonitrile, 
methanol, ethanol and propranol.   
Essentially, 1450 μl of solvent were added to 50 μl of 0.5 μM or 5 μM of 
palmitoyl-carnitine and vortexed vigorously for about 30 seconds. Then 200 μl of 
sample was taken for injection (with injection volume to be 20 μl). Triplicates were 
performed.  
 First, it was found that palmitoyl-carnitine could not be dissolved in 
propranol. Then it was found that both concentrations of palmitoyl-carnitine 
dissolved in acetonitrile did not provide visible peak heights; whereas samples 
dissolved in methanol provided peak heights greater than that of ethanol, with  
retention times ranging from 3.2 to 3.8 minutes.  
Therefore, methanol was selected for subsequent precipitation of incubates 
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7.4.1.5 Optimisation of protein concentration and reaction time 
 
To confirm that the enzyme reactions occured at optimal protein 
concentration and duration of reaction, experiments with variable incubation time 
(0, 1, 2, 4, 10, 20 and 30 minutes; see Figure 7-I) and protein concentration (for 
isolated mitochondria: 0, 0,5, 1, 2, 4 mg/ml; for tissue homogenate: 0, 0.5, 1, 2, 4, 
8 mg/ml; see 7-II A and B respectively) were performed.  
In view of near linearity of rates of formation of product palmitoyl-carnitine 
under the first 5 minutes of incubation, this was utilized for subsequent 
quantitation. For all subsequent studies, enzyme reaction time was set at 1.5 
minutes; isolated mitochondrial protein concentration was set at 1 mg/ml and 
whole tissue homogenate protein concentration was set at 2 mg/ml (same as 
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Figure 7-I: Optimisation of reaction time in tissue homogenate at 2mg/ml 
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Figure 7-II: Optimisation of mitochondrial protein concentrations during 1.5 
minutes of incubation.  
 
A. Evaluation in isolated hepatic mitochondria  
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7.4.2 Changes made to enzymatic assay and quantitation method 
 
Due to difficulty in a lack of sensitivity of quantitation by scintillation (as 
explained earlier), changes were then made to quantitation via LCMS/MS. As the 
detection method had been changed to non-radioactive detection by LCMS/MS, 
some changes are made to the final stages of sample preparation after solubility of 
palmitoyl-carnitine was determined.  
Instead of stopping enzyme reaction with concentrated HCl and extracted 
desired sample, 500 μl of ice-cold methanol was added to the incubate to 
precipitate and to stop reaction. The final product was then vortexed vigorously 
and placed on ice. Another 500 μl of methanol containing d3-palmitoyl-carnitine 
(for final concentration of 1.67 nM) was added and the solution was vortexed 
vigorously for approximately 30 seconds. The samples were then centrifuged at 
10,000 rpm for 10 minutes, and 200 μl of the supernatant was placed in a blank 
tube ready for injection into LCMS/MS. A series of calibration curves, ranging from 
0 to 500 nM of palmitoyl-carnitine were prepared.  
The use of internal standard and calibration curves were employed in some 
initial studies. However, subsequent studies abolished the use of calibration curve. 
Instead, concentration-response (expressed as percentage of inhibition) was 
established with each study: 100% of palmitoyl-carnitine production was 
established when no agent of interest was added (i.e. vehicle control only; or 0% 
of inhibition); and subsequent production of palmitoyl-carnitine by various 
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7.4.3 Comparison of the CPT-1 IC50 of perhexiline enantiomers, fluorinated 
analogues and dronedarone 
 
Inhibition of hepatic and myocardial CPT-1 activity by each potential 
inhibitor was firstly compared with racemic perhexiline in tissue homogenates (n=2 
to 3 per compound), and subsequently in isolated mitochondria (n=3 to 4 per 
compound). Examples of concentration-response curves for each inhibitor were 
shown in Figure 7-III (for hepatic mitochondria) and Figure 7-IV (for myocardial 
mitochondria). Relative inhibitory potentcies were estimated by comparing the 
percentage of inhibition for each compound at a concentration of 100μM. Using 
this measure the relative potencies were dronedarone (most potent) > racemic or 
(+)- or (-)-perhexiline > amiodarone > FPER1 > FPER 3 > FPER2 > FPER4 (least 
potent). Overall, (+) and (-)-perhexiline were equipotent to that of racemic 
perhexiline; dronedarone was approximately 3-fold more potent than amiodarone, 
and equipotent in both heart and liver. On the other hand, at 100 µM, FPER4 
inhibited cardiac CPT-1 by only approximately 15%.  
Formal calculation of IC50 values was only performed in hepatic and 
myocardial mitochondria for racemic, (+)- and (-)-perhexiline, FPER1 and 
dronedarone, as shown in Table 7-IV. The small amounts available, poor solubility 
and relatively low potency of the remaining compounds meant I was unable to 
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Figure 7-III Comparison of concentration-response curves of perhexiline 
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Figure 7-IV: Comparison of concentration-response curve of perhexiline 
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Table 7-IV: Comparison of the CPT-1 IC50 of perhexiline enantiomers, FPER1 
and dronedarone with racemic mixture 
 
 Mitochondria (n=4) 
Hepatic Cardiac 
Rac-Px 49 
(35 - 69) 
63 
(51 - 79) 
(+)-Px 54 
(43 - 69) 
65 
(55 - 76) 
(-)-Px 45 
(35 – 58) 
56 
(45 – 69) 
FPER1 179  
(130 - 247) 
344  
(272 – 435) 
Dronedarone 39 
(28 - 54) 
- 
 
Data shown were best fit value (95% confidence intervals). * p = ns (+) vs (-) Px 
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Samples without inhibitor yielded maximal palmitoyl-carnitine during 
reaction time, whereas samples without substrate yielded undetectable 
palmitoyl-carnitine. Malonyl-CoA inhibited >90% of palmitoyl-carnitine 
formation in both heart and liver. Table 7-VI provides a summary of the IC50 
of both racemic and perhexiline enantiomers in either hepatic or cardiac 
tissue. The results did not differ significantly between those for isolated 
mitochondria and tissue homogenate (result of latter not shown). The IC50 of 
racemic perhexiline did not differ significantly from those of of (+) and (-)-
perhexiline and there was also no significant difference between CPT-1 of 
hepatic or cardiac origin.  
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7.5 Discussion and conclusions 
 
This evaluation was based on the idea that the enantiomers of perhexiline 
might exhibit variable CPT-1 inhibition. Since CPT-1 inhibition probably contributes 
to hepato- and neuro-toxicity of perhexiline, identification of a poor substrate for at 
least hepatic CPT-1 would have been of theoretical interest.  
In fact, the major findings were: 
(1) There is no difference in potency of CPT-1 inhibition between (+) and (-)-
perhexiline in either rat liver or heart. 
(2) Perhexiline and its enantiomers are approximately equipotent in the heart and 
liver. This is different from previous findings by Kennedy et al (1996) which 
showed that perhexiline was less potent in the liver [176]. Such disparity may be 
explained by improved sensitivity of the currently employed quantitative method 
using LCMS/MS.   
The obvious implications of this finding are both therapeutic and relevant to 
toxicity. Given that CPT-1 inhibition is almost certainly a major contributor to long-
term toxicity, the implication is that differential inhibition of CPT-1 is not the basis 
for the apparently greater safety of (-)-perhexiline. It is far from clear that CPT-1 
inhibition is central to clinical efficacy [207], but again there is no basis here for 
differential effects. Thus the preliminary observation of differential toxicity of 
enantiomers can be based only on accessory properties, e.g. NAD(P)H oxidase 
inhibition [208], or CPT-2 inhibition [396].  
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An extension to the issue examined with perhexiline enantiomers is the 
search for bioactive derivatives of perhexiline with predictable pharmacokinetics. 
Staffs of the Kosterlitz Institute (Aberdeen, UK) have synthesized a number of 
perhexiline derivatives, which should be poor targets for CYP2D6, by means of 
fluorinating sites for potential hydroxylation, and substituting methyl groups.  
Preliminary analyses were performed on four of these compounds, using 
the same methodology as perhexiline enantiomers. One compound (FPER4) 
lacked detectable CPT-1 inhibition. The remainder were CPT-1 inhibitors but were 
all less potent than perhexiline, with FPER1 showing the greatest inhibition of the 
four. None appeared to differ in the tissue selectivity from perhexiline itself. 
However, these data must be regarded  as semi-quantitative by virtue of low 
numbers of experiments. The experiments of the new fluorinated analogues 
therefore emphasize the value of assessing CPT-1 activity as a component of the 
evaluation of “new” perhexiline derivatives while being cognizant that CPT-1 is not 
the only target of such drugs.  
As regards dronedarone, the data from these experiments establish that 
dronedarone acts at least in part, as a CPT-1 inhibitor, with approximately equal 
potency in heart and liver tissue. Theoretically, CPT-1 inhibition should provide 
incremental safety of the drug in patients with heart failure [235], assuming this is 
associated with increased efficiency of myocardial energetics [397]. However, this 
is not the case with dronedarone, which appears to be potentially lethal in such 
patients as shown in the ANDROMEDA trial [391]. Presumable the basis for this is 
sodium channel blockade, which appears from the CAST study [390], to be 
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The occurrence of hepatotoxicity with dronedarone [393,398] has never 
been widely investigated. Felser et al (2014) reported that the pattern of toxicity 
was consistent with CPT-1 inhibition [399] but no studies thus far have evaluated 
whether the appearance of hepatotoxicity is predictable in terms of plasma and 
tissue dronedarone concentrations nor whether it is associated with hepatic 
phospholipid accumulation: this should now be a major priority.  
In conclusion: 
(1) The enantiomers of perhexiline do not display heterogeneity as regards 
CPT-1 inhibition.  
(2) Structural analogues of perhexiline synthesised to be poor substrates for 
CYP2D6 retain some CPT-1 inhibition, which in the bases of at least two of the 
compounds tested (FPER1 and FPER3) are not markedly less than that for 
perhexiline. 
(3) Dronedarone is a strong CPT-1 inhibitor: more potent than amiodarone, 
and slightly more potent than perhexiline. It is therefore to be anticipated that it will 
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The experimental chapters in this thesis have originated from two concepts: 
1. That energetic impairment within the myocardium is a commonplace 
occurrence in many forms of heart disease, including myocardial ischaemia (acute 
and chronic), hypertrophic cardiomyopathy, and systolic heart failure.  
2. That perhexiline is now established as an acute treatment for all of 
the above problems, but it remains a potentially toxic agent which even now is 
incompletely understood. There is therefore a great need both to improve 
understanding and safety of perhexiline administration, and to seek less complex 
and more effective “metabolic” treatment.  
The major findings from these experiments can be summarized as follows: 
Chapter 3: Long-term follow-up of a large cohort of patients treated with 
perhexiline revealed that there was a very low incidence of definite hepato- or 
neurotoxicity, despite suboptimal monitoring of perhexiline levels in the majority of 
patients. There was a suggestion that symptomatic improvement might occur with 
plasma levels of perhexiline which would previously considered subtherapeutic. 
This finding should stimulate prospective investigation of the plasma level: effect 
relationship at lower levels than previously considered. Additionally, it was noted 
that survival in this group of patients with ischaemia and often impaired left 
ventricular systolic function was remarkably good. There are no control 
prospective studies of perhexiline effects on mortality, but if financially feasible, 
this should stimulate such studies. Furthermore, it is possible that this is a generic 
rather than specific finding: any agent with predominant energetic effects might 
theoretically have beneficial effects on patients’ survival.  
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Chapter 4 evaluated the determinants of acute myocardial uptake of 
perhexiline, utilizing cardiac biopsy approximately ten days after initiation of 
therapy. This study is virtually unique in literature, most other investigations of 
drug uptake being conducted via mass-balance principles with single dose of the 
drug concerned. It was shown that perhexiline uptake into the myocardium 
revealed some evidence of saturability, but is still closely related to plasma 
perhexiline levels. Thus the results were hardly surprising, even though strictly 
speaking uptake of perhexiline into the left ventricle has not quite reached steady 
state within ten days.  The results of the study were also interesting in that despite 
apparent failure of perhexiline to alter metabolomic spectrum, it was found that in 
this non-diabetic group there was significant fall in blood sugar level and evidence 
of both activation of AMPK and suppression of TXNIP expression [280]. Thus, the 
results of this study, apart from validating cardiac uptake methodology of this type, 
also provide evidence that even non-diabetics perhexiline increases efficiency of 
glucose utilization possibly via AMPK activation and TXNIP suppression.  
Follow-up investigations prompted by this finding would be to investigate 
the effects of perhexiline on energetics in the presence and absence of AMPK 
inhibitors, e.g. compound C, and of chronic TXNIP suppression, e.g. utilizing 
siRNA knockdown. It is important in particular to determine whether the beneficial 
effects of perhexiline are AMPK or TXNIP-dependent because in such a case, the 
effects of perhexiline would be diminished in the presence of agents which activate 
AMPK and suppress TXNIP respectively. 
Chapter 5 evaluated the acute impact of reversal of severe hyperglycaemia 
at hte levels of autocoidal function and formation of endothelial progenitor cels 
(EPCs). The basis for this study was a previous observation [306] that insulin 
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infusion for 12 hours increased NO signaling and suppressed superoxide release. 
In view of a subsequent finding of a reciprocal relationship between NO signaling 
and platelet TXNIP content in the setting of (1) physiological ageing [400], and (2) 
two weeks' of ramipril therapy [138], and the known effects of hypoglycaemic 
agents in suppressing TXNIP expression [81], we sought to determine whether 
TXNIP might mediate the suppression of superoxide release. Furthermore, as 
EPC formation is partially NO-dependent, we examined changes in EPC function 
by monitoring colony-forming unit formation. The results confirmed that reversal of 
hyperglycaemia by insulin for 12 hours increased NO anti-aggregatory response 
and decreased whole blood reactive oxygen species. Furthermore, EPC function 
was markedly augmented. However, neither platelet TXNIP content, nor plasma 
concentrations of the NO/sGC inhibitor TSP-1, fell significantly. Therefore the latter 
factors are unlikely to mediate the acute beneficial effects of insulin on platelet 
reactivity in this setting. 
The study has a number of limitations. First, it is well established that the 
gene for TXNIP has a glucose-responsive element. Therefore, it is virtually certain 
that long-term reversal of hyperglycaemia would suppress TXNIP expression. The 
explanation for the negative result here might be:- 
(1) Type 2 errors, but 95% confidence interval excludes any large effect;  
(2) Insufficient time for change to occur; and/or 
(3) A pecularity of platelet homeostasis is, depending on the lack of DNA in 
non-nucleated platelets.  
To clarify these issues, the following might be considerd in the future: 
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(1) A substantially larger study of similar design 
(2) A more prolonged study period (say, 24 hours); and most importantly 
(3) Evaluation of these principles in vitro utilizing nucleated cells (e.g. 
endothelial cells and megakaryocytes).  
From a practical point of view, the results of the study reinforce the clinical 
priority of rapidly achieving normal blood sugar levels in patients with acute 
coronary syndrome.  
Chapter 6 evaluated the impact of 2 weeks of perhexiline therapy on 
diabetic control and platelet reactivity. In many respects, this study was analogous 
to the short-term insulin protocol in Chapter 5. However, it sought to manipulate 
the entire Randle cycle (using CPT-1 inhibitor with perhexiline), rather than just 
stimulate glucose utilization as a primary effect (with insulin). The results 
confirmed the previously known NO-dependent anti-aggregatory effect of 
perhexiline [209]. Two weeks of perhexiline therapy significantly improved platelet 
responsiveness to the anti-aggregatory effects of sodium nitroprusside in this 
group of diabetic patients, even in the setting of modern pharmacotherapy, where 
the majority of patients were already on ACE-inhibitors, which were also shown to 
improve nitric oxide responsiveness [138].  
Of equal importance were the results of the main aim of the study: to 
evaluate the possible impact of perhexiline on diabetic control in patients already 
receiving appropriate pharmacotherapy. Although both perhexiline itself and also 
other CPT-1 inhibitors have well-documented hypoglycaemic effects, in the setting 
of frequent use of metformin and of ACE-inhibitors the insulin-sensitizing effects of 
perhexiline were marginal. No patient exhibited marked falls in blood sugar level.  
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Therefore the main two conclusions of the study, one “positive” and the 
other “negative” pose intrinsic challenges as regards the underlying biochemical 
mechanisms. Given that there is minimal insulin sensitization, it would be 
surprising if TXNIP expression fell markedly: indeed there was only a non-
significant fall in TXNIP in platelets. We were also able to exclude a substantial 
decrease in TSP-1 release into plasma. Therefore, a major future priority is to 
determine exactly how perhexiline potentiated platelet NO signaling in this 
population. The only potential answer on the basis of the previous literature is 
inhibition of NAD(P)H oxidase, perhaps primarily in neutrophils, an effect 
demonstrated as an NO/perhexiline interaction by Liberts et al [210]. However, this 
hypothesis remains to be tested.  
In chapter 7 the issue of CPT-1 inhibition as a therapeutic principle was 
explored in rats’ myocardium and hepatocytes. Perhexiline and malonyl-CoA were 
utilized as index compounds to quantitate inhibiton of labelled palmitic acid 
metabolism, and CPT-1 inhibition kinetics were compared with: 
(1) Those of putative CPT-1 inhibitors (dronedarone and amiodarone) 
(2) Derivatives of perhexiline: (a) enantiomers; (b) conjugates 
It was confirmed that amiodarone exhibits moderate CPT-1 inhibtion, which 
may have contributed to its potential cardioprotective effects. Interestingly, 
dronedarone was also a moderate CPT-1 inhibitor. This might contribute to the 
reputed “soft landing” effect noted in AF patients in the ATHENA trial, but it is 
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As regards the enantiomer studies, these suggest that there is no 
significant difference in potency between (+) and (-) perhexiline: thus differences in 
effect between enantiomers must have other causes.  
Experiments with conjugates revealed that these were all less potent than 
perhexiline. However, two conjugates (FPER1 and FPER3) had reasonably CPT-1 
inhibitory effects, and might be suitable for clinical development subject to 
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Addenda and Corrigenda 
 
A number of additions and alterations have been made within the body of the text 
of this thesis in response to comments made by the examiners of the thesis. 
These changes are summarized below, together with the location within the 
revised text of the various alterations. 
 
 
Chapter 1  
1. An inclusion of the benefit of GIK in viable myocardium with dobutamine 
echocardiography is now added on page 43.  
2. Measurements of cardiac function, apart from ejection fraction, in patients with 
“preserved ejection fraction” is now provided on page 45.  
 
Chapter 3  
3. The introduction section of Chapter 3, on page 100, is now shortened to avoid 
repetition of previous chapters. 
4. The limitations of this study, is now re-written, as well as how the study could 
be designed in the future (page 114 and 115). 
5. Discussion of patients’ symptom control is omitted due to the lack of available 
objective definition of clinical assessment and availability of record in all of the 
case notes. However, this is acknowledged on page 115.  
6. The Cox and Snell R2 is now provided in Table 3-IV (page 112).  
 
Chapter 4 
7. The method section of Chapter 4 is now amended, to clearly provide the 
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Chapter 5 
8. The potential for type 2 errors regarding the involvement of known modulators 
of NOgeneration and/or effect is now discussed (p164-165).  
 
Chapter 6 
9. Part of the Introduction section is now re-written to provide basis for using a 
myocardial metabolic agent (which is used for angina or heart failure clinically) 
to restore systemic metabolic homeostasis (see pages 167-169).   
10. The word “commonly” is omitted to describe the frequency of hypoglycaemia 
associated with perhexiline on page 177.  
 
Chapter 7 
11. The information of the newer analogues of perhexiline and the limitations on 
revealing their structures are discussed on page 197-198.  
12. The purpose of the current study is now being elaborated (see page 197). 
 
Overall 
13. Typos, errors in tenses, inconsistent spelling, and the use of “diabetic” as 
adjective have now been corrected. 
14. An acknowledgement is added at the end of Chapters 3 to 7 to provide clearer 
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Abstract Approaches to the pharmacotherapy of angina
pectoris have previously centred on the concept that a transient
imbalance between myocardial oxygen Bdemand^ and supply
within the myocardium can best be addressed by reducing de-
mand (for example, with β–adrenoceptor antagonist) or by
increasing availability of blood (via coronary vasomotor reac-
tivity adjustment or coronary revascularization). However, this
principle is potentially challenged by the emergence of cases of
angina unsuitable for such therapies (for example because of
concomitant severe systolic heart failure) and by the recogni-
tion that impaired myocardial energetics may precipitate angina
in the absence of fixed or variable coronary obstruction (for
example in hypertrophic cardiomyopathy). The past 20 years
have seen the re-emergence of a class of anti-anginal agents
which act primarily by improving efficiency of myocardial ox-
ygen utilization, and thus can correct impaired energetics, si-
multaneously treating angina and heart failure symptoms. We
review the principles underlying the safe use of such agents,
beginning with the prototype drug perhexiline maleate, which
despite complex pharmacokinetics and potential hepato- or
neuro-toxicity has emerged as an attractive management option
in many Bcomplicated^ cases of angina pectoris.
Keywords Angina . Perhexiline . Myocardial metabolism
Introduction
Myocardial ischaemia, irrespective of the severity of underly-
ing coronary artery disease, is a process whereby part or all of
the myocardium exhibits reversible impairment of oxygen up-
take, with resultant limitation of a number of processes of
aerobic cellular metabolism [1–3]. A central aspect of ischae-
mia is the coincident appearance or aggravation of disturbed
myocardial relaxation, that is, diastolic heart failure: this in
turn may result in further compromise of coronary blood flow,
resulting in a Bvicious cycle^ of further reduction in oxygen
delivery, particularly to the subendocardium [4].
In recent years, it has become practicable to monitor the
process of ATP generation, largely within cardiac mitochon-
dria, and the activity of the creatine kinase pathways, which
facilitate the transfer of ATP to the cytoplasm via the produc-
tion of phosphocreatine. Investigations of cardiac energetic
status of this type, typically utilizing 31P-magnetic resonance
spectroscopy, have demonstrated that in both myocardial is-
chaemia and also heart failure associated with congestive or
hypertrophic cardiomyopathies, there is a fall in phosphocre-
atine to ATP ratios [5–7]. The data indicate an overlap in the
myocardial metabolic consequences of ischaemia (for exam-
ple due to coronary stenosis and increased cardiac workload)
and various forms of heart failure, and suggest reciprocal re-
lationships between heart failure and ischaemia are possible
[8]. Indeed, it is common for conditions such as aortic valve
stenosis and hypertrophic cardiomyopathy to present with
ischaemic-type chest pain, despite the absence of large vessel
coronary stenosis.
If myocardial ischaemia is fundamentally linked with the
development of energetic impairment, it is important to
* John D. Horowitz
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understand exactly how such energetic impairment may be
produced. In fact, the heart is able to generate ATP, largely
within the mitochondria, primarily via metabolism of either
glucose or fatty acids. Conversely, the development of defi-
ciency of high energy phosphates results from extensive fail-
ure of interlinked generation pathways.
CardiacMetabolic Pathways: Reciprocity of Glucose
and Fatty Acid Utilization: Randle Cycle
Approximately 70 % of ATP generation by the myocardium
results from oxidation of fatty acids (under fasting conditions),
but there are a large number of modulating mechanisms which
control the process of tissue uptake, which are potential-
ly subject to considerable variability [9]. Importantly, extent of
fatty acid oxidation may be modulated both acutely and
chronically.
Fatty acid uptake into the heart is initiated via a number of
fatty acid binding proteins and a fatty acid translocase (CD
36), and is facilitated by the actions of lipoprotein lipases in
releasing fatty acids from triglycerides. The transfer of long-
chain fatty acids (LCFAs) across mitochondrial membranes
utilizes the Bcarnitine shuttle^, whereby LCFAs are conjugat-
ed with carnitine on the outer mitochondrial membrane via the
enzyme carnitine palmitoyltransferase-1 (CPT-1) [10]. The
resultant acylcarnitine derivatives cross the mitochondrial
membrane and are deconjugated from carnitine on the inner
mitochondrial membrane by CPT-2 (see Fig. 1). Activity of
CPT-1 represents the rate-limiting step in LCFA metabolism:
once traversing the mitochondrial membrane, the LCFA un-
dergoes β-oxidation within the mitochondrion: the latter
process generates acetyl CoA, which enters the tricarboxylic
acid (TCA) cycle and thus contributes to cellular ATP
production [10].
There are a number of important modulating factors rele-
vant to rates of LCFA metabolism. First, acetyl-CoA generat-
ed in the process of LCFAmetabolism is partially converted to
malonyl-CoA (by the enzyme acetyl-CoA carboxylase).
Malonyl-CoA is a potent inhibitor of CPT-1 (Fig. 1), but ac-
cumulation of malonyl-CoA is usually limited by malonyl-
CoA decarboxylase, which catalyses breakdown of malonyl-
CoA [11, 12]. Second, a number of other ligands and en-
zymes modify the expression of genes involved in
fatty acid metabolism. For example, the peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC-1α) alters expression of several genes involved in fatty
acid metabolism [13]. Furthermore, both sirtuin 1 and adeno-
sine monophosphate kinase (AMPK) function as energy sen-
sors, with the ability to modulate fatty acid metabolism
[14, 15] (see Fig. 2). Thus even in isolation the control of fatty
acid metabolism is complex, and potentially subject to phar-
macological modulation at several points.
Critically, glucose utilization is also subject to a number of
physiological controls, although in the fasting state this ac-
counts for only 10–30 % of myocardial ATP generation [9].
The uptake of glucose into the myocardial cytoplasm is par-
tially insulin-dependent: in the cytoplasm glucose is converted
to pyruvate (Fig. 1), which undergoes active transport into the
mitochondria to enter the TCA cycle. A critical role is played
by pyruvate dehydrogenase (PDH), an enzyme complex lo-
cated within mitochondrial membranes, which represents the
rate-limiting step in glucose utilization. A major inhibitor of
PDH activity is acetyl CoA, which is generated from LCFA
metabolism [16]. Conversely, increased activity of the TCA
cycle as a result of extensive glucose utilization results in
cytoplasmic accumulation of citrate, and eventually increased
malonyl CoA production, inhibiting CPT-1.
In 1963, Randle et al. proposed what has come to be called
the Randle Cycle [17]: a reciprocity of utilization of long-
chain fatty acids and of glucose by the heart. It has emerged
that the key controls of this reciprocity are the activities of
CPT-1 and PDH, together with generation of the relevant en-
dogenous inhibitors malonyl CoA and acetyl CoA.
β-oxidation of fatty acids and glucose utilization via the
TCA cycle represent the two major sources of ATP generation
within mitochondria [9]. Glucose utilization carries a small
(approximately 13 %) advantage in terms of ATP generation
per unit oxygen consumption. In addition, smaller quantities
of ATP may be generated within the cytoplasm under anaero-
bic conditions via glycolysis, a process which is accelerated
when PDH is inhibited by hypoxia-inducible factor 1 under
hypoxic conditions [18].
Other Modulation of Myocardial Energetics:
Mitochondrial Dysfunction and Energetic Depletion
Production of reactive oxygen species (ROS), within mito-
chondria in particular, increases under a number of patholog-
ical conditions, including anoxia and hyperglycaemia [19].
This may lead to dysfunction of the mitochondrial membrane
and of the mitochondrial electron transport chain, with an
associated further increase in ROS production [19].
During stressful conditions, the excessively generated su-
peroxide will react with nitric oxide to form peroxynitrite [20].
Peroxynitrite triggers DNA single strand breakage and subse-
quent activation of poly(ADP-ribose) polymerase (PARP).
Once activated, PARP cleaves NAD+ into nicotinamide and
ADP-ribose, a process that depletes NAD+ and consumes
ATP. Therefore, overactivation of PARP has been shown to
not only deplete its substrate NAD+, but also slow the rate of
glycolysis, reduce ATP formation and cause eventual cell
death [20]. In animal models, PARP-1 knock-out was associ-
ated, surprisingly, with enhanced energy expenditure, together
with increased glucose clearance, but also protection against
Cardiovasc Drugs Ther
diabetes while maintaining normal pancreatic insulin content
and islet cell morphology [21].
Potential Targets for Therapeutic Modulation
of Myocardial Metabolism
A large number of strategies have been proposed to increase
generation of ATP in disorders of cardiac energetics, as sum-
marized in Table 1.
Among the various strategies for which data are available
indicating beneficial effects on myocardial energetics are in-
fusion of glucose and insulin together with potassium (GIK),
which in theory increases availability of glucose for myocar-
dial metabolism. However, clinical data on this type of strat-
egy are inconsistent: perhaps the most encouraging finding is
of stabilization of haemodynamics during valve replacement
surgery for aortic stenosis [22].
Inhibition of CPT-1 represents a component of the anti-
ischaemic effects of perhexiline and amiodarone. However,
excessive or irreversible CPT-1 inhibition tends to cause tissue
accumulation of lipoprotein deposits, including the develop-
ment of apparent myocardial hypertrophy with oxfenicine
[23] and etomoxir [24–26].
Partial fatty acid oxidation inhibiton, via the enzyme long-
chain 3 ketoacyl-CoA-thiolase, is probably the main action of
trimetazidine [27], and a component of the effects of
ranolazine [28]. The net effect is a reduction in LCFA metab-
olism:- indeed recent studies have suggested that trimetazidine
Fig. 1 The reciprocal regulation
between glucose and fatty acid
metabolism – Randle cycle.
Abbreviations: GLUT = glucose
transporter; HK = hexokinase;
PFK-1 = phosphofructose
kinase-1; OMM = outer
mitochondrial membrane;
IMM = inner mitochondrial
membrane; PDH = pyruvate
dehydrogenase; ETC = electron
transport chain;




FABP = fatty acid binding
protein; CPT-1/2 = carnitine
palmitoyl transferase-1 (or 2)
Fig. 2 Sirtuin-1 (SIRT-1) functions as an Benergy sensor .̂ Through
deacetylation of post-translational proteins, SIRT-1 increases PGC-1α
activity and the expression of insulin receptor substates, both of which
eventually modify fatty acid or glucose metabolism, and lead to increased
ATP production. Abbreviation: IRS = insulin receptor substrate
Table 1 Categories of proposed therapeutic strategies to accelerate
myocardial ATP generation in the presence of ischaemia and/or other
energetic impairment
1. Increased substrate utilization
• Glucose-insulin-potassium (GIK)







3. Partial fatty acid oxidation inhibitors
• Trimetazidine
• Ranolazine
4. Malonyl-CoA decarboxylase inhibitors
5. Coenzyme Q10
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may have similar efficacy in heart failure to that of perhexiline
[29]. Comparisons between CPT-1 and partial fatty acid oxi-
dation inhibition have not yet been reported.
To date, no clinical studies of malonyl-CoA decarboxylase
inhibitor therapy have been reported, but in theory their effects
should be similar to those of CPT-1 inhibitors. Coenzyme
Q10, an important factor in mitochondrial respiration, was
recently reported to exert beneficial effects on outcomes in
patients with chronic heart failure [30].
Perhexiline
(1) Studies of anti-anginal efficiency: Initial experience
Perhexiline was developed by Richardson-Merrell
Pharmaceuticals (Cincinnatti, Ohio, USA) in the 1960s as a
prophylactic anti-anginal. Early animal studies suggested that
the antianginal properties of perhexiline may have arisen on
the basis that it exerted systemic and coronary vasodilator
effects, increased coronary arterial and venous blood flow,
slowed the heart rate and increased pulmonary vascular com-
pliance [31, 32]. Perhexiline was subsequently marketed es-
sentially outside the USA in the 1970s, both as monotherapy
[33, 34] and also later as incremental therapy beyond β-
adrenoceptor antagonists [35], typically in doses between
200 to 400 mg daily. It is important to recognize that
perhexiline was released for general clinical use in many
countries despite little understanding at that time of its mech-
anisms of action, pharmacokinetics in humans and potential
toxicity. As an example of the level of understanding, the drug
was thought to be unsafe in the presence of renal disease, but
in fact that is not the case [36].
(2) Experience regarding toxicity
In the 1970s, reports of hepatotoxicity and peripheral neu-
ropathy associated with long-term use of perhexiline emerged
[37–40]. These adverse effects were poorly understood at that
time, apart from the fact that the toxicity was associated with
phospholipid deposition in hepatocytes and Schwann cells
[41–43], but soon led to the global gradual withdrawal of
the drug during the 1980s, except in Australia and New
Zealand. However, several observations during the late
1970s and early 1980s paved the way to better understanding
of the role that pharmacokinetics and pharmacogenetics of
perhexiline play in its potential toxic effects.
First, Singlas et al. (1978) observed that plasma concentra-
tions of perhexiline were elevated in patients with long-term
therapy who experienced hepatotoxicity and neuropathy com-
pared to unaffected individuals [44]. It was also noted that
there was a large interindividual variation in the apparent plas-
ma half-life of perhexiline, and therefore that perhexiline-
induced toxicity was secondary to some inborn metabolic var-
iability which increased individuals’ susceptibility to drug ac-
cumulation [45, 46]. Shah et al. (1982) later noticed that a
genetic mutation in the metabolism of debrisoquine and
perhexiline led to impaired metabolism and potential toxicity
[47]. Together with these findings, Horowitz et al. (1986)
demonstrated that the metabolism of perhexiline in unselected
individuals with angina was non-linear (or Bsaturable^), and
established that maintenance of concentrations of perhexiline
at steady-state between 0.15 to 0.6 mg/L was effective in
avoiding clinically overt toxicity [48]. The achievement of
therapeutic drug concentrations corresponds to daily
perhexiline dosage ranging from approximately 10 mg for
poor metabolizers through to 500 mg for ultra-rapid
metabolizers [49].
It is now known that cytochrome P450 2D6 (CYP 2D6)
plays a major role in the metabolism of perhexiline, and that
monitoring the concentration ratio between hydroxyperhexiline
and perhexiline provides an indication of patients’ metabolic
capacity and need for further dosage adjustment [49]. Through
continual research to better understand the cellular mechanisms
of the drug and careful plasma drug concentration monitoring,
perhexiline is now regarded as potentially conferring great ben-
efits to patients with refractory angina [35] but also to other
cardiovascular disease states (see below). It has been re-regis-
tered in several European countries, due to favourable
clinical trials and has also very recently been projected as a
treatment for symptomatic non-obstructive hypertrophic
cardiomyopathy.
(3) How does perhexiline work?
The initial postulate that perhexiline was essentially a coro-
nary vasodilator was rapidly replaced by the idea that it might
be an L-type calcium antagonist [50, 51]. However, this was a
relatively weak effect [52]. In 1980, Vaughan Williams first
proposed that perhexiline’s mechanisms of action might be
based upon changes in myocardial metabolism improving effi-
ciency of energy generation, but did not specify the specific
changes involved [53]. Jeffrey et al. (1995) also provided evi-
dence that perhexiline might increase efficiency of myocardial
oxygen utilization, consistent with the presence of such an ef-
fect [54]. In 1996, over 20 years after perhexiline had first been
utilized clinically, it was found to be a potent inhibitor of the
carnitine shuttle [55]. Inhibition of CPT-1 [55], and to a lesser
extent CPT-2 [29] would result in secondary activation of glu-
cose utilization via increased activity of the pyruvate dehydro-
genase complex (the BRandle cycle^) [56]. Like oxfenicine,
which was initially introduced primarily for the treatment of
diabetes, perhexiline exerts moderate hypoglycaemic effects
[57], potentially mediated by insulin sensitization.
However, perhexiline clearly exerts effects beyond CPT-1/
CPT-2 inhibition. In 2005, Unger and colleagues found that in
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isolated non-ischaemic working rat hearts, pre-treatment with
perhexiline increased cardiac efficiency by about 30 %.
However this was independent of changes in palmitate
oxidation [58]. It remains quite possible that effects other than
CPT-1 inhibition contribute to the therapeutic efficacy of
perhexiline.
Indeed, perhexiline was subsequently found to inhibit pre-
assembled neutrophil NADPH oxidase [59], which is respon-
sible for the inflammatory process known as the “neutrophil
burst”. This anti-inflammatory effect of perhexiline could con-
tribute to the related finding of potentiation of platelet respon-
siveness to nitric oxide by perhexiline when platelet aggrega-
tion was evaluated in whole blood [60].
Finally, in a recent study, perhexiline was found to activate
Kruppel-like factor 14 and increase high density lipoprotein in
animal models of atherosclerosis [61]. This finding raises the
potential for an anti-atherogenic effect of perhexiline, which
has not yet been evaluated formally.
(4) Integration of clinical experience with pharmacokinetics:
Recent experience
Since the introduction of routine therapeutic drug monitor-
ing of perhexiline, several clinical studies have provided evi-
dence that perhexiline conferred significant clinical improve-
ment with minimal risk of adverse effects. In 1990, Cole et al.
first consolidated the effectiveness of therapeutic drug moni-
toring of perhexiline, demonstrating that in patients with oth-
erwise refractory angina unsuitable for coronary revasculari-
zation, perhexiline treatment substantially improved anginal
symptoms [35].
Perhexiline has also been shown to be useful in the man-
agement of patients with unstable angina pectoris, with reso-
lution of symptoms correlating with attainment of therapeutic
drug levels [62]. As regards long-term safety of the drug, a
recent audit of 170 patients treated for a median period of
50 months revealed no hepatotoxicity and only 3 cases of
peripheral neuropathy [63].
Given that perhexiline’s therapeutic effects are independent
of changes in coronary vasomotor tone, a number of studies
have recently investigated its possible therapeutic effects in
conditions associated with impaired myocardial energetics
(with or without angina) but in the absence of underlying se-
vere coronary disease-related ischaemia. An initial report on
symptomatic response in elderly patients with aortic stenosis
[64] has not been followed up with controlled data. However,
Lee et al. demonstrated in a double-blind, placebo-controlled
trial that perhexiline was markedly beneficial in chronic sys-
tolic heart failure, irrespective of the presence or absence of
associated coronary disease [65]. This has led to widespread
use of the drug in this context, particularly in patients with
limitations to alternative pharmacotherapy, such as those with
severe renal insufficiency [36]. Finally, Abozguia et al., in an
elegant double-blind study showed that perhexiline improved
symptomatic status in patients with non-obstructive hypertro-
phic cardiomyopathy, with concomitant improvement both in
left ventricular relaxation, maximal oxygen consumption and
myocardial energetics [66].
Conclusions and Future Directions
In summary, perhexiline is now established as a relatively safe
treatment for myocardial ischaemia and other cardiac condi-
tions associated with impaired cardiac energetics. On the other
hand, it is a relatively difficult drug to use, requiring individual
dose titration on the basis of plasma level monitoring. Efforts
are currently being made to develop derivatives of perhexiline
with more predictable pharmacokinetics in order to facilitate
more widespread utilization of the drug.
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Introduction
Patients with diabetes mellitus are at substantially increased 
risk for adverse outcomes in association with occurrence of 
acute coronary syndromes (1) and in the presence of atrial 
fibrillation (2). Although the occurrence of acute myocardial 
dysfunction in the presence of hyperglycaemia has been 
shown to be associated with poor short-term outcomes, 
the issue of the contribution of instantaneous (or recent) 
elevation of blood sugar level (BSL) to this risk remains 
incompletely evaluated. Currently there is only fragmentary 
understanding of the potential nexus between elevation of 
BSL and thrombotic diathesis. 
A number of studies in the literature have evaluated 
the cardiovascular effects of transient increases in BSL, 
whether in normal subjects or in patients with underlying 
cardiometabolic disease states in virtually all cases focusing 
on effects on vascular reactivity, and in particular vascular 
endothelial function. We now examine the significance of 
these findings, their implications regarding nitric oxide 
(NO) signalling in other tissue such as platelets, and the 
potential mechanisms underlying these physiological 
changes. Finally, we review the arguments for rapid reversal 
of hyperglycaemia during cardiovascular crises as a form of 
ancillary therapeutic measure. 
Impact of hyperglycaemia on the generation and 
signalling of NO
Acute elevation of BSL is associated with increases in 
oxidative stress [for review see (3)], and hence has the 
potential to result in disordered vascular, myocardial and 
platelet physiology. In practice, effects of hyperglycaemia 
on vascular function might theoretically involve impairment 
of generation of NO, for example via increased tissue 
concentrations of the NO synthase inhibitor asymmetric 
dimethylarginine (ADMA) (4) and/or via increased tissue 
arginase activity (5), either of which might also be associated 
with “uncoupling” of NO synthase. On the other hand, 
increased oxidative stress in association with hyperglycaemia 
might well contribute to “scavenging” of NO by superoxide 
anion (O2
–) and/or partial inactivation of soluble guanylate 
cyclase (sGC), resulting in attenuation of tissue responses (6) 
to NO (see Figure 1 for schematic representation). 
Assessment of vascular function using flow-
mediated dilatation (FMD)
FMD represents one of several techniques in common 
clinical use which can quantitate vascular endothelial 
function (7), in this case via measuring post-ischemic 
react ive  hyperaemia  ( l a rge ly  NO-independent ) . 
Investigation of FMD physiology suggests that the 
hyperaemic response of the circulation to a period of 
relative ischemia is mediated largely by formation and 
release of NO (8). On the other hand, few investigations 
have addressed the extent to which FMD responses reflect 
changes in NO generation versus integrity of NO signalling: 
indeed it has been found that there is only a moderate 
correlation in individual patients between magnitude of 
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FMD and extent of response to NO donors (9), as a probe 
of integrity of NO signalling pathways. Recent studies have 
also raised some doubts about the reproducibility of FMD 
data for individual subjects (10), somewhat limiting the 
clinical utility of this measure. 
The significance of findings from Loader et al. 
[2015]
A recent study (11) examined the impact of acute glucose 
loading on FMD, utilizing a design involving meta-analysis 
of the published literature, focusing on 39 articles. The vast 
majority of these studies had utilized changes in FMD (as 
a “macrovascular” test of endothelial function) in healthy 
subjects treated with a single oral glucose load (usually of 
75 grams). A minority of studies had evaluated similar 
changes in type 2 diabetic subjects. Few studies had evaluated 
“vascular smooth muscle function” simultaneously. However, 
as this evaluation was achieved via infusion of either sodium 
nitroprusside or glyceryl trinitrate (GTN) (both NO donors), 
the process was actually an evaluation of integrity of vascular 
NO signalling, rather than vascular smooth muscle function. 
In summary, the available data suggested a decrease in FMD 
of approximately 1.5% in both normal subjects and type 2 
diabetics in the presence of acute hyperglycaemia. On the 
other hand, there was no consistent change in responses to 
NO donors during acute hyperglycaemia. 
Superficially, this analysis argues that the adverse 
effects of acute hyperglycaemia on vascular function are 
mediated largely or entirely by decreased formation of 
NO. Therefore it is appropriate that we examine the 
known effects of acute hyperglycaemia on factors such as 
kinetics of ADMA and of arginases, which might represent 
mechanisms for decreasing NO release. 
Potential mechanisms affecting NO signalling 
during hyperglycaemia
There is some evidence that activation of tissue arginases 
may be insulin-dependent.  For example, Kashyap 
et al. (12) showed a direct correlation between extent of 
hyperglycaemia in diabetics and plasma arginase activity, 
with insulin infusion decreasing arginase activity. Ishizaka 
et al. (5) also showed that hyperglycaemia in rabbits was 
associated with enhanced arginase activity. A number of 
studies have also linked hyperglycaemia with increased 
ADMA production. For example, Mah et al. (13) showed 
that ADMA concentrations increase with post-prandial 
Figure 1 Schematic for impact of hyperglycaemia on nitric oxide (NO)/soluble guanylate cyclase (sGC) pathways. Under normal 
physiological conditions, NO is generated mainly from L-arginine under the influence of nitric oxide synthase (NOS), which is negatively 
regulated by asymmetric dimethylarginine (ADMA). Via activation of sGC/cyclic GMP pathway, NO exerts various physiological effects 
such as anti-aggregation, anti-oxidation and vasodilation. However, during acute hyperglycaemia (BSL ↑), the excessively generated 
superoxide “scavenges” NO, contributing to attenuation of tissue responsiveness of NO and formation of peroxynitrite (ONOO–). 
Furthermore, increased expression of the pro-inflammatory protein thioredoxin-interacting protein (TXNIP) increases oxidative stress, 
potentially contributing to dysfunction of sGC. Major sites of resultant impairment of NO effect are: (I) “scavenging” of NO; (II) sGC 
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hyperglycaemia. Therefore the finding that FMD decreases 
with increasing BSL is easily explained by data of this type, 
although it is somewhat surprising that glucose loading 
in diabetics, which would be expected to more markedly 
increase oxidative stress, does not lead to greater changes 
in FMD. 
The total failure of this meta-analysis to document 
variability in vascular responses to NO according to BSL 
is, however, surprising. For example, Adams et al. (9) 
previously documented (Figure 2) that FMD responses 
are directly correlated with extent of vascular response to 
NO donors, a finding which suggests partial commonality 
of controlling factors. In order to understand this more 
fully, it is appropriate to consider the literature related 
to NO responses in platelets, where influence of variable 
Figure 2 Relationship between FMD and vascular response 
to GTN. EDD, endothelium dependent dilation; FMD, flow-
mediated dilatation; GTN, glyceryl trinitrate. [Reprinted with 
permission (9)].
Figure 3 The anti-aggregatory response to NO is negatively 
correlated with the platelet content of TXNIP, r=−0.5, P<0.0001. 
NO, nitric oxide; TXNIP, thioredoxin-interacting protein. 


































NO generation tends to be less important than integrity of 
signalling mechanisms. 
Given the known mechanistic overlap (Figure 1) and 
the previously demonstrated nexus between FMD and NO 
response (9), it is possible that the failure of some studies 
to document changes in vascular responses to NO donors 
in response to hyperglycaemia results from the common 
practice of utilizing drug doses which induce near-maximal 
responses. 
Studies in platelets: impact of hyperglycaemia
The major stimulus for evaluation of the impact of 
changes in BSL on platelet responsiveness to NO and its 
determinants has been a series of clinical findings which 
indirectly implicate hyperglycaemia as a focus of impaired 
NO signalling. Hyperglycaemia represents a basis for 
increased mortality risk in acute myocardial infarction (14) 
and the results of the DIGAMI-I trial suggest that rapid 
reversal of hyperglycaemia by intravenously infused insulin 
might also reverse this risk (15). 
Is there a need to reverse hyperglycaemia 
during cardiovascular crisis? 
In 2007, Worthley et al. (16) reported that in diabetic 
patients with acute coronary syndromes there was an 
inverse relationship between instantaneous BSL and extent 
of inhibition of platelet aggregation by the NO donor 
sodium nitroprusside. This reflected primarily incremental 
“scavenging” of NO by O2
− release. With insulin infusion 
leading to rapid reversal of hyperglycaemia, there was also 
a fall in O2
− generation, together with marked improvement 
in NO response. 
More recently, we have noted that the pro-inflammatory 
protein thioredoxin-interacting protein (TXNIP) appears 
to control platelet NO signalling under chronic conditions 
irrespective of hyperglycaemia: there was a reciprocal 
relationship between NO response and platelet TXNIP 
content at steady state (17) (Figure 3), while treatment with 
ramipril simultaneously suppressed TXNIP expression 
and potentiated platelet NO signalling (17,18). It would 
be expected that TXNIP expression would also change 
in response to variability in BSL: after all, there is a 
glucose response element on the gene coding for TXNIP 
expression (19). However, platelet TXNIP content did 
not fall significantly over 12 hours of insulin infusion in 
hyperglycaemic patients (20), despite restoration of NO 
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responses, suggesting that the associated falls in O2
− release 
were TXNIP-independent. This evidence of relatively slow 
changes in TXNIP expression may be relatively specific 
for platelets by virtue of limited DNA content. Previous 
studies suggest that TXNIP expression may be more rapidly 
adjusted in vasculature (21). It seems more likely that 
insulin-induced suppression of protein kinase C-dependent 
activation of NAD(P)H oxidase (22) may have been critical 
to decreases in O2
− formation affecting NO “scavenging” in 
platelets. 
Conclusions
It therefore appears that acute hyperglycaemia markedly 
impairs vascular endothelial function, primarily via 
diminished NO formation, and also impairs NO signalling, 
mainly in platelets. These findings constitute a compelling 
argument for limiting hyperglycaemia (for example via 
insulin infusion) at the time of all cardiovascular crises. 
The failure of the CREATE-ECLA trial (23) to improve 
outcomes in acute myocardial infarction should remind 
us that the latter was not really a study of reversal of 
hyperglycaemia, but rather evaluation of a strategy of 
increasing myocardial glucose utilization. 
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Over the last 20 years, it has emerged that, while surgical revascularisation of extensive ischaemic 
heart disease may have prognostic advantages, the main issues considered regarding individual 
management are usually those of symptomatic improvement only. The major impetus towards 
invasive intervention is therefore failure of prophylactic anti-anginal therapy. On the other hand, 
many patients, especially the elderly, now present the clinical problem of ongoing angina without 
residual invasive options. There is an ongoing need for more effective anti-anginal therapies. Of 
the currently available major classes of prophylactic anti-anginal agents, neither nitrates, β-blo- 
ckers nor calcium antagonists generally produce marked improvements in exercise duration. 
Three areas of new therapeutic development in anti-anginal therapy are worthy of note. These 
involve the sinus node inhibitor ivabradine, high dose allopurinol (xanthine oxidase inhibitor) 
and a new class of “metabolic modulators” represented by perhexiline, trimetazidine and proba-
bly ranolazine. The current review addresses the therapeutic potential of these agents. Notably, all 
of these “new” drugs are potentially suitable for management of angina in the setting of impaired 
left ventricular systolic function, and they may also be utilized in patients with angina independ-
ent of the presence of coronary disease (for example in hypertrophic cardiomyopathy). The cur-
rent evidence for efficacy and potential future development in this area are reviewed. 
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“If I were an ischaemic cardiac cell, and someone offered me drugs or blood, I think I’d take blood!” 
—Dr. W. Paulus, 1986 
The history of development of anti-ischaemic therapy for angina pectoris has been bedevilled by the notion that 
a strategy of predominantly medical treatment is essentially palliative, while interventional restoration of nor- 
mal coronary haemodynamics is “curative”. Interestingly, evidence to support this philosophy in patients with 
stable angina is very limited, beyond the findings of the CASS study more than 25 years ago [1]. Notably, the 
results of the COURAGE trial [2] challenge the idea that coronary stenting should play a primary role in such 
patients. 
If therefore the major efficacy of drugs of surgical/percutaneous intervention relates to amelioration of symp-
toms in patients with angina, how effective are our “core” medical anti-anginal therapies? The major groups of 
prophylactic anti-anginal agents are long-acting nitrates, β-blockers and calcium antagonists (especially non- 
dihydropyridine agents such as verapamil and diltiazem). The key findings from studies of mono-therapy with 
these agents are summarized in Table 1, and the “core” mechanisms of action of these agents are schematized in 
Figure 1.  
In general, these show that long-acting nitrates and β-blockers induce only small prolongations of exercise 
duration, while both verapamil and diltiazem are a little more effective. On the other hand, there is no evidence 
that any of these forms of therapy improves long-term outcomes in patients with stable angina (although admit-
tedly β-blockers have prognostic utility if patients have concomitant heart failure). Indeed, there is a concern 
that long-acting nitrates may have a number of important disadvantages, including potential aggravation of en-
dothelial dysfunction [3] and also the precipitation of “rebound” ischaemia [4]. Interestingly, nicoradil, an or-
ganic nitrate/potassium channel activation, appears to reduce risk of hospitalization during chronic therapy [5] 
although the mechanism(s) of this beneficial effect remain uncertain. 
The clinical characteristics of patients treated medically for angina pectoris have also evolved with the rela-
tively widespread availability of coronary surgery/stenting. In most societies, such patients now tend to be eld-
erly, with multiple comorbidities. Many such patients have undergone surgical interventions previously and are 
technically unsuitable for further invasive procedures: many have concomitant severe impairment of left ventri- 
 
Table 1. Placebo-controlled studies of efficacy of long-acting nitrates, β-blockers, and calcium antagonists in prolonging ex-





(Category/Authors) (Daily dose) prolongation 
1. Nitrates     
Parker et al., 1995 [40]  Nitroglycerine (patches 0.4 mg/h for 12 hrs) 291 16 <0.001 
Chrysant et al., 1993 [41]  Isosorbide-5-mononitrate (240 mg) 313 18 <0.01 
2. β-blockers     
Jamal et al., 1987 [42]  Carvedilol (50 mg) 12 24 <0.05 
Schnellbacher et al., 1986 [43]  Bisoprolol: 10 mg 12 22 <0.05 
 20 mg  31  
DiBianco et al., 1980 [44]  Acebutolol (1155 mg) 44 14 <0.01 
Schwartz et al., 1981 [45]  Atenolol (100 - 200 mg) 12 32 <0.01 
3. Calcium antagonists     
Hung et al., 1983 [46]  Diltiazem (360 mg) 12 31 <0.05 
Pine et al., 1982 [47]  Verapamil (240 - 480 mg) 18 42 <0.001 
Andreasen et al., 1975 [48]  Verapamil (240 mg) 47 20 <0.05 





Figure 1. Determinants of therapeutic amelioration of myocardial ischaemia: 
emerging options (ROS: reactive oxygen species).                          
 
cular systolic function. In such individuals, there is a clear-cut need for a transition to “new” anti-anginal thera-
pies. Notably, treatment with verapamil or diltiazem is contra-indicated in the presence of severe systolic heart 
failure [6]. 
This review addresses the evolving role of a number of newly recognised/developed anti-anginal agents in the 
setting of “difficult” angina pectoris. The major sites of action of these agents in ameliorating ischaemia are 
schematized in Figure 1. A potential role for all of these agents in angina pectoris refractory or unsuitable for 
β-blockers or calcium antagonists was also included in current textbook recommendations [7]. 
2. Ivabradine 
Ivabradine is a sino-atrial node inhibitor which specifically inhibits the If channel of pacemaker cells, leading to 
a reduction in both resting and exercise-induced heart rate and improvement in myocardial O2 balance. It has no 
effect on other intracardiac conduction system as well as on blood pressure and myocardial contractility. Be-
cause of these limited sites of action, it will not induce bronchospasm (unlike β-blockers), it is devoid of interac-
tions with diabetic status, and does not adversely affect symptomatic status in the presence of systolic heart fail-
ure. On the other hand, it is totally ineffective in patients with no sinus node activity (e.g. atrial fibrillation). 
To date, ivabradine has been evaluated as an anti-anginal agent both in monotherapy and in combination with 
β-blockers, as summarized in Table 2. In both circumstances, there was a moderate increase in exercise duration. 
The only common adverse effects seen were those of phosphenes (flashing lights) development, due to If current 
inhibition in the retina. Interestingly, recent clinical trial developments with ivabradine have focused mainly on 
its role as a secondary treatment in heart failure [8]. No long-term data are available regarding effects on car-
diovascular events. 
3. High Dose Allopurinol 
One other agent that has been proposed as an anti-anginal recently is allopurinol, a xanthine oxidase inhibitor. 
Allopurinol has been traditionally used in the treatment of gout. The application of allopurinol in coronary artery 
disease is based on previous evidence that xanthine oxidase is a potent mediator of oxidative stress. Indeed early 
studies have shown the potential of allopurinol to reduce vascular oxidative stress and thereby improve endothe-
lial function [9]. Furthermore, alterations in cardiac metabolism, primarily in oxygen consumption and contrac-
tility have been demonstrated in heart failure models with allopurinol [10] [11].  




Table 2. Placebo-controlled studies of anti-angina efficacy of ivabradine in prolonging exercise duration in stable angina 
pectoris: (a) monotherapy, (b) addition to β-blockers.                                                            
Study 




1. vs. placebo      
Borer et al., 2003 [49]  - 10 mg for 2 weeks then 360 9 0.02 
 - 20 mg for 2 - 3 months  18.5 - 
2. Add-on therapy      
Tardif et al., 2009 [50]  Atenolol 50 mg 10 mg for 2 months then 889 4 0.02 
  15 mg for 2 months  5 <0.001 
 
The first randomized double-blind placebo controlled trial of the use of allopurinol in the management of sta-
ble angina, offered promising results. In this study, 65 patients with documented coronary artery disease and 
positive exercise test were randomized to receive high dose allopurinol, 600 mg a day on top of a standard treat- 
ment, in a double-blinded controlled trial [12]. Allopurinol use was associated with a median increase in exer-
cise time to ST-segment depression of 43 seconds (p = 0.0002), a median increase in total exercise time of 58 
seconds (p = 0.0003), and a median increase in time to chest pain of 38 seconds (p = 0.001). These findings were 
backed up by a second study by the same group, which explored the potential mechanisms of the benefits of al-
lopurinol in 80 patients with stable coronary artery disease, on maximal anti-anginal treatment [13]. Endothelial 
function was assessed by forearm venous occlusion plethysmography, flow-mediated dilation, and pulse wave 
analysis and vascular oxidative stress was assessed by intra-arterial co-infusion of vitamin C and acetylcholine. 
They found that indeed allopurinol use was associated with improved endothelium-dependent vasodilation, by 
both forearm venous occlusion plethysmography (93% ± 67% vs. 145% ± 106%, p = 0.006) and flow-mediated 
dilation (4.2% ± 1.8% vs. 5.4% ± 1.7%, p < 0.001). Arterial stiffness was also improved significantly (central 
augmentation index improved by 2.6% ± 7.0%, p < 0.001), and furthermore, vascular oxidative stress was com-
pletely abolished by allopurinol.  
However, these studies are small and although no adverse effects were reported, further data in regards to 
safety and impact on long term cardiovascular outcomes in larger studies are prudent. More importantly, it is as 
yet unclear whether addition of allopurinol to other anti-anginal drugs improves long-term prognosis in patient 
with CAD. We have also seen benefits in similar small animal and human studies with allopurinol in congestive 
heart failure [9], and yet the recent large clinical trial OPT-CHF in 405 patients failed to produce any clinical 
benefits [14]. 
4. Agents Modifying Myocardial Metabolism 
The association of exertional ischaemia with impairment of myocardial energetics raises the option of address-
ing this problem without either limiting myocardial work (for example by preventing tachycardia and/or exer-
cise-induced increases in contractile function) or by improving coronary haemodynamics. 
In theory, the generation of high energy phosphates by the myocardium should be critical to maintenance of 
homeostasis irrespective of whether the underlying problem is limitation of myocardial perfusion, increased left 
ventricular afterload (for example with aortic valvular stenosis) or even impairment of systolic and/or diastolic 
left ventricular dysfunction. However, pharmacological manipulation of myocardial energetics has been a slowly 
evolving area. 
Initial attempts to “feed the heart” were associated with treatment for evolving myocardial infarction, where 
the glucose-insulin-potassium (GIK) treatment algorithm was proposed and then tried extensively (for review 
see [15]). Interestingly, this idea of promoting glucose uptake and utilization has generally been unsuccessful, 
with the possible exception of prevention of myocardial ischaemia associated with open-heart surgery [16]. 
Subsequently, there have been extensive developments of drugs which potentially affect myocardial energet-
ics during chronic oral administration. Some of these agents inhibit long-chain fatty acid catabolism, whether via 
inhibiting the “carnitine shuttle” (which controls their uptake into mitochondria) or fatty acid oxidases. Such 




agents may activate the so-called “Randle shift”: a process of transition to more oxygen-efficient ATP generation 
from glucose utilization [17]. 
However, it appears possible to improve efficiency of myocardial oxygen utilization by more than the 13% - 
15% expected from activation of a “Randle shift” [18]. Many of the agents concerned exert multiple effects, in-
cluding interactions with “energy sensor” such as AMP kinase (AMPK) and the pro-oxidant thioredoxin-inte- 
racting protein (TxNIP). Specifically, metformin, which reduces mortality in diabetics, is an AMPK activator, 
and ACE inhibitors, among their many effects, reduce TxNIP expression. Amiodarone, apart from its anti-an- 
ginal effects through β-blockade/calcium channel blockade, also blocks the “carnitine shuttle” [19]. 
However, of the numerous agents with “metabolic” anti-ischaemic actions, there are of particular significance: 
perhexiline, trimetazidine and ranolazine. These will be discussed more fully. 
4.1. Perhexiline 
Perhexiline is a myocardial “metabolic” agent that was introduced in the 1970s as a prophylactic anti-anginal 
agent which was initially presumed to be a coronary vasodilator. Perhexiline proved to be an extremely effective 
treatment for exertional angina, whether in monotherapy [20] or in combination with other agents [21]. Despite 
its early success, its use was rapidly declined after reports of serious hepato- and neurotoxicity associated with 
long-term administration, which was poorly understood at that time. In the mid 1980s, many countries removed 
it from their markets following those reports. However, hepato- and neurotoxicity was later recognised to be at-
tributable to drug accumulation, by virtue of inter-individual variability in pharmacokinetics, due to genetic 
polymorphism of cytochrome P450 2D6. Subsequently, significant long-term side effects were shown to be 
largely eliminated by dosage adjustment according to plasma perhexiline concentrations [22] [23].  
Although there were early proposals about the potential “myocardial metabolic” effects of perhexiline, it was 
not until in 1996 [19] (almost 30 years after it was used clinically as an anti-anginal) that it was found to be a 
potent inhibitor of the carnitine shuttle. Inhibition of carnitine palmitoyl transferase-1 (CPT-1), and to a lesser 
extent, CPT-2 [24] led to secondary activation of glucose utilization via increased pyruvate dehydogenase activ-
ity, as a component of the “Randle cycle”.  
This metabolic shift in theory resulted in greater glucose utilization, and therefore increased ATP production. 
These findings therefore provide a potential explanation of the anti-ischaemic benefit of the drug. However, it 
was later shown that in working non-ischaemic rat hearts, perhexiline increased cardiac efficiency by approxi- 
mately 30%, without reduction of long-chain fatty acid utilization under these conditions [25]. As inhibition of 
CPT-1 and 2 could not have accounted for all these effects, it has been suggested that there are additional me- 
chanisms of therapeutic action. Indeed, subsequent studies showed that perhexiline possess some “anti-inflame- 
matory” effects, including potentiation of nitric oxide [26]. It also inhibits superoxide formation in intact neu-
trophils, aortic valve interstitial cells, human umbilical vein endothelial cells and NADPH oxidase-2 [27] [28], 
and reduces expression of TXNIP in human cardiac tissue [29].  
Clinically, beyond its well-known anti-anginal effect, clinical efficacy of perhexiline has also been demon-
strated in symptomatic inoperable aortic stenosis [30], systolic heart failure [31] and in symptomatic non-ob- 
structive hypertrophic cardiomyopathy [32]. In the latter study, despite the relatively short duration of treatment, 
perhexiline demonstrated improvement in myocardial energetic status (as measured by phosphocreatine to ATP 
ratios), oxygen consumption during peak exertion (peak VO2), ejection fraction and symptomatic status.  
4.2. Trimetazidine 
Trimetazidine inhibits 3-ketoacyl thiolase, the terminal enzyme involved in β-oxidation. It has therefore been 
shown to inhibit fatty acid oxidation in vitro and in vivo. It exerts moderate effects on exercise duration in pa-
tients with stable angina pectoris both as monotherapy [33] and in combination with β-blockers [34] [35]. It is 
widely used in Europe and Asia as anti-anginal treatment, without compromising haemodynamics. Similar to 
perhexiline, it has also been investigated in some small and relatively short clinical studies of heart failure, with 
promising endpoints focusing on left ventricular functions. Some of the studies also showed reduction in plasma 
cytokines and brain natriuretic peptide, suggesting its potential anti-inflammatory effect. However, it is note-
worthy that there has been increasing reports of development of Parkinsonism after long-term treatment with 
trimetazidine. Although the rate is relatively low and the effect is usually reversible, such events should be 
evaluated and distinguished as a consequence of the individual agent or potentially of a particular drug class.  





Ranolazine has been utilized as an anti-anginal agent only relatively recently, with evidence of moderate efficacy, 
rather similar to that of trimetazidine [36], and standard anti-anginal drugs [37]. Its main advantage has been 
freedom from major adverse effects, including safety in patients with heart failure. Initial studies suggested that 
ranolazine might act primarily as a partial fatty acid oxidation inhibitor [38]. However, more recently it has been 
suggested that inhibition of the late sodium current might contribute significantly to its anti-ischaemic effects 
[39]. Unlike perhexiline, human data on effects of ranolazine on myocardial energetic status are currently lack-
ing. On the other hand, ranolazine appears to be devoid of major adverse effects. 
5. Conclusions 
There is an increasing evidence that elective coronary revascularization, except in the circumstance of surgical 
intervention for extensive ischaemia, lacks major prognostic impact. Furthermore, an increasing proportion of 
patients with severe stable angina pectoris are unsuitable for any form of coronary revascularization. 
On the other hand, long-acting nitrates, β-blockers, and calcium antagonists are only moderately effective in 
improving angina symptoms, and there is therefore a considerable need for new anti-anginal drugs. 
The emerging data suggest that ivabradine, allopurinol, trimetazidine, and ranolazine all offer some incre-
mental effect, and can be utilized as “add-on” therapy in most patients, including those with impaired left ven-
tricular systolic dysfunction. Perhexiline, while extremely potent as an anti-anginal agent, has potentially serious 
long-term toxicity and should be utilized only with therapeutic drug monitoring. There is no evidence that any of 
these agents is effective in treatment of angina induced by coronary vasomotor disorders: they appear to act es-
sentially on the determinants of ATP availability to myocardium. The development of the “new” anti-ischaemic 
options serves to remind us of the need for further progress in this area. 
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Abstract The thioredoxin system, which consists of
thioredoxin (Trx), nicotinamide adenine dinucleotide phosphate
(NADPH) and thioredoxin reductase (TrxR), has emerged as a
major anti-oxidant involved in the maintenance of cellular phys-
iology and survival. Dysregulation in this system has been
associated with metabolic, cardiovascular, and malignant disor-
ders. Thioredoxin-interacting protein (TXNIP), also known as
vitamin D-upregulated protein or thioredoxin-binding-protein-2,
functions as a physiological inhibitor of Trx, and pathological
suppression of Trx by TXNIP has been demonstrated in diabetes
and cardiovascular diseases. Furthermore, TXNIP effects are
partially Trx-independent; these include direct activation of in-
flammation and inhibition of glucose uptake.Many of the effects
of TXNIP are initiated by its dissociation from intra-nuclear
binding with Trx or other SH-containing proteins: these effects
include its migration to cytoplasm, modulating stress responses
in mitochondria and endoplasmic reticulum, and also potentially
activating apoptotic pathways. TXNIP also interacts with the
nitric oxide (NO) signaling system, with apparent suppression
of NO effect. TXNIP production is modulated by redox stress,
glucose levels, hypoxia and several inflammatory activators. In
recent studies, it has been shown that therapeutic agents includ-
ing insulin, metformin, angiotensin converting enzyme inhibitors
and calcium channel blockers reduce TXNIP expression, al-
though it is uncertain to what extent TXNIP suppression
contributes to their clinical efficacy. This review addresses the
role of TXNIP in health and in cardiovascular and metabolic
disorders. Finally, the potential advantages (and disadvantages)
of pharmacological suppression of TXNIP in cardiovascular
disease and diabetes are summarized
Keywords Thioredoxin-interacting protein . Thioredoxin .
Diabetes . Cardiovascular diseases . Oxidative stress .
Inflammation . Nitric oxide . Therapeutics
Introduction
TXNIP Physiology: Original Observations and Relationship
to Thioredoxin Activity
The thioredoxin system is a functionally intracellular and pivotal
component of cellular anti-oxidant mechanisms, which includes
thioredoxin (Trx) and thioredoxin reductase (TrxR). Trx func-
tions by reducing oxidized cysteine groups on intracellular pro-
teins, being itself simultaneously oxidized and inactivated. In
turn, oxidized Trx is re-activated by TrxR. This inactivation of
Trx occurs by sulphydryl oxidization, and capacity to regenerate
active (reduced) Trx via TrxR is therefore critical (Fig. 1).
Distinct forms of Trx are found in different subcellular
compartments: Trx-1 is a 12 kDa protein distributed between
the nucleus and cytosol according to a variety of modulating
stimuli, while Trx-2 is an 18 kDa protein found in the mito-
chondria. These play critical roles in the modulation of cellular
physiology, including limitation of apoptosis, anti-oxidant
effects, modulation of DNA synthesis and repair, modulation
of cell membrane signaling and control of the cell cycle (for
review see reference [1]). This subcellular compartmental
regulation of the redox state is critically dependent on regional
integrity of Trx activity in these cellular compartments.
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In 1999, Nishiyama et al. [2] identified a number of Trx-
binding proteins. One of these, designated thioredoxin-
binding protein-2 (TBP-2) was found to be identical to a
previously described protein termed vitamin D-upregulated
protein 1 (VDUP-1), so named because its expression in
isolated cells was increased by 1α,25-dihydroxyvitamin D3.
It was observed that this protein, subsequently re-designated
as thioredoxin-interacting protein (TXNIP), acted as a physi-
ological inhibitor of Trx expression and activity [2]. It is now
appreciated that the interaction between (reduced) Trx and the
oxidized form of TXNIP results in Trx inactivation [3].
Subsequent investigations have demonstrated that TXNIP
exerts a wide variety of physiological (and potentially patho-
physiological) effects, but that not all of these result from
attenuation of Trx effect.
TXNIP Structure
TXNIP has been found to conform to the structural
characteristics of the α-arrestin family [4]. Within the
scaffold-like structure of the molecule, distinct binding
sites are found for a number of proteins. For example,
two SH3-binding domains adjacent to the N-terminal
amino acid bind apoptosis signaling kinase-1 (ASK1)
and Src, while binding sites for ubiquitin ligase (in-
volved in endocytosis) are adjacent the C-terminal [5,
6]. Overall, the importance of the α-arrestin structure of
TXNIP is that irrespective of its intracellular site it acts
as a scaffold protein which expedites a number of signal
transduction pathways (for review, see reference [7]).
Intracellular Localization of TXNIP: Physiological
Translocation and Regioselective Effects
While TXNIP was originally thought to reside only in
the cytoplasm [8, 9], several studies later found that
TXNIP “shuttles” between various intracellular locations,
exerting distinct effects according to intracellular site
[10, 11]. Indeed, it now appears that the actions of
TXNIP depend substantially on the pattern of intracellu-
lar distribution, with specific actions emerging in
particular within mitochondria and at the cell surface.
TXNIP is located entirely in the nucleus under basal
conditions [12], and under such conditions it binds to a
number of intranuclear proteins, such as poly [ADP-
ribose] polymerase-1 (PARP-1).
“Shuttling” of TXNIP from nucleus to cytoplasm (includ-
ing both mitochondria and plasma membrane) appears to be
engendered by dissociation of TXNIP from its various
intranuclear binding sites. For example, in pancreatic β cells,
Saxena and colleagues [10] found that in response to oxidative
stress, TXNIP translocates from the nucleus to mitochondria,
potentially via binding to importin-α, and competes with the
proapoptotic protein apoptotic signaling kinase-2 (ASK-2) to
bind with Trx-2. This leads to subsequent mitochondrial dys-
function and activation of apoptosis. Furthermore, binding of
TXNIP to (mitochondrial) Trx-2 is critical to development of
intra-mitochondrial redox stress and inflammatory activation
[10, 13].
Within the endoplasmic reticulum (ER), TXNIP limits
protein ubiquination, and binds to protein disulphide
isomerase, potentially contributing to ER dysfunction
[14]. ER stress activates a signaling cascade called the
unfolded protein response (UPR), resulting in activation
of a number of sensor proteins, whose function is to
promote synthesis of proteins which tend to restore ER
homeostasis. However, marked UPR activation induces
inflammation and potentially cell death. Two of these
sensor proteins, PERK and IRE1, stimulate increased
synthesis of TXNIP [15]; in the case of IRE1 activation,
there is also an additional effect of stabilization of TXNIP
mRNA [16].
Within the nucleus, TXNIP binding to PARP-1 is critically
important in maintaining its “quiescent” state. On dissociation
from PARP-1, TXNIP translocates to the plasma membrane
[12], where it plays a major role in a number of effects
including activation of the vascular endothelial growth factor
(VEGF) pathway [11]. Components of the physiological role
of TXNIP with regard to VEGF signaling include facilitation
of Trx transport to the cell membrane where it tends to activate
the interaction between VEGF and its receptor (VEGFR2), as
well as promotion of VEGFR2 internalisation, which
Fig. 1 Redox cycling
interactions between Trx and
TXNIP. Trx in reduced form acts
as a reductase 1 for oxidized
proteins 2, being itself oxidized to
Trx-S2. Reactivation of Trx is
achieved by TrxR 3. TXNIP in
oxidized form binds to Trx 4,




potentiates the initiation of angiogenic change in endothelial
cells [11, 17].
Therefore, it is likely that regulating the intracellular
localisation of TXNIP as well as modulating its expression
may prove to be potential strategies to alter its biological
effects.
Trx-Dependent and Independent Actions of TXNIP
The “classical” (redox-dependent) effect of TXNIP is binding
to Trx. The reduced form of Trx, via cysteine 32, binds to the
oxidised form of TXNIP via cysteine 247 [3]. It was initially
considered that such interaction with Trx not only limits
TXNIP degradation, but also constitutes the basis for all
biological effects of TXNIP. Such interaction also appears to
be critical to the role of TXNIP in limiting protein
denitrosylation, thus contributing to nett nitrosative stress
[18]. It has been shown that the apoptosis-signaling kinases
(ASK-1 and 2) normally are tightly bound to Trx-1, under
which circumstances they are inactive [19]. TXNIP displaces
ASK-1/2, and binds to Trx itself. This process frees ASK
within cells, initiating proapoptotic signaling [see
Cardiovascular disease: key mechanisms section].
However, TXNIP interacts with numerous other pro-
teins, largely or entirely in a Trx-independent manner.
The structural similarity of TXNIP with that of the α-
arrestin group of proteins facilitated delineation of Trx-
independent from Trx-dependent effects. Arrestin-
mediated effects of TXNIP are redox-independent and
are mediated by the “scaffold-like” structure of the α-
arrestin protein. Table 1 summarises redox-dependent
versus independent actions of TXNIP. For example,
inhibition of glucose uptake into adipocytes and skin
fibroblasts occurred to a similar extent in cells with
wild-type TXNIP and in those with the mutant TXNIP
C247S (which is incapable of binding Trx), thereby
establishing independence of this effect from binding
to Trx. Furthermore, other α-arrestins, none of which
can bind to Trx, also inhibited glucose uptake [4].
These findings led to a modification of understanding
of the TXNIP-Trx interaction: not only does binding of
TXNIP inactivate Trx, but also this complex is relative-
ly stable, being resistant to clearance via ubiquination-
proteasomal pathway [20, 21]. On the other hand, the
duration of effect of “free” TXNIP in inhibiting glucose
uptake is limited by rapid clearance [7].
Finally, there is recent evidence that the α-arrestin structure
of TXNIP is critical to its role in expediting the transport of
Trx from cytoplasm to the nucleus, where Trx suppresses
expression of genes associated with hypertrophic responses
[22]. Interestingly, the implication of this effect is that TXNIP
exerts both direct pro-hypertrophic and indirect anti-
hypertrophic effects.
TXNIP Pathophysiology
The potential involvement of TXNIP in cardiovascular and
non-cardiovascular pathological processes is predicated on its
extensive physiological significance. Thus the major physio-
logical effects of TXNIP all have potential pathophysiological
connotations. Additionally, TXNIP appears to function as a
general metabolic sensor and modulator of cellular energetics,
a stimulus to abnormal calcification, with impact as an im-
mune modulator and vascular mechanosensor.
For the purpose of this review, however, we will concen-
trate in particular on the critical roles played by TXNIP in
modulating various forms of cardiovascular disease and in the
(cardio)-vascular complications of diabetes mellitus.
Cardiovascular Disease: key Mechanisms
The major physiological effects of TXNIP relevant to its roles
in cardiovascular pathophysiology are summarised in Table 2.
Critical to these effects are:
(i) the interactions between TXNIP and activation of inflam-
matory pathways
(ii) the impact of disordered patterns of flow as a stimulus
for TXNIP expression
(iii) the potential activation of apoptotic signaling pathways
by TXNIP
(iv) increases in TXNIP expression during prolonged
hypoxia
(v) interactions between nitric oxide (NO) signaling and
TXNIP expression
TXNIP and Inflammatory Activation
It is now widely appreciated that within mitochondria TXNIP
amplifies inflammatory response to redox stress: in this aspect
Table 1 Summary: major redox-dependent (Trx-associated) and inde-
pendent (scaffold protein-associated) effects of TXNIP
Redox dependent actions
Inhibition of Trx activity
Stimulation of hypertrophy and angiogenesis
Stimulation of inflammation
Increase in oxidative stress
Redox independent actions
Initiation of apoptosis*
Stimulation of insulin secretion
Regulation of cell growth
Control of response to hypoxia
* This includes displacement of ASK-1/2 from binding to Trx
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it functions as a physiological antagonist to the anti-oxidant
transcription factor nuclear factor erythroid factor-2 related
factor 2 (Nrf2) [23]. Specifically, TXNIP expression is in-
creased by superoxide (O2
−), for example after NAD (P) H
oxidase activation [24], or in association with hyperglycaemia.
In turn, this results in activation of the nod-like receptor
protein 3 (NLRP3) inflammasome [see Diabetes Mellitus/
induction of islet cell inflammation section], and activation
of a number of downstream inflammatory mediators, includ-
ing interleukin (IL)-1β, as summarised in Fig. 2. Similar
mechanisms have been demonstrated to underlie TXNIP re-
lease and inflammatory activation with high fat diets [25].
Nrf2 is activated by a range of oxidants and electrophiles,
and has also recently been identified to negatively regulate
TXNIP expression in diabetic murine models, via binding to
the antioxidant response element of the TXNIP promoter [23].
Following dissociation from its cytosolic adaptor protein
Keap1, Nrf2 accumulates in the nucleus and activates a wide
range of genes encoding antioxidant proteins. In Nrf2 knock-
out mice, both basal and glucose-induced expression of TXNIP
was increased, associated with reduced Trx activity. This sug-
gests that Nrf2 controls both basal and stimulated TXNIP
expression [23]. Future therapeutic agents targeting the Nrf2
system may therefore serve to modulate TXNIP expression.
Mechanosensor Effects: Disturbances of Flow and TXNIP
Expression
There is substantial evidence that the maintenance of “nor-
mal” laminar flow facilitates eNOS expression, with apparent
associated suppression of TXNIP, and the creation of an “anti-
inflammatory” milieu [26–28].
Non-laminar or low flow exerts opposite effects: there is
markedly increased TXNIP expression and that of vascular/
intercellular cell adhesion molecules, resulting in increased
recruitment of leukocyte adhesions [26, 29]. Although the
precise interaction is unknown, it is thought that TXNIP re-
presses Kruppel-like factor 2, an important anti-inflammatory
transcription factor induced by steady flow [26]. The potential
consequences of TXNIP expression within the endothelium
include inflammatory activation and a pro-atherogenic state,
[as described in Cardiovascular disease: Implications of TXNIP
physiology in myocardial ischaemia and reperfusion section].
It is also possible that stimulation of TXNIP expression
with non-laminar flow influences cardiac hypertrophy.
TXNIP knockout animals developed less cardiac hypertrophy
during the first 4 weeks of pressure overload, suggesting that
the development of abnormal myocardial contractile function
may normally be associated with increased TXNIP expres-
sion, which may contribute to the hypertrophic process.
However, such effect was attenuated after 4 weeks with the
development of left ventricular remodeling [30].
TXNIP and Apoptosis Signaling Pathway
Increased TXNIP can cause apoptosis via several mecha-
nisms. It disrupts the Trx-ASK1 complex [as described in
Trx-dependent and independent actions of TXNIP section]
activating the ASK-1-c-jun-N-terminal kinase (JNK) and
p38 MAP kinase pathway. It also disrupts antioxidant defence
mechanisms, induces the release of pro-inflammatory media-
tors such as TNF-α or IL-1β, and induces cell cycle arrest [31]
(see Fig. 2).
TXNIP During Hypoxia: Implications on Angiogenesis
The effect of hypoxia on TXNIP is biphasic: during the initial
stage, TXNIP expression is decreased. However, during
prolonged hypoxia, TXNIP expression is increased, as a result
of inhibition of the mTORC1 signaling pathway [32].
Additionally, overexpression of TXNIP is known to reduce
hypoxia-inducible factor activity and to inhibit VEGF signal-
ing, independent of its binding to Trx via cysteine 247 [33]:
this may contribute to inhibition of angiogenesis. However,
translocation of TXNIP from nucleus to plasma membrane
includes promotion of vascular endothelial growth factor sig-
naling [12], which potentially leads to angiogenesis and pro-
motion of cell survival.
TXNIP and NO Signaling
Mechanisms of Interaction There is increasing evidence for
the existence of multiple interactions between TXNIP and
nitric oxide (NO) signaling which result potentially both in
suppression of TXNIP expression by NO and suppression of
both NO generation and biological effects by TXNIP. For
example, TXNIP-null mice exhibited increased NO produc-
tion and increased iNOS expression in response to lipopoly-
saccharide [34]. Conversely, endothelial-specific over-
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expression of Trx-2 in ApoE−/− mice led to increases in NO
availability (via decreased scavenging) [35]: increases in Trx-
2 activity associated with impaired TXNIP expression or
translocation to mitochondria would be expected to exert
similar effects.
As regards the various sites of interaction, these might
reflect direct effects of TXNIP (for example, inhibition of S-
nitrosoprotein dethiolation [18]), thus increasing the relative
extent of soluble guanylate cyclase (sGC)-independent effects
of NO, or they might reflect TXNIP-induced augmentation of
O2
− production (e.g. inactivation of dimethylarginine
dimethylaminohydrolase, partial inactivation of sGC, and
“scavenging” of NO to generate peroxynitrite). The nett im-
pact of all of these effects of TXNIP would be a diminution in
NO signaling via inhibition of protein kinase G activity.
Therefore, in theory, it would be expected that increased
TXNIP expression, for example in diabetes, would be associ-
ated with impairment of endothelial function. A schematic for
TXNIP effects on the NO signaling cascade is provided in
Fig. 3.
Conversely, it has been demonstrated (both directly and
indirectly) that NO suppresses TXNIP expression. The prob-
ability of a direct interaction with NO was demonstrated by
Schultze et al. [36], who showed that in rat pulmonary artery
smooth muscle cells the NO donor S-nitrosoglutathione sup-
pressed TXNIP expression at the mRNA level. This was
further supported by Shaked et al. [37] who demonstrated that
the NO synthase inhibitor, L-NAME, not only abolished
PKB/Akt phosphorylation and increased TXNIP protein ex-
pression in β-cells, but also attenuated the inhibition of
TXNIP by glucagon like peptide-1 (GLP-1) agonists and
phosphodiesterase inhibitors.
Impact of Interaction With NO Signaling More recently, a
study was performed in order to delineate the relationship
between TXNIP expression and efficacy of NO signaling in
human platelets [38]. In this setting, NO functions as an
inhibitor of platelet aggregation and tissue responsiveness to
NO can be quantitated conveniently via inhibition of ADP-
induced aggregation in whole blood. It was found that platelet
TXNIP content varies inversely with platelet NO responsive-
ness, with a highly significant negative correlation between
these parameters in otherwise normal aging subjects (Fig. 4).
Furthermore, platelet TXNIP content increased with age in the
normal population, corresponding to an increased incidence of
platelet resistance to NO in aging subjects. These data further
established evidence of a reciprocal regulation of TXNIP
expression and integrity of NO signaling, without identifying
the precise mechanism (s) involved. It remains possible that
the suppression of TXNIP expression byNO (as demonstrated
by Schulze et al. [36]) is dependent on the integrity of sGC
activity, as is platelet NO responsiveness. It is also theoreti-
cally possible that the interaction may be mediated, in whole
or part, by TXNIP-enhanced effects on activity of protein
kinase G, although this putative effect has not yet been
evaluated fully.
Fig. 2 Schematic: impact of
increased TXNIP expression on
inflammatory activation and that
of pro-apoptotic pathways
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Alternatively TXNIP may provide a form of protection
against excessive NO production which could lead to
nitrosative stress, for example during septic shock [34].
However, the main issue which emerges from analysis of the
NO-TXNIP interaction is whether some of the reported anti-
inflammatory effects of NO, in particular, may be partially
mediated by suppression of TXNIP effect [39].
Cardiovascular Disease: Implications of TXNIP Physiology
in Myocardial Ischaemia and Reperfusion
All of the various components of the cardiovascular physio-
logical effects of TXNIP described above are relevant to its
emerging roles in modulation of myocardial ischaemia and
reperfusion injury. Initial evidence that TXNIP might play a
critical modulating role came from a study by Yoshioka et al.
[40] evaluating the effect of TXNIP knockout on post ischae-
mia recovery. TXNIP knockout mice appeared to have im-
paired mitochondrial function, but following periods of
ischaemia-reperfusion they displayed better preservation of
mitochondrial activity, with less generation of reactive oxygen
species (ROS) and better recovery of adenosine triphosphate
(ATP) generation.
It has emerged progressively that the complex potential
effects of modulation of TXNIP in the context of myocardial
Fig. 3 Potential interactions
between NO and TXNIP
generation (1) Inhibition of
denitrosylation. (2) ? TXNIP→
O2
− ↑→inhibition of DDAH→
ADMA↑→NO production↓. (3)
NO suppresses TXNIP
expression. (4) Redox stress→
sGC inactivation→NO effect ↓.
(5) TXNIP→O2
− ↑→ONOO−→
NO effect↓. (6) ? ↓ activity of
PKG→effect ↓
Fig. 4 Reciprocal regulation between platelet TXNIP content and plate-
let anti-aggregatory effect of NO (Reproduced with permission from
reference [38])
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ischaemia reflect the intracellular translocation of TXNIP
under conditions of redox stress (for review, see reference
[13]). In this context, the impact of TXNIP in impairing
glucose utilization is likely to be of critical importance, thus
reducing the capacity of ischaemic cells to limit mitochondrial
damage by down-regulating β-oxidation and Krebs cycle
activity while maintaining extra-mitochondrial production of
ATP through anaerobic glycolysis [41].
Although human studies are currently lacking, the thrust of
the available investigations is that the functions of TXNIP
during myocardial ischaemia-reperfusion tend to be deleteri-
ous, contributing to mitochondrial ROS production, dysfunc-
tion and activation of apoptotic signaling. Indeed, it is possible
that inter-individual variability in TXNIP production is a
critical modulator of outcomes in ischaemia-reperfusion, for
example in diabetics. The corresponding therapeutic implica-
tions are discussed in Potential for pharmacological manipu-
lation: modulation of TXNIP synthesis and clearance section.
Diabetes Mellitus/Induction of Islet Cell Inflammation
As previously outlined, hyperglycaemia provides a stimulus
for increased TXNIP expression, and TXNIP exerts a delete-
rious effect on pancreatic islet β-cell function inducing apo-
ptotic changes. In isolated human pancreatic islet cells,
TXNIP was the most significantly upregulated gene in re-
sponse to glucose in an oligonucleotide microarray study [42].
The recently described critically important role of TXNIP in
activation of the NLRP3 inflammasome [15, 16, 43–45] plays
a central role in its modulation of the response to
hyperglycaemia. The inflammasome is a macromolecular
complex which is activated in response to redox stress and
induces caspase-1 mediated secretion of IL-1β and tends to
induce cell death (see Fig. 2). ROS (such as H2O2) caused
TXNIP to dissociate from Trx [43]: the generation of “free”
TXNIP enables activation of the NLRP3 inflammasome, lead-
ing to release of active caspase-1 and generation of IL-1β. This
could potentially lead to pancreatic β-cell dysfunction or death
[46]. Although there are inflammasome activators other than
NLRP3, this form of activation appeared to be entirely TXNIP-
dependent. Critically, it was also shown that inflammasome
activation in response to hyperglycaemia and increased tissue
uric acid concentrations utilized this TXNIP/NLRP3 pathway
[47]. Conversely, TXNIP inhibits expression of the anti-
inflammatory transcription factor Kruppel-like factor 2 [26].
TXNIP-related activation of the inflammasome also in-
duces inflammation and endothelial dysfunction of intra-
ocular vessels in diabetic models [48]. Increased TXNIP
generation in association with hyperglycaemia has been im-
plicated in the pathogenesis of diabetic cardiomyopathy [44,
45, 49], presumably in part via analogous inflammatory acti-
vation. In a rat model of diabetes, TXNIP mediated renal
oxidative stress and fibrosis [50].
Hyperglycaemia is associated with incremental oxidative
stress, and with impairment of NO signaling, as well as poor
outcomes in patients with concomitant myocardial ischaemia
[51]. Reversal of hyperglycaemia reduces oxidative stress and
tends to normalise NO signaling [52]. However, it remains
uncertain whether suppression of TXNIP plays a major part in
this restoration of cardiovascular homeostasis:- there is evi-
dence that activation of Nox4 in the presence of
hyperglycaemia may play a more central role [53].
Clinical Monitoring of TXNIP Expression
Given the pivotal role of TXNIP in various metabolic and
cardiovascular disorders, it is attractive to be able to evaluate
changes in tissue expression in a clinical setting.
As the known physiological effects of TXNIP are all
exerted within cells, it is questionable whether any assay for
plasma TXNIP concentrations is relevant to its (patho) phys-
iological actions. On the other hand, there is very limited
clinical potential for determination of TXNIP concentrations
in “target” tissues, such as myocardium and pancreas.
We have recently developed an immunohistochemical as-
say for platelet TXNIP content and validated this against
immunoblotting technology [38]. While this technique has
contributed to insights regarding the potential role of TXNIP
in platelet physiology and in particular its relationship to
platelet NO signaling, it remains uncertain to what extent this
reflects its expression elsewhere in the body.
Potential for Pharmacological Manipulation: Modulation
of TXNIP Synthesis and Clearance
Stimuli for TXNIP Synthesis and Clearance
In theory, modulation of TXNIP-dependent pathophysiologi-
cal effects may be achieved by altering its rate of production
and/or of clearance or even by modifying its binding to Trx
and to other critically important proteins such as PARP-1 and
ASK-1. This would also have major consequences on the
intracellular translocation of TXNIP and the intensity of its
potential effects outside the nucleus.
TXNIP Synthesis: Modulation
The established stimuli for increased TXNIP synthesis are
schematised in Fig. 5. Several of these are worthy of specific
comment in the context of potential for therapeutic manipula-
tion of synthesis.
Vitamin D3, the originally described stimulus for increased
TXNIP synthesis, appears to interact with two CCAATmotifs
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in the gene regulatory region [54]. Heat shock protein [8] and
PPARα and γ ligands [55, 56] interact with distinct sites on
the gene promoter to increase TXNIP expression.
Perhaps the most physiologically important stimulus for
TXNIP synthesis is increased tissue glucose concentration. In
this case, the mechanism of increased TXNIP expression
revolves around a carbohydrate-response element binding
protein (ChREBP) on the TXNIP gene promoter [57]. In
diabetics, therefore, the combination of hyperglycaemia and
ER stress contribute to TXNIP activation; there is also evi-
dence that increased tissue concentrations of fatty acids may
potentiate TXNIP secretion in such patients [58].
Other described stimuli for increased TXNIP expression
include transforming growth factor-β1 (TGF- β1) [59].
Intriguingly it appears that TXNIP in turn suppresses
TGF-β1 expression [60].
Mechanisms of Diminution of TXNIP Effect
As previously outlined, dissociation of TXNIP from its bind-
ing protein leads to its accelerated clearance. A fundamental
mechanism for rapid TXNIP clearance involves the
ubiquination-proteasomal pathway [61]. Inhibitory effects on
promoter gene sites may also decrease TXNIP expression. It
might also be postulated that Trx functions to “reciprocally
regulate” TXNIP [58], but definitive evidence for this regula-
tion is currently lacking.
There is extensive evidence that insulin rapidly decreases
TXNIP protein levels in many, but not all, tissues. For exam-
ple, Robinson et al. [61] showed that 100nM insulin acceler-
ated TXNIP degradation in adipocytes but not in pancreaticβ-
cells, by a process involving proteasomal degradation. This
effect was inhibited by wortmannin, suggesting that PI-3
kinase was involved in activating the ubiquitin/proteasome
pathway.
Key experimental evidence that AMPK activation contrib-
utes to TXNIP degradation was recently provided [62].
Energetic depletion results in activation of AMPK, with a
resultant increase in nett ATP production [63]. It had already
been shown that AMPK regulated the responsiveness of
ChREBP, with secondary effects on TXNIP expression [64].
However, Wu et al. [62] additionally found that glucose
“starvation” in Hep G2 cells resulted in AMPK-activation-
dependent phosphorylation of TXNIP (a process which could
be mimicked with pharmacological activators of AMPK).
Phosphorylation increased the rates of degradation of
TXNIP, resulting in prolonged increases in rates of glucose
utilization (and potential restoration of cellular ATP synthesis
rates).
It is also probable that suppression of TXNIP expression
may be associated with activation of histone deacetylases
(HDAC), which are also critical to physiological hypoxic
signaling. The relationship between hypoxic effects on
TXNIP expression and its suppression in association with
some cancers [65, 66] remains incompletely understood.
However, tumour angiogenesis depends substantially on the
fact that hypoxia-inducible factor-1α (HIF-1α), which is nor-
mally rapidly degraded via interaction with von Hippel-
Lindau factor under normoxia, becomes stabilized in hypoxic
conditions and facilitates angiogenesis [67]. A number of
HDACs increase expression of HIF-1α, potentially mimick-
ing “hypoxic” signaling. (Conversely, HDAC inhibitors are
increasingly utilized to suppress tumour angiogenesis). It is
increasingly clear that HDAC-10 in particular also functions
as a suppressor of TXNIP expression [68]. Therefore the
likelihood is that this interaction is pivotal to TXNIP suppres-
sion in association with carcinogenesis.
Therapeutic Manipulation: Current Status
Although no currently utilized therapeutic agents, whether for
cardiovascular or other disease states, were specifically de-
signed to interact with TXNIP expression, it is increasingly
clear that many of the beneficial and potentially harmful
effects of such agents are TXNIP-modulated.
Mechanisms of effect of agents which decrease expression
of TXNIP are schematized in Fig. 5: these various classes of
drugs will be discussed individually.
Insulin and Oral Hypoglycaemics
TXNIP overexpression increases rates of pancreatic β-cell
apoptosis and also impairs glucose metabolism [57, 69].
Conversely, many hypoglycemic agents have been shown to
reduce TXNIP expression [37, 64, 70]. However it is not
entirely certain if the effects seen are direct or indirect: for
example via reduction of circulating glucose levels.
The suppression of TXNIP by insulin was first demonstrat-
ed in human muscle biopsies and adipocytes in cell culture
[71]. It was shown that there is a reciprocal regulation of
TXNIP by insulin and glucose. Four-hour exposure to insulin
was associated with reduction in mRNA expression of
TXNIP. This effect was dependent on intact insulin receptor
signaling, rather than simply a reduction in circulating glucose
levels: in muscle insulin receptor knockout mice treated with
streptozotocin (STZ), insulin failed to suppress TXNIP ex-
pression [71]. Although degradation of TXNIP by insulin
seems to be cell and tissue-specific [61], given that TXNIP
plays a significant role in the development of insulin resis-
tance and diabetes, this has nonetheless provided a potential
mechanism and therapeutic application for the restoration of
insulin sensitivity in diabetics or pre-diabetics.
Insulin seretagogues such as GLP-1 agonists also suppress
TXNIP expression. Similar ubiquination and proteasomal
degradation pathway also seem to be at least partially respon-
sible for the reduction of TXNIP expression by GLP [37, 70,
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72]. Treatment with exendin-4, a GLP-1 agonist, reduced
pancreatic β-cell expression of TXNIP in vitro [37, 70].
This was associated with an increase in cAMP signaling,
involving not only protein kinase A but also exchange protein
activated by cAMP (Epac) signaling [70]. Forskolin, an ade-
nylate cyclase activator, enhanced the effect of TXNIP
ubiquination during hyperglycaemia, suggesting that cAMP
enhancement may potentially be employed as a strategy to
increase degradation of TXNIP [70].
Metformin, which functions as an insulin-sensitising agent,
is a potent activator of AMPK signaling. The AMPK signal-
ing cascade, which is activated during cellular depletion of
ATP and plays a significant role in cellular metabolic homeo-
stasis, has also been implicated in the regulation of TXNIP.
Specifically, AMPK suppresses TXNIP expression in pancre-
atic β-cells [64] and also has been shown to accelerate degra-
dation of TXNIP [62]. Recently cultured fibroblasts are uti-
lized to demonstrate that metformin reduced transcription of
the TXNIP gene, partially via AMPK-dependent mechanisms.
[73] However to date, no studies have evaluated the extent to
which this effect is manifested clinically.
Agents Potentiating NO Effect: ACE-Inhibitors,
Angiotensin-II Receptor Blockers & Perhexiline
As discussed in Cardiovascular disease: key mechanisms
section, potentiation of NO signaling, perhaps by virtue of
reducing NO “scavenging”, could potentially be another clin-
ical strategy in targeting the suppression of TXNIP. NO sig-
naling includes activation of sGC leading to the production of
cGMP, which exerts its effect on a number of cGMP-effector
proteins. Theoretically, increasing NO availability and effect
could ameliorate endothelial dysfunction, and suppress plate-
let hyperaggregability [74].
There is substantial evidence that the angiotensin
converting enzyme (ACE) inhibitor ramipril suppresses
TXNIP expression. For example, in vitamin D-treated rabbits,
aortic valve calcification was associated with increased
Fig. 5 Activation/Inactivation
pathways of TXNIP: Potential
sites for therapeutic
manipulations. (Blue box or dash
line arrows: inhibitory effects;
pink box or solid line arrows:
stimulatory effects). NO=nitric
oxide; Nrf2=nuclear receptor











expression of TXNIP within valve matrix [75]. Concomitant
treatment with ramipril diminished valve narrowing, and was
associated with a reduction in intra-valvular accumulation of
TXNIP (Fig. 6), as well as with salvage of NO signaling [76].
Furthermore, in humans at increased risk of coronary events,
2 weeks’ therapy with ramipril decreased intra-platelet TXNIP
expression while potentiating NO response [38]. This study
represents the first “clinical” evidence that TXNIP expression
can be suppressed by commonly utilized cardioprotective
agents. However, it remains to be determined to what extent
this contributes to the effects of ramipril in reducing frequency
of acute cardiac events. It also remains to be determined
whether:-
(a) The NO-potentiating effects of ACE inhibitors are me-
diated primarily via TXNIP suppression, as would be
suggested by the data for platelet function [38].
(b) Angiotensin-II receptor blockers (ARBs) exert similar
effects in humans. It has been reported that telmisartan
also suppressed TXNIP expression in the kidneys of rats
with STZ-induced diabetes [77].
Perhexiline, a myocardial energetic agent with clinical
benefits in refractory angina, congestive heart failure, symp-
tomatic aortic stenosis and hypertrophic cardiomyopathy, has
also recently been shown to reduce myocardial content of
TXNIP in patients awaiting coronary artery bypass surgery
after approximately 2 weeks of treatment [78]. This could
contribute to the beneficial effects seen with perhexiline treat-
ment on energetic improvement and oxidative stress [79, 80],
potentially via induction of autophagy [81].
Calcium Channel Blockers
A number of recent studies have provided strong evidence that
verapamil and diltiazem suppress TXNIP expression. In 2008,
Chen et al. [49] reported that verapamil and diltiazem reduced
TXNIP transcription and protein levels in the presence of
elevated glucose concentrations in cultured cardiomyocytes,
and that 3 weeks’ verapamil therapy duplicated this effect in
STZ-diabetic mice. Subsequently, the same group demonstrat-
ed that verapamil protected pancreatic β-cell survival in STZ-
diabetic mice, effectively via attenuation of the pro-apoptotic
effects of TXNIP [82].
A key issue is whether this finding is clinically relevant. To
date, there has been no definitive study to show that any
calcium channel antagonist exerts particular nephroprotective
effects in diabetics, nor any clinical evidence that verapamil or
diltiazem may be clinically more effective in diabetics than
dihydropyridine calcium channel antagonists. However, there
is equivocal evidence that verapamil and diltiazem may be
more effective than dihydropyridines in limiting proteinuria in
diabetics [83]. Furthermore, verapamil treatment for
hypertension appears to reduce the likelihood of development
of diabetes [84], consistent with a protective effect on pancre-
atic β-cell function. Clearly further clinical correlative studies
in diabetes would help to delineate this area.
Although not yet evaluated from a mechanistic point
of view, one major clinical role of calcium channel
antagonists is in the prophylaxis of coronary artery
spasm. It has already been shown that disturbances of
laminar vascular flow increase TXNIP expression [26,
27]. Furthermore, 5-fluorouracil, an anti-neoplastic agent
which often precipitates coronary spasm [85–87], in-
creases TXNIP expression [88]. Therefore, it is also
appropriate to determine whether TXNIP suppression
might contribute to the clinical effectiveness of calcium
channel blockers in inhibiting coronary artery spasm.
Agents Under Current Investigation
Several other agents in various stages of investigation for
treatment of cardiovascular and non-cardiovascular disorders
have been shown under experimental (but not yet clinical)
circumstances to potentially suppress TXNIP expression and/
or signaling. Specifically:
Fig. 6 Section of micrographs: rabbit aortic valveA treated with vitamin
D2 alone, and B treated with vitamin D2 plus ramipril. Note suppression
of TXNIP expression (brown pigment) with ramipril treatment
(Reproduced with permission from reference [76])
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a) PARP-1 inhibitors (e.g. rucaparib, olaparib) are currently
under investigation predominantly as adjuncts to anti-
neoplastic therapy (for review see reference [89]).
However, they may also be effective in reducing reperfu-
sion injury in the myocardium [90–92]. The potential
relevance in this context is that PARP-1 inhibition in-
creases intracellular translocation of TXNIP [12] and thus
alters its effects on inflammatory activation.
b) Nrf2 activators, as described previously, could potentially
be employed as a therapeutic target to augment cellular
antioxidant capacity by enhancing the antioxidant gene
expression. Such agents include many phytochemicals,
e.g. isothiocyanates, dithiolethiones and cinnamaldehyde
(for review, see reference [93]). The synthetic Nrf2 acti-
vator bardozolone has recently been investigated as a
potential therapy for patients with diabetes and advanced
renal functional impairment. In the absence of a substan-
tial reduction in the incidence of end-stage renal disease,
there was a significantly increased risk of onset of cardiac
failure, causing premature termination of the trial [94].
c) Curcumin is a component of turmeric which is under inves-
tigation as an anti-inflammatory and nephroprotective agent.
Amongst its documented effects in a mouse model was
inhibition of TXNIP expression [95].
d) Resveratrol exerts anti-oxidant effects and is being devel-
oped as an adjunct to the treatment of acute myocardial
ischaemia. Amongst the many effects documented for
resveratrol is suppression of TXNIP expression [96, 97].
This may be a secondary rather than primary effect of the
agent.
Does TXNIP Inhibition Increase Risk of Carcinogenesis?
As a growth suppressor that causes G1 cell cycle arrest,
reduced expression of TXNIP has been implicated with vari-
ous human cancers [65, 66, 98, 99]. Therefore the major
theoretical concern deriving from pharmacological suppres-
sion of TXNIP is the potential for increased risk of carcino-
genesis. Recently, administration of ARBs has been linked to
increased risk of prostate cancer [100], although other larger
studies found no such association [101–103].
Summary/Conclusions
This review presents evidence that TXNIP functions not only
as an antagonist to Trx, but also as an α-arrestin-type scaf-
folding intracellular protein which modulates the function of
mitochondria and ER in conditions of redox stress, counter-
balancing anti-oxidant effects such as those of Nrf2. TXNIP
exerts critically important effects in “amplifying”
inflammatory activation and apoptotic pathways, as well as
modulating metabolic responses to increases in glucose and
fatty acid availability. It exerts profound influences on disor-
ders of blood flow, tissue oxygenation/perfusion, particularly
in the presence of diabetes. Its effects include physiological
antagonism of NO. Hence development of therapeutic strate-
gies to decrease TXNIP expression is potentially
advantageous.
As regards the treatment of diabetes, it is not surprising that
many hypoglycaemic agents suppress TXNIP: this effect
should tend to render them protective against pancreatic and
vascular injury, but cause-effect data remain incomplete.
There is experimental evidence that the calcium channel
antagonists verapamil and diltiazem decrease tissue expres-
sion of TXNIP [104]. What remains to be ascertained is
whether this occurs to an important extent clinically, and
whether TXNIP suppression is critical to the salutary effects
of these agents in patients with increased risk of cardiovascu-
lar events. Similarly, it appears that ACE inhibitors and ARBs
also suppress TXNIP, but it is not clear precisely which
receptor systems are involved, whether this action is NO-
independent, or indeed whether this represents the main basis
for cardioprotection.
Given the fact that all current therapeutic methods for
TXNIP suppression in humans also exert other potentially
important effects, the clinical advantages inherent in such
strategies can only be extrapolated from the results of animal
experiments involving TXNIP knock-down or mutation. At
least from the point of view of evaluation of mechanisms of
therapeutic effect, it would be theoretically desirable to devel-
op more specific TXNIP-suppressing therapies for clinical
use. This being the case, we can surmise that TXNIP suppres-
sion is likely to represent an important advance in the man-
agement of diabetes, ischaemic and valvular heart disease.
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Can Perhexiline Be Utilized Without Long-Term Toxicity?
A Clinical Practice Audit
Helen Phuong, BPharm (Hons),* Bo Y. Choi, MBBS,† Cher-Rin Chong, BPharm,*†
Betty Raman, MBBS,† and John D. Horowitz, MBBS, PhD†
Background: Perhexiline, originally used as a first-line prophy-
lactic antianginal agent, is now regarded primarily as a treatment for
otherwise refractory myocardial ischemia. Recent studies have also
demonstrated its short-term utility in heart failure, hypertrophic
cardiomyopathy, and inoperable aortic stenosis. Its benefits on
myocardial energetics state are potentially counter-balanced by risk
of hepatotoxicity and peripheral neuropathy during long-term
treatment if drug accumulation occurs. Since perhexiline exhibits
complex pharmacokinetics with wide inter-individual variability, its
long-term use requires regular plasma concentration monitoring. In
this study, the risk of neuro- and hepato-toxicity during long-term
perhexiline therapy in relation to the intensity of therapeutic drug
monitoring was investigated. Furthermore, determinants of mortality
during perhexiline treatment were evaluated.
Methods: In 170 patients treated with perhexiline for a median of
50 months (interquartile range: 31–94 months), outcomes and rela-
tionship to plasma drug concentrations were documented.
Results: Rationale for treatment with perhexiline included myo-
cardial ischemia in 88% and severe systolic heart failure in 38%.
Plasma concentrations were within the therapeutic range of 150–600
ng/mL on 65% of assay occasions and toxic levels accounted for
8.8% of measurements. No patient developed hepatotoxicity attribut-
able to perhexiline while 3 developed peripheral neuropathy possibly
induced by treatment. Actuarial 5-year survival rate was 83% over-
all, and 76.3% in patients with associated systolic heart failure.
Conclusions: This first audit of a large population treated long-
term perhexiline demonstrates the following: (1) Although the
frequency of monitoring is less than ideal, therapeutic drug
monitoring effectively limits occurrence of toxic drug concentrations
and virtually eliminates long-term hepato- and neuro-toxicity and (2)
Mortality rates during long-term therapy, notably for patients with
concomitant heart failure, are surprisingly low.
Key Words: perhexiline, myocardial energetics, hepatotoxicity,
peripheral neuropathy, safety
(Ther Drug Monit 2016;38:73–78)
INTRODUCTION
Perhexiline maleate was developed clinically as a first-
line, prophylactic anti-anginal agent approximately 50 years
ago, largely on the basis of its exerting coronary vasodilator
effects in isolated heart models.1,2 Indeed, clinical trials estab-
lished a remarkable degree of efficiency in suppressing angi-
nal symptoms, when used as monotherapy,3,4 typically in
dosage regimens of 200–400 mg per day. Subsequently, it
was found that perhexiline also induced marked improvement
of anginal status when added to other prophylactic anti-
ischemic treatment regimens.5
From 1973 onwards, reports began to appear of devel-
opment of hepatitis and/or peripheral neuropathy during long-
term (.3 months) therapy with perhexiline.6–9 As these reports
coincided with the increasing clinical use of b-adrenoceptor
antagonists, long-acting nitrates, and nondihydropyridine cal-
cium antagonists as medical treatment options for angina
pectoris, and with increased availability of coronary revascular-
ization, they led to a decline in the use of perhexiline. Further-
more, it was demonstrated that perhexiline had calcium
antagonist properties10,11; if it were merely a potentially toxic
calcium antagonist, there seemed to be little reason to continue
using the drug.
A number of critically important findings since that
time have led to a gradual return in clinical interest of the
drug. Firstly, it was demonstrated that in the majority of
patients with perhexiline toxicity, plasma concentrations of
the drug were unusually elevated.12 Prospective studies dem-
onstrated that adjusting drug dosage to maintain plasma per-
hexiline concentrations below 600 ng/mL markedly decreased
the risk of hepato- and neuro-toxicity in the medium-term,5,13
and led to the inception of routine therapeutic drug monitor-
ing. Pharmacokinetic studies revealed nonlinear (saturable)
metabolism,14,15 and that perhexiline, a substrate of CYP2D6,
tended to accumulate dramatically in “slow hydroxylators,”
representing 6%–7% of the White population.16,17
Finally progress was made regarding understanding
both the mechanisms of effect of the drug and its potential
spectrum of clinical utility. Concordant with Vaughan
Williams’ initial suggestion that perhexiline might modulate
metabolism,18 and findings by Malloy’s group of increased
efficiency of cardiac work per unit of oxygen consumption,19
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Kennedy et al showed that perhexiline inhibited carnitine
palmitoyl transferase-1, a key enzyme in the “carnitine shut-
tle,” thus limiting long-chain fatty acid metabolism, and
potentially activating the “Randle Cycle” and associated in-
creases in glucose utilization.20 In view of these findings, the
potential clinical utility of perhexiline extended to disorders
of myocardial energetics without fixed coronary artery dis-
ease. Subsequent studies provided evidence that it might
improve symptomatic status in patients with aortic stenosis,21
systolic heart failure (ischemic or otherwise),22 and hypertro-
phic cardiomyopathy.23
In the current analysis, we have evaluated the long-term
safety of perhexiline in a cohort of Australian patients treated
mainly for otherwise refractory ischemia and/or heart failure.
We sought to determine the following:
1. The incidence and determinants of serious long-term per-
hexiline toxicity (ie, hepatotoxicity and/or peripheral
neuropathy),
2. Mortality rates during perhexiline therapy for the entire
patient cohort and for those with concomitant systolic
heart failure, and
3. The relationships between long-term outcomes and
• Achievement of therapeutic drug concentrations
• Frequency of monitoring of steady-state perhexiline
concentrations, given that trimonthly determination of
concentrations is currently recommended.24
The results provide incremental evidence of the safety
of perhexiline in long-term treatment. Furthermore, the
survival data raise the possibility that this form of treatment




Patients were evaluated on the basis of at least 12
months of perhexiline therapy for a currently recommended
indication with associated records of predominantly out-of-
hospital follow-up including cardiac clinic review.
The only criteria for non-prescription of perhexiline in
this cohort were
1. Severe chronic hepatocellular disease,
2. Previous severe acute adverse reaction to perhexiline, for
example, dizziness, nausea, and vomiting, and
3. Anticipated inability to comply with monitoring
requirements.
Diabetes mellitus (with or without associated peripheral
neuropathy), concomitant renal insufficiency, and treatment
with potentially interacting drugs (such as amiodarone,25
selective serotonin reuptake inhibitors,26 or antifungal terbi-
nafine27) were not contraindications to perhexiline therapy at
entry.
Therapeutic Drug Monitoring
Determinations of plasma perhexiline concentrations
(and those of its major monohydroxylated metabolite) were
performed via high-performance liquid chromatography as
previously described.14 Ideally, monitoring was repeated
frequently until levels were stable within the previously
described therapeutic range and then repeated trimonthly.24
However, this was a suggested rather than strictly enforced
frequency of monitoring. Actual frequency of monitoring was
documented throughout the treatment period, together with
results of these analyses.
Clinical Follow-Up
Patients were assessed symptomatically both by their
general practitioners, and by treating cardiologists at regular
intervals. Measurements of liver function were performed
routinely with other biochemical tests; and formal neurolog-
ical assessment was performed only on the basis of clinical
symptoms or abnormal physical findings.
Hepatotoxicity, whether likely due to perhexiline or
otherwise, was defined on the basis of at least 3-fold elevation
of liver function tests beyond the upper limit quoted by the
testing laboratory. Peripheral neuropathy, whether predomi-
nantly sensory, motor, or autonomic was diagnosed only in
the presence of objective clinical abnormalities. In all cases,
appearance of such anomalies was correlated with simulta-
neous plasma perhexiline concentrations.
Data regarding mortality rates were retrieved from the
Registry of Births, Deaths, and Marriages of South Australia
and presumptive causes of death recorded. Variables selected
for multivariate backward logistic regression analyses to
identify independent predictors of mortality were age, gender,
duration of perhexiline therapy, history of coronary artery
disease, presence of aortic stenosis, heart failure, diabetes
mellitus, proportion of drug assays within therapeutic range,
and proportion of drug assays over therapeutic range.
Statistics
All data for normally distributed parameters are
described as mean 6 SEM; for skewed data, medians and
interquartile ranges are given.
Survival rates (overall and for patients who had
concomitant heart failure) were quantitated by Kaplan–Meier
analysis, and correlates of survival rate were evaluated by
multiple logistic backward regression analysis. All analyses
were performed with the SPSS version 20 software (SPSS,
Chicago, IL).
RESULTS
Table 1 summarizes the clinical demographics of the
170 patients in this study cohort. In general, patients were
elderly. Known coronary disease and therefore potential myo-
cardial ischemia was present in 88% of cases while 37.6%
had symptomatic heart failure. Furthermore, aortic stenosis
represented an occasional component of the indication for
perhexiline therapy (12.9%).
Figure 1 summarizes metabolizer phenotype. The major-
ity of the patients were intermediate to extensive metabolizers
(criteria15 are shown in Fig. 1) and received daily doses of
perhexiline maleate between 125 mg and 200 mg; 1.8% were
poor metabolizers who received 50–100 mg weekly; and
4.12% were ultra-rapid metabolizers who received 100–250
mg daily. To determine if in practice steady-state perhexiline
Phuong et al Ther Drug Monit  Volume 38, Number 1, February 2016
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concentrations might be varied according to metabolizer status,
we tested the hypothesis that extensive and intermediate me-
tabolizers would have identical probability of achieving.70%
of plasma drug concentrations within the therapeutic range. It
was found that the probability of such a degree of achievement
of therapeutic levels did not differ by the metabolizer status
(x2 = 0.10; P = 0.7).
Over the period of follow-up, as shown in Table 2, 65%
of drug concentrations measured were within the therapeutic
range of 150–600 ng/mL13; the majority of other concentra-
tions were subtherapeutic (26.2%) rather than potentially
toxic (8.8%). Only 20% of patients experienced $2 consec-
utive toxic concentrations, and 16.4% had periods of toxicity
extending $3 months. The overall frequency of monitoring
appeared suboptimal; only 32% of patients had at least tri-
monthly drug monitoring, as currently recommended by the
Australian guidelines.24
Elevation of hepatic enzyme levels beyond population
norms, detected during routine monitoring in asymptomatic
patients, were usually transient and occurred in 51 cases. Of
these, potential causes included 21 cases of gastrointestinal
disease (cholecystitis, pancreatitis, and gallstones), 2 of
known hepatitis B or C, and 2 of metastatic hepatic
infiltration. There were also 8 cases of ischemic hepatitis
associated with acute heart failure. Two of the cases appeared
to be related to other drugs such as HMG-CoA inhibitors
(statins). In another 12 cases of hepatitis, although of
uncertain cause, could not be attributed to perhexiline as the
elevation of plasma levels of hepatic enzyme was transient
and resolved despite continuation of therapy. Overall, none of
the cases of abnormal hepatic function appeared likely to be
related to perhexiline therapy. In particular, in no case “clas-
sical” perhexiline hepatotoxicity was there; that is, simulta-
neous elevation of perhexiline concentrations and
development of abnormal liver function.13,28,29
There were also a total of 4 new cases of presumptive
peripheral neuropathy in the course of the study, although in 1
case, objective signs were never elicited. In the 3 other
suspected cases, perhexiline could not be excluded as
FIGURE 1. Distribution of metabolizer’s phenotype in this
cohort of patients. (Metabolizer status was defined as the ratio
of plasma concentrations of cis-hydroxyperhexiline to per-
hexiline at steady-state. Poor metabolizer was defined by
a ratio of #0.3; intermediate metabolizer was defined by
a ratio of 0.3–2.5; extensive metabolizer was defined by a ratio
of 2.5–20; and ultra-rapid metabolizer was defined by a ratio
of $20).
TABLE 2. The Distribution of Concentrations With Respect to
Therapeutic Range of 150–600 ng/mL and the Frequency of
Monitoring During Study Period
Quality of monitoring (%)
Proportion of concentration within
therapeutic range
65
Proportion of concentrations above
therapeutic range
8.8
Proportion of concentrations below
therapeutic range
26.2
Frequency of monitoring over total
study period (%)
At least trimonthly 32
Three to six monthly 48
Less than six monthly 20
TABLE 1. Baseline Characteristics of the 170 Patients in This
Study Cohort
Male (%) 58
Age (yrs) 74 (65–81)*
Duration of treatment (mo) 50 (31–94)*
Cardiovascular history (%)
Coronary artery disease 88.2
Previous myocardial infarction 58.8









Known peripheral neuropathy (pre
perhexiline)†
7.1
Known hepatic disease (pre
perhexiline)‡
1.2














†10 of 12 patients had diabetes.
‡Mild abnormalities of liver function tests at entry.
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a potential cause of peripheral neuropathy. Of these 3 patients
1 had diabetes. In the 2 non-diabetic patients with defined
peripheral neuropathy suspected to be perhexiline-induced, 1
had known peripheral vascular disease. Once again, none of
these cases were associated with supra-therapeutic perhexiline
concentrations and none occurred in poor metabolizers
(Table 3).
As regards to mortality, actuarial survival of the entire
cohort and that of patients with concomitant systolic heart
failure is shown in Figure 2. Five and 10-year survival rates
were 83% and 72.6% respectively for the entire cohort, and
76.3% and 63.4% for patients with heart failure. On multi-
variate analyses (Table 4), deaths on perhexiline tend to occur
significantly more commonly during initial years of therapy
(P = 0.021), and there were trends towards increased mortal-
ity with advanced age (P = 0.064) and for patients with asso-
ciated coronary artery disease (P = 0.068).
DISCUSSION
The current data represent the most extensive docu-
mentation of long-term safety of perhexiline in the modern
era of routine therapeutic drug monitoring. Initial experience
with perhexiline, confined to its role as a prophylactic anti-
anginal agent, suggested remarkable clinical efficacy, but the
serious long-term complications of hepatitis and peripheral
neuropathy were documented in as many as 40% of cases.4 In
the current series, presumptive long-term toxicity (limited to 3
cases of peripheral neuropathy) occurred with an incidence of
only approximately 1 case per 236 patient-years’ utilization.
The basis for this vastly improved safety profile was
superficially routine monitoring of plasma perhexiline concen-
trations. There is ample evidence that most cases of previously
reported long-term toxicity occur with prolonged (.3 months)
elevation of plasma perhexiline concentrations, beyond
600 ng/mL.13,29 The strategy of maintaining concentrations
below that point has been successful in limiting toxicity,
although this has been tested previously mainly in short-term
exposure.22,23 Plasma concentration monitoring at trimonthly
intervals is recommended on the basis that no long-term toxicity
emerges in shorter intervals,13,30 and the upper limit of the
therapeutic range has been set according to the lowest levels
at which hepato- or neuro-toxicity has been observed. On the
other hand, designation of 150 ng/mL as the lower limit of the
range was essentially arbitrary, never being formally correlated
with the extent of suppression of symptoms.13
Although the current data did not capture details
regarding concomitant CYP2D6 inhibitor therapy, this study
confirms the considerable inter-individual variability in the
pharmacokinetics of perhexiline. As expected, daily dosage to
achieve therapeutic levels ranged widely (from less than 100
mg per week to 400 mg per day). Less patients than expected
were poor metabolizers of the drug. Furthermore, very few
monitored concentrations (approximately 8.8% of total read-
ings, occurring in 57% of patients) were above the therapeutic
range, and concentrations of more than twice the therapeutic
range were virtually never seen. Additionally, consecutive
toxic drug concentrations and exposures to toxic concentra-
tion $3 months were also relatively low. Hence the avoid-
ance of toxicity was less than startling.
Surprisingly this occurred despite apparently subopti-
mal frequency of monitoring in two-thirds of cases.
TABLE 3. Serious Toxicity Potentially Caused by Long-Term Perhexiline







1 Peripheral vascular disease Intermediate Less than 6-monthly 197 7.15
2 Nil Rapid 3–6 monthly 58 0
3 (Dietcontrolled) Diabetes mellitus Extensive Less than 6-monthly 124 10
No cases of hepatotoxicity were deemed likely to be induced by perhexiline.
FIGURE 2. Kaplain–Meier curves over the first 10 years of
therapy for all patients (n = 170), and for those who had
concomitant systolic heart failure (HF) (n = 82).
TABLE 4. Multivariate (Backward Stepwise Multiple Logistic
Regression Analysis) Correlates of Mortality in the Current
Study Cohort (n = 170)
Parameter b-Coefficient P
Age 0.026 0.064
Duration of perhexiline treatment 21.447 0.021
History of coronary artery disease 1.258 0.068
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Furthermore, patients apparently experienced adequate symp-
tomatic response in some cases with associated plasma
perhexiline concentrations below the therapeutic range (ie,
,150 ng/mL). The issue of extent of therapeutic effect asso-
ciated with such low concentrations should therefore be eval-
uated in placebo-controlled studies.
The other important change which has occurred in the
general utilization of perhexiline in the last 20 years has been
the transition from use only as a prophylactic anti-anginal
agent to that of a second-line treatment for systolic heart
failure,22,31 particularly in patients with contra-indications to
use of other agents. A substantial minority of the current
patient series had heart failure, often with associated renal
insufficiency. In a recent analysis of survival trends for
chronic systolic heart failure among patients treated with
extensive pharmacotherapy in a tertiary hospital, 5-year sur-
vival, free of heart transplantation was approximately only
55% irrespective of the presence or absence of underlying
myocardial ischemia, despite a substantially younger mean
age of patients than the currently evaluated population.32
Additionally, in a recent systematic review in developed
countries, the 5-year observed survival rate for heart failure
was between 26% and 52%.33 In this study cohort, the 5-year
survival rate of the entire cohort was 83%, while in the pres-
ence of heart failure that fell only slightly. Although our
current data are not placebo-controlled and are subject to
limitations of interpretations, the very extensive survival of
a group of elderly individuals with serious and multiple mor-
bidities seems remarkable. On multivariate analyses, neither
the presence of impaired systolic function nor the proportion
of therapeutic or toxic assay results predicted increased death
rates; these results are superficially surprising.
The study has several limitations. In the 3 cases of
hepato- and neuro-toxicity of uncertain cause, perhexiline
was potentially, but not definitely, implicated. Indeed, none
of these cases had associated “toxic” drug concentrations.
Secondly, the therapeutic efficacy of perhexiline cannot be
adequately determined, given that the study was not
placebo-controlled and the overall inability of the study to
assess individual patient’s compliance to prescribed ther-
apy. Thirdly, CYP2D6 genotype was not determined given
that previous study provided evidence of positive correla-
tion between CYP2D6 genotype and its phenotype,
expressed as the metabolizer ratio between cis-
OH-perhexiline and perhexiline.34 Nevertheless, the data
demonstrate considerable safety, and suggest that therapy
with perhexiline should now be regarded as an appropriate
option for difficult cases of myocardial ischemia and/or
heart failure.
CONCLUSIONS
This is the first large scale audit that investigates the
incidence of adverse effects in patients on long-term perhexi-
line therapy. Although the drug monitoring frequency is less
than ideal, this study showed that therapeutic drug monitoring
is effective in limiting (and virtually eliminating) hepato- and
neuro-toxicities. Approximately two-thirds of the drug con-
centrations measured were within therapeutic range, and
among those drug concentrations which were nontherapeutic,
they were mostly subtherapeutic rather than supratherapeutic.
Additionally, the mortality rate in this current cohort of
patients, particularly those with concomitant heart failure, is
surprisingly low.
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Abstract
Purpose Perhexiline is a prophylactic anti-ischaemic agent
with weak calcium antagonist effect which has been increas-
ingly utilised in the management of refractory angina. The
metabolic clearance of perhexiline is modulated by CYP2D6
metaboliser status and stereoselectivity. The current study
sought to (1) determine whether the acute accumulation of
perhexiline in the myocardium is stereoselective and (2) in-
vestigate the relationship between duration of short-term ther-
apy and the potential stereoselective effects of perhexiline
within myocardium.
Method Patients (n=129) from the active arm of a randomised
controlled trial of preoperative perhexiline in cardiac surgery
were treated with oral perhexiline for a median of 9 days. Cor-
relates of atrial and ventricular concentrations of enantiomers
were sought via univariate followed by multivariate analyses.
Results Myocardial uptake of both (+) and (−) perhexiline
was greater in ventricles than in atria, and there was more
rapid clearance of (−) than (+) perhexiline. The main determi-
nants of atrial uptake of both (+) and (−) perhexiline were the
plasma concentrations [(+) perhexiline: β=−0.256, p=0.015;
(−) perhexiline: β=−0.347, p=0.001] and patients’ age [(+)
perhexiline: β=0.300, p=0.004; (−) perhexiline: β=0.288, p=
0.005]. Atrial uptake of (+) enantiomer also varied directly
with duration of therapy (β=0.228, p=0.025), while atrial
uptake of (−) perhexiline varied inversely with simultaneous
heart rate (β=−0.240, p=0.015).
Conclusion (1) Uptake of both perhexiline enantiomers into
atrium is greater with advanced age and displays evidence of
both saturability and minor stereoselectivity. (2) Atrial uptake of
(−) perhexiline may selectively modulate heart rate reduction.
Keywords Perhexiline .Metabolism . Pharmacokinetics .
Drug uptake . Stereoselectivity
Introduction
Perhexiline is a metabolic modulating agent that was first
introduced into clinical practice as a prophylactic anti-
anginal drug in the 1970s. It exerts multiple effects which
increase efficiency of myocardial metabolism: amongst these,
it is known to inhibit mitochondrial carnitine palmitoyl
transferase-1 [1], potentially resulting in a shift from fatty acid
to glucose utilisation with more adenosine triphosphate pro-
duction per unit oxygen consumption.
Despite the considerable clinical efficacy of perhexiline in
prophylaxis of exertional angina [2, 3], its use declined be-
cause of the substantial risk of hepato- and neuro-toxicity
during chronic therapy [4–6]. However, it emerged that this
toxicity reflected drug accumulation in plasma [7] which in
turn resulted from inter-individual variability in CYP2D6-
mediated metabolism [8, 9]. With widespread availability of
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therapeutic drug monitoring [10, 11] and greater understand-
ing of its potential widespread utility for disorders of cardiac
energetics [12], the clinical use of perhexiline is now
increasing.
Pharmacokinetically, perhexiline is a lipophilic drug well
absorbed from the gastrointestinal tract. It is highly protein
bound and has a large volume of distribution. As it is
subject to hepatic metabolism by CYP2D6, the plasma
half-life of perhexiline ranges from several hours to several
weeks [7, 13].
A number of studies have specifically evaluated short-term
utility of perhexiline in the management of potential cardiac
crises, such as the management of high-risk patients with un-
stable ischaemia and for cardioprotection during coronary
revascularisation [14–16]. The recently reported CASPER tri-
al evaluated its use as an adjunct to myocardial protection in
patients undergoing coronary artery surgery but found no
clear-cut beneficial effect of prophylactic perhexiline therapy
[17]. During this trial, atrial and ventricular myocardial biop-
sies were taken at the time of surgery. We have previously
reported on analyses of these samples to evaluate the relation-
ship between plasma and myocardial drug concentrations
[18]. The objective of the current analysis stems from our
recent observation that the effects of racemic perhexiline
may result from unequal steady-state concentrations of its
two enantiomers [19].
In human liver microsomes, the intrinsic clearance of
(−) perhexiline is greater than that of the (+) enantiomer
[20], which explains the greater clearance rate of (−)
perhexiline at steady state in patients receiving racemic
perhexiline [21]. Interestingly, it appears from studies in
a rat model, that the safety of the two enantiomers may
vary, with greater hepatotoxicity associated with the (+)
enantiomer [22].
Therefore, we have re-evaluated the CASPER data in order
to determine the following:
(1) Whether atrial and ventricular myocardial accumulation of
perhexiline during short-term treatment is stereoselective,
and whether this reflects similar trends in plasma enan-
tiomer concentrations.
(2) The relationship between duration of (short-term)
perhexiline therapy and the potential for stereoselective
effects of perhexiline within the myocardium.
Methods
Data were mainly derived from patients in the active treatment
arm of the CASPER (Coronary Artery Surgery with
PERhexiline therapy) trial (NCT00845364). In brief, this
was a double-blind, randomised, placebo-controlled clinical
trial evaluating whether preoperative oral perhexiline im-
proves myocardial protection in patients undergoing cardiac
surgery. Non-diabetic patients, who were not taking CYP2D6
inhibitors, undergoing first-time coronary artery bypass graft
surgery were randomised to either perhexiline maleate or pla-
cebo for at least 5 days prior to surgery. All patients received
the following medication regimen: 200 mg twice daily for
3 days then 100 mg twice daily until the morning of the sur-
gery [17]. On-treatment heart rate was determined by preop-
erative resting electrocardiogram.
Following induction of anaesthesia but prior to commenc-
ing surgery, the haemodynamic status of each patient, includ-
ing arterial pressures and cardiac index, were determined.
Plasma collected at this time point was centrifuged and stored
at −80 °C, and had previously been used to phenotype patients
for CYP2D6 metaboliser status [17] according to the plasma
concentration ratios of perhexiline monohydroxylated metab-
olite to parent drug [13]. During preparation for cardiopulmo-
nary bypass but prior to aortic cross-clamping, right atrial
and left ventricular myocardial biopsies were obtained, as
previously described [17]. These biopsies were initially
snap-frozen in liquid nitrogen and stored at −80 °C, then
later digested in 0.15 M of phosphate buffer solution (pH
6.0) using a homogeniser and tissue grinder to form a
suspension (approximately 100 mg tissue in 5 mL buffer).
Plasma and myocardial perhexiline enantiomer concentra-
tions were determined utilising a modification of a previously
described HPLC assay [23]. Thresholds for detection of
myocardial (+) and (−) perhexiline were 0.01 mg/L with
sensitivity and accuracy between 0.01 and 2.00 mg/L with
intra-assay coefficients of variation and bias <20 % at
0.01 mg/L [23].
Analysis of results
1. Determination of relative uptake of enantiomers
Concentrations of each enantiomer in atrial and ventric-
ular myocardium were correlated with plasma enantiomer
concentrations to derive tissue to plasma concentration
ratios.
Potential stereoselectivity of uptake was evaluated via
determination of
(a) Differential (+) to (−) enantiomer ratio in myo-
cardium versus plasma (in order to determine whether
uptake, rather than clearance, might engender
stereoselective myocardial effects).
(b) Percentage of (+) enantiomer concentrations in plas-
ma and myocardium, in relation to time (in order to
determine the net effects of stereoselective kinetics
on the myocardial uptake of the drug).
2. Identification of determinants or correlates of myocardial
(+) and (−) perhexiline uptake
Univariate (evaluated utilising Spearman’s correlation)
followed by multivariate analyses were utilised for assess-
ment of the atrial uptake of each enantiomer. Parameters
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evaluated were plasma concentration, metaboliser status,
age, weight, duration of therapy, resting heart rate, creat-
inine clearance, and cardiac index. Multivariate backward
stepwise analyses were performed using statistical soft-
ware SPSS (version 20, Chicago).
3. Data from poor metabolisers (n=7) were excluded from
analysis (unless specified otherwise) because of potential
for differential clearance mechanisms and non-attainment
of near-steady-state kinetics.
4. Data are expressed throughout as mean±SD for normally
distributed parameters and median (interquartile range)
for skewed data.
Results
Patient demographics: metaboliser status and absence
of dose titration
One hundred and twenty-nine patients from the active arm of
CASPER trial were included and their clinical characteristics
are summarised in Table 1. While patients had well-preserved
renal function, their pre-treatment cardiac function is not
known, with formal estimation of cardiac indices and heart
rates performed following the induction of anaesthesia for
surgery; these data therefore reflect the potential interaction
of perhexiline and pre-treatment status. However, the gener-
ally low cardiac indices in these patients imply some degree of
systolic left ventricular dysfunction at least at the time of mea-
surement. The median plasma concentrations of perhexiline at
the time of blood sampling were 0.27 mg/L (IQR 0.13–0.47),
with approximately one third of patients having subtherapeu-
tic levels (i.e. <0.15 mg/L).
Figure 1 examines the relationship between plasma cis-
OH-perhexiline/perhexiline ratio (used to categorise
metaboliser status) and plasma perhexiline concentration at
the time of surgery. It is apparent that there was substantial
variability in racemic perhexiline concentrations, such that
therapeutic concentrations were not generally attained in rapid
metabolisers. There were a total of seven poor metabolisers,
all of whom attained therapeutic or potentially toxic
perhexiline concentrations.
Myocardial concentrations of enantiomers
The relationships between plasma and atrial or ventricular
concentrations of (+) and (−) perhexiline are depicted in
Fig. 2a and b, respectively. There were strong direct correla-
tions for both enantiomers, with slightly greater concentra-
tions of both enantiomers in ventricle than in atrium
(p<0.001 for both, Spearman’s test).
The impact of metaboliser status on these plasma/
myocardial concentration relationships is summarised in
Table 2. All but two plasma enantiomer concentrations were
>0.02 mg/L. In summary, plasma concentrations of (+)
perhexiline tended to be greater than those of (−) perhexiline
for both plasma and myocardium, irrespective of metaboliser
status.
We next sought to determine whether stereoselective clear-
ance of perhexiline and/or of its uptake into myocardium
might vary with duration of therapy. The proportion of (+)
perhexiline in plasma did not vary significantly with duration
of therapy (Fig. 3a), while that in atria increased significantly
(p=0.004) with time (Fig. 3b). Thus, the ratio of (+)
perhexiline in the atrium to that in the plasma tended to in-
crease progressively (r=0.19, p=0.07).
Concentrations of both (+) and (−) perhexiline into the
ventricle increased significantly with time (p=0.005 and
0.004, respectively, Fig. 4), with no significant difference be-
tween the enantiomers.
Multivariate correlates of uptake of enantiomer
Table 3 summarises atrial/plasma concentration ratios,
with all patients (excluding poor metabolisers)
Table 1 Clinical characteristics of patients (n=129)
Parameters
Age (years)a 66 (58–73) a
Weight (kg) 83±14
Creatinine clearance (mL/min)a 70 (60–85) a
Baseline cardiac index 2.04 (1.78–2.34) a
Resting heart rate (beats per minute)b 59±10
Duration of therapy (days)a 9 (6–12) a
a Expressed as median (interquartile range)
b On treatment, while under anaesthesia immediately prior to surgery
Fig. 1 The relationship between CYP2D6 metaboliser status (expressed
as cis-OH-perhexiline/perhexiline ratio) and plasma perhexiline
enantiomer concentrations at the time of surgery. Data to the left of the
dashed line (ratio <0.3) correspond to Bpoor metaboliser^ status
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evaluated. Plasma perhexiline concentration was a
strong negative correlate and age was a positive corre-
late of this ratio for both enantiomers.
Uptake of (−) perhexiline also varied inversely with simul-
taneous heart rate. Similar trends were also apparent with uni-
variate correlations (Fig. 5).
Fig. 2 Correlations between
plasma and myocardial (atrial and
ventricular) concentrations for a
(+) perhexiline and b (−)
perhexiline. Spearman’s
correlations are shown
Table 2 Perhexiline enantiomer concentrations in plasma and atrial and
ventricular myocardium across all metabolic phenotypes. Metaboliser
status was defined by the ratio of plasma concentrations of cis-
hydroxyperhexiline to perhexiline. Poor metaboliser was defined by a
ratio of ≤0.3; intermediate metaboliser was defined by a ratio of 0.3 to
2.5; extensive metaboliser was defined by a ratio of 2.5 to 20; and
ultrarapid metaboliser was defined by a ratio of ≥20
Metaboliser status Plasma concentrations (mg/L) Atrial concentrations (μg/g) Ventricular concentrations (μg/g)
(+) (−) (+) (−) (+) (−)
Poor metaboliser n=7 n=3 n=1
0.67±0.32* 0.48±0.21 16.57±6.57 13.22±4.89 17.5 12.5
Intermediate metaboliser n=28 n=19 n=6
0.28 (0.24–0.37)* 0.23 (0.18–0.29) 6.17 (5.45–8.16)* 5.11 (4.28–6.58) 11.07±5.41Δ 9.08±4.54Δ
Extensive metabolisers n=85 n=64 n=21
0.11 (0.07–0.17)* 0.08 (0.05–0.13) 2.77 (1.50–3.99)* 2.17 (1.26–3.24) 5.16±2.48Δ 3.55±2.17Δ
Ultrarapid metabolisers n=9 n=8 n=2
0.03 (0.026–0.037)* 0.023 (0.017–0.027) 0.84±0.31 0.623±0.314 3.41±0.41 1.56±2.21
Data expressed as mean±SD or median (interquartile range)
*p<0.05 vs antipode (Wilcoxon); Δ p<0.005 vs atrial/plasma ratio
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Discussions
The current analyses complement our previously published
evaluation of the uptake of racemic perhexiline into the human
myocardium [18]. It is apparent from the current studies that
the perhexiline dosing regimen utilised, with inadequate time
available for adjustment of dosage on the basis of metaboliser
status, led to wide variability in plasma and myocardial drug
concentrations but, nonetheless, allowed exploration of deter-
minants of myocardial uptake of perhexiline enantiomers.
The main findings of the current analysis are that
1. Plasma concentrations of (+) or (−) perhexiline and the
corresponding myocardial concentrations are closely and
directly correlated.
2. Just as plasma (+) enantiomer concentration exceeds that
of (−) enantiomer, similar trends are present in myocardi-
um, especially atrial muscle.
3. Myocardial uptake of each enantiomer also depends on
plasma drug concentrations, where a strong inverse rela-
tionship is present, and patients’ age.
4. Atrial uptake of (+) perhexiline also varies with duration
of therapy.
5. Atrial uptake of (−) perhexiline varies inversely with
simultaneous heart rate.
These findings carry a number of important implications
regarding the myocardial handling and effects of perhexiline
enantiomers.
The higher concentrations of (+) than (−) enantiomer in
plasma are consistent with more rapid clearance of the latter.
These data are consistent with previous publications regarding
the stereoselective clearance of perhexiline [20, 21]. On the
other hand, myocardial concentration ratios of the enantio-
mers generally parallel with those in plasma, suggesting the
absence of major stereoselectivity in myocardial uptake. The
exception to this is the small but statistically significant in-
crease in the proportion of (+) enantiomer in the atrial myo-
cardium with time (Fig. 3b). These data suggest that myocar-
dial uptake and efflux of (−) perhexiline may be slightly more
rapid than that of the (+) enantiomer.
The relatively prolonged time required to reach steady-state
perhexiline concentrations in the ventricular myocardiummay
reflect greater distribution into mitochondria [24], known to
represent a site of intracellular drug accumulation for
perhexiline in hepatocytes [25].
As regards the interactions between advanced age and car-
diac uptake of the enantiomers, the current data suggest that
uptake of both perhexiline enantiomers is greater in older pa-
tients, perhaps related to decreased skeletal muscle mass. In-
deed we have previously also shown that steady-state dosage
requirements for perhexiline tend to fall with age [26], and in
the current study, plasma perhexiline concentrations increased
with patient age (r=0.24, p=0.029). Together, these data sug-
gest that elderly individuals may benefit from perhexiline ther-
apy despite apparently borderline subtherapeutic plasma drug
levels.
Finally, atrial uptake of (−) perhexiline varied inversely
with concurrent heart rate. This is not consistent with the usual
accelerating effect of tachycardia on myocardial drug uptake
[27] and suggests another mechanism for the association.
Perhexiline is a weak L-type calcium channel antagonist [28,
29], although its effects on the myocardium have undergone
only limited study. The IC50 for inhibition of calcium fluxes in
chick embryo ventricular myocardium by racemic perhexiline
Fig. 3 Variations in the percentage of (+) perhexiline in a plasma and b
atrial myocardium relative to duration of therapy. Spearman’s correlations
are shown
Fig. 4 Impact of duration of treatment on concentrations of perhexiline
enantiomers in ventricular myocardium. Spearman’s correlations are
shown
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was 8.3×10−7 M [28]. In the current study, atrial concentra-
tions of (−) perhexiline approximated to these values. It is
therefore possible that the calcium antagonist effect of rac-
perhexiline is mediated primarily by the (−) enantiomer, de-
spite the current limitation of the understanding of pharmaco-
logical actions of the perhexiline enantiomers.
The current study has several limitations.Most importantly,
correlation with cardiac effects of perhexiline is limited by the
absence of true pre-treatment data and that evaluation of the
effects of the enantiomers is only extrapolated on the basis of
administration of rac-perhexiline. Second, myocardial drug
content after a median of 9 days of therapy reflects both up-
take into and efflux from the myocardium, and there is no way
to determine the precise component of each, given that steady
state has not been reached. Finally, the full implications of the
widely variable plasma perhexiline concentrations on variabil-
ity in drug uptake cannot be fully understood without a strat-
egy of multiple drug dosing per patient.
The current results also need to be related to the clin-
ical context. Recently, we have reported on acute loading
of perhexiline in patients with severe ischaemia [14, 15].
The current data are consistent with the idea that there
may be early onset of cardioprotective effects, especially
in the elderly, at a time when plasma drug concentrations
are notionally subtherapeutic. Furthermore, the data re-
garding heart rate correlations should stimulate evaluation
of whether the calcium antagonist effects of perhexiline
can be dissociated from its Bmetabolic^ cardioprotective
effects [30, 31], by selective administration of the (+)
enantiomer.
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Little is known regarding the steady-state uptake of drugs into the human
myocardium. Perhexiline is a prophylactic anti-anginal drug which is
increasingly also used in the treatment of heart failure and hypertrophic
cardiomyopathy. We explored the relationship between plasma perhexiline
concentrations and its uptake into the myocardium.
METHODS
Blood, right atrium ± left ventricle biopsies were obtained from patients treated
with perhexiline for a median of 8.5 days before undergoing coronary surgery in
the perhexiline arm of a randomized controlled trial. Perhexiline concentrations
in plasma and heart tissue were determined by HPLC.
RESULTS
Atrial biopsies were obtained from 94 patients and ventricular biopsies from 28
patients. The median plasma perhexiline concentration was within the
therapeutic range at 0.24 mg l−1 (IQR 0.12–0.44), the median atrial concentration
was 6.02 mg kg–1 (IQR 2.70–9.06) and median ventricular concentration was
10.0 mg kg–1 (IQR 5.76–13.1). Atrial (r2 = 0.76) and ventricular (r2 = 0.73)
perhexiline concentrations were closely and directly correlated with plasma
concentrations (both P < 0.001). The median atrial : plasma ratio was 21.5 (IQR
18.1–27.1), ventricular : plasma ratio was 34.9 (IQR 24.5–55.2) and
ventricular : atrial ratio was 1.67 (IQR 1.39–2.22). Using multiple regression, the
best model for predicting steady-state atrial concentration included plasma
perhexiline, heart rate and age (r2 = 0.83). Ventricular concentrations were
directly correlated with plasma perhexiline concentration and length of therapy
(r2 = 0.84).
CONCLUSIONS
This study demonstrates that plasma perhexiline concentrations are predictive
of myocardial drug concentrations, a major determinant of drug effect.
However, net myocardial perhexiline uptake is significantly modulated by
patient age, potentially via alteration of myocardial:extracardiac drug uptake.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Perhexiline is a modulator of myocardial
metabolism used for treatment of angina,
and increasingly, heart failure and
hypertrophic cardiomyopathy.
• Perhexiline has a small therapeutic index
and highly variable pharmacokinetics
(polymorphic and saturable), necessitating
therapeutic drug monitoring to
individualize dosage and minimize the risk
of hepatotoxicity and peripheral
neuropathy.
WHAT THIS STUDY ADDS
• Plasma perhexiline concentrations are
highly predictive of myocardial
concentrations, with net uptake into the left
ventricle being more extensive than into the
right atrium and requiring more time to
reach steady-state.
• Net myocardial drug uptake also appears to
be affected, to a lesser extent, by age and
heart rate.
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Introduction
Little is known regarding the steady-state uptake of
drugs from the blood into the human heart, their accu-
mulation or partitioning, in part due to the inherent dif-
ficulty of obtaining heart tissue from patients. Although
indirect measurement of uptake in humans has utilized
paired arterial and coronary sinus blood sampling, this
can only measure acute drug uptake following intrave-
nous bolus injection [1]. On the other hand, animal
studies have provided much information on the princi-
ples modulating drug uptake into the heart. In general,
uptake is affected not only by plasma drug concentration
but also by heart rate and the relative octanol : water
partition coefficients [2]. Additionally, active transport
mechanisms may be further modulators of the uptake
process [1]. Therefore in theory, the ratio of plasma
to myocardial drug concentrations may vary between
patients.
Perhexiline is a modulator of myocardial metabolism
that is effective in the treatment of patients with refractory
angina unsuitable for revascularization [3]. More recently it
has also been shown to improve myocardial energetics
and function in chronic cardiac failure [4] and symptomatic
hypertrophic cardiomyopathy [5]. Historically, there have
been difficulties in balancing the clinical effectiveness
of perhexiline with significant toxicity, due to marked
inter-individual variation in its pharmacokinetics, princi-
pally differences in elimination resulting from genetic
polymorphisms of CYP2D6. These polymorphisms give rise
to approximately 100-fold inter-individual differences in
apparent oral clearance and plasma half-lives that range
from 1–2 days in most subjects and up to 40 days in poor
metabolizers [6]. Severe adverse events, including hepato-
toxicity and peripheral neuropathy, can be avoided
by therapeutic drug monitoring to maintain plasma
perhexiline concentration within a defined therapeutic
range (0.15–0.6 mg l−1) [7]. Perhexiline has been shown to
inhibit carnitine palmitoyltransferase-1 (CPT-1), the key
uptake enzyme for long chain fatty acids into mitochon-
dria, and this is thought to be its principal mechanism of
action [8]. This promotes a switch in myocardial energy
metabolism from fatty acid to glucose utilization, provid-
ing a significant oxygen-sparing effect. Perhexiline has
been shown in a number of studies in isolated tissues and
animal models to be highly concentrated in many tissues,
including myocardium and hepatocytes [8, 9], to an extent
consistent with intracellular CPT-1 inhibition. This is
despite the fact that the IC50 for CPT-1 inhibition in rat
myocardium is approximately 50–100 fold greater than
therapeutic plasma perhexiline concentrations [8]. No
human tissue concentration data have previously been
reported.
In the current study, we evaluated the relation-
ship between plasma and myocardial perhexiline
concentrations in a cohort of chronically treated patients
undergoing non-emergent coronary artery surgery. The
purposes of the study were to:
1 determine the extent of the nexus between plasma and
myocardial drug concentrations;
2 determine whether the concentration of perhexiline
within the myocardium varies between atria and ventri-
cle; and
3 identify demographic/chemical factors which might
modulate the nexus between plasma drug concentra-
tions and perhexiline uptake into the myocardium.
Methods
Study design
Perhexiline administration occurred in the setting of a pro-
spective, double-blind, randomized, placebo-controlled
trial of pre-operative perhexiline. This was conducted in
patients undergoing isolated, first time coronary artery
bypass grafting (CABG) on cardiopulmonary bypass (CPB)
for multi-vessel coronary artery disease (http://www
.clinicaltrials.gov/show/NCT00845364). The study was
approved by the Cambridgeshire 1 Research Ethics Com-
mittee (06/Q0104/41) and the Medicines and Healthcare
products Regulatory Agency (2006-003164-62), and
patients were enrolled between February 2007 and April
2010. All research was performed in accordance with the
Declaration of Helsinki and the UK Human Tissue Act 2004
within a research governance framework. Following
written informed consent, patients were randomized to
either rac-perhexiline maleate (Aspen Pharmacare, St
Leonards, NSW, Australia) or placebo and trial medication
was commenced at least 5 days prior to the planned date
of surgery. A standardized loading and maintenance
regime was used: 200 mg twice daily for 3 days followed by
100 mg twice daily until the morning of surgery.
Plasma analysis
Blood was drawn prior to the induction of anaesthesia,
centrifuged and the plasma stored at −80°C. Concentra-
tions of perhexiline (CPx) and OH-perhexiline (COHPx) were
measured in all patients by high performance liquid chro-
matography (HPLC) as previously described [6]. This
enabled identification of poor metabolizers in the treat-
ment group and confirmation of zero levels in controls.
CYP2D6 metabolizer phenotype was determined by the
plasma concentration ratio (COHPx : CPx) and classified
according to published criteria [6].
Myocardial biopsies, extraction and analysis
Atrial and ventricular biopsies were obtained during
surgery and promptly snap-frozen in liquid nitrogen. The
right atrial appendage was truncated during venous
cannulation for CPB. Transmural Tru-Cut needle (Alle-
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giance, McGaw Park, IL, USA) biopsies of the left ventricular
free-wall between the left anterior descending artery and
the first diagonal branch were taken whilst on CPB but
before application of the aortic cross clamp.
Myocardial perhexiline concentrations were deter-
mined using techniques adapted from a published
method [10] and previously validated in an animal model.
In brief, right atrial biopsies were mechanically digested
in 0.15 M phosphate buffer solution (pH 6.0) using a
homogenizer and a tissue grinder to form a suspension
(approximately 100 mg tissue in 5 ml buffer). A fine tissue
grinder alone was used for the left ventricular biopsies
which had far lower masses (approximately 5 mg tissue in
0.5 ml buffer). Atrial and ventricular biopsies from patients
in the perhexiline arm constituted the experimental
groups. Right atrial homogenate from patients in the
control arm, with proven zero plasma perhexiline concen-
trations, was also prepared for generating standard curves
and quality control (QC) samples. The precision and accu-
racy of the method were evaluated over a perhexiline cali-
bration range of 0.01–2.0 mg l−1. Both inter- and intra-
assay coefficients of variation and bias over the calibration
range were within ± 15%.
Statistical analysis
Analyses were conducted using SPSS Statistics version
17.0 (SPSS Inc., Chicago, IL, USA). Poor metabolizers of
perhexiline (COHPx : CPx ratio ≤ 0.3) were excluded from the
primary analysis as they were unlikely to have reached
steady-state in either the plasma or myocardium [6]. Data
are presented as mean (SD) or median (interquartile range,
IQR). The concentration of perhexiline is reported as the
sum of the concentration of the two enantiomers. Spear-
man’s rank test was used to correlate non-parametric data
and Wilcoxon signed-rank test to compare paired atrial
and ventricular concentrations. The relationship between
variables was modelled using simple and multiple linear
regression.
The authors had full access to and take full responsibil-
ity for the integrity of the data. All authors have read and
agreed with the manuscript as written.
Results
The study group consisted of 97 patients treated with
perhexiline for whom paired plasma perhexiline concen-
trations and atrial biopsies were available. Of these, three
were analyzed separately because of poor metabolizer
status, making it unlikely that steady-state had been
approached at the time of study. Primary analyses were
therefore performed in 94 patients, who had been treated
with perhexiline for a median of 8.5 days with median total
perhexiline dose of 2300 mg (Table 1).
Plasma perhexiline concentration
The median plasma perhexiline concentration at the time
of surgery was 0.24 mg l−1 (IQR 0.12–0.44) with 64%
patients within the established therapeutic range of 0.15–
0.60 mg l−1, 28% sub-therapeutic and 9% above the range.
Of the total study group, three were poor metabolizers
(mean CPx 1.67 mg l−1), 18 were intermediate metabolizers
(0.65 mg l−1), 68 were extensive (0.25 mg l−1) and eight
were ultra-rapid metabolizers (0.05 mg l−1). Excluding the
poor metabolizers, there was no correlation between
plasma CPx and length of therapy (rs coefficient 0.05,
P = 0.60) (Figure 1).
Myocardial perhexiline uptake: data excluding
poor metabolizers
Atrial perhexiline concentration Right atrial biopsies from
all 94 patients in the primary analysis group had a mean
mass of 114 mg (range 10–458) and median perhexiline
concentration of 6.02 mg kg–1 of tissue (IQR 2.70–9.06).
Atrial and plasma perhexiline concentrations were closely
correlated (r = 0.87, P < 0.001, Figure 2) and the median
atrial:plasma perhexiline ratio was 21.5 (IQR 18.1–27.1)
with a range from 4.9–55.6. Stepwise multiple linear
regression was performed using plasma perhexiline,
length of therapy, age, weight, pre-anaesthesia heart rate,
pre-sternotomy cardiac index, gender and creatinine clear-
ance as potential correlates of atrial concentration. A
model containing plasma perhexiline (β 0.87, P < 0.001),
age (β 0.12, P < 0.01) and heart rate (β −0.09, P < 0.05)
achieved an r value of 0.91, r2 of 0.83 and an F ratio of 108.0
(P < 0.001), noting that plasma perhexiline alone has an r
Table 1
Characteristics of patients included in the study
Variable Perhexiline (n = 94)
Plasma perhexiline, median (IQR) (mg l−1) 0.24 (0.12–0.44)
Plasma OH-perhexiline, median (IQR) (mg l−1) 1.18 (0.96–1.52)




Length of therapy, median (IQR) (days) 8.5 (6.5–12.5)
Age, mean (SD) (years) 64.3 (8.9)
Weight, mean (SD) (kg) 84.2 (15.0)
Pre-treatment heart rate, mean (SD) (beats min−1) 60 (10)
Left ventricular function, n (%)
Good (≥50%) 77 (82)
Moderate (30–49%) 17 (18)
Pre-ischaemia cardiac index, mean (SD) (l min−1 m−2) 2.13 (0.60)
Pre-operative medications, n (%)
ACE inhibitor or ARB 60 (63.8)
Statin 87 (92.6)
β-adrenoceptor antagonist 66 (70.2)
Calcium channel antagonist 34 (36.2)
Long acting oral nitrate 32 (34.0)
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.
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value of 0.87. Length of therapy had no impact on the
model suggesting that atrial perhexiline concentration
was not significantly affected by the length of therapy
beyond 5 days and that most patients had reached a
steady-state of atrial perhexiline concentrations.
Ventricular perhexiline concentration Left ventricular
biopsies were available in only 28 patients in the study
group who had been treated for a median of 9.5 days (IQR
7.0–14.0) and had a median perhexiline concentration of
10.0 mg kg–1 (IQR 5.76–13.1). As with the atrial biopsies,
there was a close correlation (r = 0.85, P < 0.001) between
plasma and ventricular perhexiline concentrations
(Figure 3). The median ventricular : plasma perhexiline
concentration ratio was 34.9 (IQR 24.5–55.2) with a range
of 16.7–89.3. The ventricular concentration was signifi-
cantly higher than the atrial concentration (Z −4.4, P < 0.01)
with a median ventricular : atrial ratio of 1.67 (IQR 1.39–
2.22) and a range from 0.9–5.0. The atrial concentration
was also strongly correlated with ventricular concentra-
tion (r = 0.88, P < 0.001).
However, unlike atrial concentrations, ventricular con-
centrations of perhexiline were directly correlated with
duration of therapy (r = 0.54, P < 0.001, Figure 1). Stepwise
multiple linear regression was used to identify correlates of
ventricular concentration. Plasma perhexiline concentra-
tion (β 0.74, P < 0.001) remained the principal correlate but
the model was improved by the addition of length of
therapy (β 0.30, P < 0.01), with an overall r value of 0.92 and
F ratio of 43.0 (P < 0.001).
Myocardial perhexiline uptake in
poor metabolizers
In all, seven phenotypic CYP2D6 poor metabolizers were
treated with perhexiline in the trial but atrial biopsies were
only available for three of these. Mean plasma perhexiline
concentration was elevated beyond the therapeutic range
in all seven of the poor metabolizers (1.35 ± 0.67 mg l−1).
Atrial perhexiline concentrations were 31.51, 17.59 and
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Linear regression demonstrating that plasma perhexiline is also predic-
tive of ventricular concentration in 28 patients (r2 = 0.73, P < 0.001)
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Discussion
The current study utilized atrial and ventricular biopsies
to compare plasma and myocardial concentrations of
perhexiline in patients treated with the drug for a median
of 8.5 days prior to undergoing surgical coronary
revascularization. The use of ongoing therapy to attain
steady-state plasma and atrial perhexiline concentrations
allowed the investigation of factors that may affect net
myocardial uptake, which at steady-state is directly related
to the myocardial : plasma concentration ratio (assuming
constant myocardial clearance). Thus, the major findings
of this study are:
1 in a group of patients whose plasma perhexiline
concentrations were generally within the thera-
peutic range, plasma perhexiline concentrations were
closely correlated with both atrial and ventricular drug
concentrations;
2 perhexiline is concentrated in the myocardium relative
to plasma, with approximately 20-fold and 35-fold myo-
cardial : plasma ratios in the right atrium and left ventri-
cle, respectively;
3 while on multivariate analysis plasma drug concentra-
tion is the major determinant of right atrial perhexiline
concentration, there is also a direct relationship
between net myocardial drug uptake and age, and a
significant inverse relationship with heart rate prior to
surgery and
4 net perhexiline uptake into the left ventricle appears to
be more extensive than into the right atrium and also
requires a greater period of time to reach steady-state.
These findings have implications both as regards the
general principles of drug uptake into the heart and thera-
peutics with perhexiline.
The dosing regimen utilized in this study was identical
to one developed over 20 years ago for the attainment of
therapeutic perhexiline concentrations within 3 days [7].
While this regimen achieves its purpose in most patients,
it is associated with sub-therapeutic concentrations
(<0.15 mg l−1) in approximately 10–15% of patients and in
toxic concentrations (>0.6 mg l−1) in a slightly higher pro-
portion [11], particularly ultra-rapid and poor metabolizers
of the drug, respectively. Current practice is for treatment
regimens to be titrated on the basis of plasma perhexiline
concentrations measured during the first week of therapy
[6] although the short term treatment strategy utilized in
the current trial did not permit this to occur.
The close linear relationship between plasma and
myocardial perhexiline concentrations suggests that net
uptake is not saturable, and is therefore relatively con-
stant within the range of concentrations evaluated. The
observation that perhexiline concentrations within the
myocardium are far greater than in plasma is consistent
with the lipophilicity of the drug and with previously
demonstrated intracellular concentrations in hepatocytes
[9]. These data also establish that the intracellular con-
centration of perhexiline within the human ventricle is
sufficient to induce substantial inhibition of myocardial
CPT-1, the postulated principal mechanism of action of
the drug [8].
The finding that left ventricular perhexiline concentra-
tions had not reached steady-state is also important, con-
firming that there may be substantial hysteresis between
attainment of the ‘therapeutic’ plasma drug concentra-
tions and steady-state therapeutic effects. However, the
impact of length of therapy on ventricular perhexiline con-
centrations was relatively small. Hence in most cases, net
myocardial uptake was at near equilibrium with plasma
concentrations, as shown in Figure 1.
The impact of increasing age on net atrial perhexiline
uptake, although small, was a potentially important
finding, especially given the frequent use of this agent
in elderly patients with angina refractory to other treat-
ment options. We postulate that the finding reflects a
diminution of the relative uptake of perhexiline into
extracardiac tissues such as skeletal muscle and/or fat,
perhaps due to decreased mass of these tissues in the
elderly [12] or, less likely, a small age-dependent decrease
in myocardial clearance. It also raises the possibility that
hepatic drug uptake, the precursor to potential long term
perhexiline toxicity, may also be increased in aged
patients, despite apparently ‘therapeutic’ plasma drug
concentrations.
Previous studies in animal models, isolated tissues
and in man have suggested that myocardial mechanical
activity, perhaps linked to coronary blood flow, increased
drug uptake into the heart [2]. This has been examined
extensively in the case of digoxin [13, 14], and in the
short term for class I anti-arrhythmic agents [15–17]. In
the current study, it is possible that the greater mechani-
cal activity (and associated perfusion) of the left ventricle
might have contributed to a greater uptake into the ven-
tricular than atrial myocardium. However, the finding that
atrial perhexiline concentrations varied inversely with
heart rate is unexpected and indeed is contrary to a
number of other reports, including acute drug uptake
studies in humans [2]. However, it is important to note
that the heart rate measurement in the patients studied
was performed prior to surgery whilst on therapy. As
perhexiline is a weak L-channel calcium antagonist [18], it
is therefore likely that the correlation between right atrial
perhexiline concentration and bradycardia resulted from
the effect of increasing perhexiline concentrations on
sinus node function, rather than constituting a paradoxi-
cal effect on drug uptake.
The study had a number of limitations. In particular, we
were unable to evaluate the impact of regional heteroge-
neity of coronary perfusion in this group of patients with
potentially severe myocardial ischaemia on the distribu-
tion of perhexiline within the left ventricular myocardium.
Perhexiline uptake into the human heart
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This is an important issue, as drug uptake into ischaemic
myocardium is critical to the improvement of myocardial
energetics which has been shown to occur during
perhexiline therapy [5], and which results, at least in part,
from CPT-1 inhibition [8, 19]. Furthermore, the study pro-
vided only limited information regarding myocardial drug
uptake in CYP2D6 poor metabolizers, who represent about
7% of Caucasian patients. Drug uptake in such patients is
likely to be in similar equilibrium with plasma perhexiline
concentrations but this is difficult to prove without a
specific investigation in poor metabolizers. Finally, tissue
biopsy was of necessity limited to the myocardium. Meas-
urement of perhexiline uptake into the liver, skeletal
muscle and adipose tissue would have been of interest,
particularly to help evaluate the basis for differential myo-
cardial uptake in the elderly.
In conclusion, this study serves to establish a close
nexus between plasma and myocardial perhexiline con-
centrations, albeit with other factors modulating net
uptake. In doing so, the results have strengthened
the basis for monitoring of plasma perhexiline concentra-
tion and perhaps for therapeutic drug monitoring in
general.
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